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ABSTRACT
Understanding the Mechanism of Hard Metal (WC-Co) Toxicity:
In vitro Studies and In vivo Exploration
Andrea Lynn Armstead
Hard metals, such as tungsten carbide cobalt (WC-Co), are frequently used for a number
of industrial applications such as surface coatings for heavy machinery and tools. In particular,
WC-Co coatings are prevalent in mining and drilling applications where extensive, repetitive use
of these tools causes wear over time. In enclosed environments, WC-Co wear particles become
airborne and present an occupational inhalation hazard. It is known that inhalation of WC-Co
“dusts”, composed of nano- and micro-sized WC-Co particles, contributes to the development of
hard metal lung disease and increased risk for lung cancer; however, the relationship between acute
WC-Co toxicity and disease progression remains poorly understood. To address this gap in
knowledge, we systematically evaluated nano-WC-Co particle toxicity using a combination of in
vitro and in vivo models. In Aim 1, we determined the toxicity of nano-WC-Co particles in BEAS2B lung epithelial cells over concentrations ranging 0.1 to 1000 μg/mL and exposure periods from
0.5 to 48 hr. Our MTT-based cell viability assay indicated that nano-WC-Co exhibits greater
toxicity than micro-WC-Co at concentrations ≥ 10 μg/mL. We also found that nano-WC-Co
exposure induces oxidative stress at the highest particle concentration tested (1000 μg/mL) using
a fluorescence-based (DCF/DHE) assay and that WC-Co particle exposure induced cellular
apoptosis, marked by increased annexin-V staining in our flow cytometry apoptosis assay. The
potential for nano-WC-Co particle internalization was also investigated using transmission
electron microscopy (TEM) and confirmed that nano-WC-Co particles are capable of being
internalized by BEAS-2B cells. In Aim 2, we determined the inflammatory response toward nanoWC-Co particles in a co-culture model of BEAS-2B cells and macrophages, to more closely
represent the dynamic tissue environment of the lung. The results of our viability assay indicated
that macrophages attenuated the toxicity of nano-WC-Co in the co-culture model compared to
BEAS-2B alone, which indicated a protective effect of the macrophages. We found that nano-WCCo exposure caused macrophage polarization toward the M1 pro-inflammatory phenotype and
determined that nano-WC-Co exposure also stimulates the secretion of cytokines such as IL-12
and IL-1β in macrophages, consistent with a pro-inflammatory response. In Aim 3, we investigated
the potential systemic (extra-pulmonary) effects of nano-WC-Co exposure in an intra-tracheal
instillation (IT) rat model and compared the outcomes with a known pulmonary irritant, cerium
dioxide (CeO2). After 24 hr exposure, nano-WC-Co exposure did not induce pulmonary or
systemic inflammation at a dose of 50, 250 or 500 μg compared to control or CeO2; this outcome
highlights the need for future in vivo studies which examine the inflammatory effects of chronic
or repeated nano-WC-Co exposure. Taken together, the results of our studies improve the current
understanding of hard metal WC-Co toxicity and may point toward potential therapeutic or
diagnostic strategies for the future.
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CHAPTER 1:

Nano-Toxicity: Emerging Concerns Regarding Nanomaterial Safety
&
Occupational Hard Metal (WC-Co) Nanoparticle Exposure

1

ABSTRACT

As the number of commercial and consumer products containing engineered
nanomaterials (ENMs) continually rises, the increased use and production of these ENMs
presents an important toxicological concern. While ENMs offer a number of advantages over
traditional materials, their extremely small size and associated characteristics greatly enhance
their toxic potential. ENM exposure can occur in a variety of consumer and industrial settings via
inhalation, ingestion or dermal routes. While the importance of accurate ENM characterization,
effective dosage metrics and selection of appropriate cell or animal-based models are universally
agreed upon as important factors in ENM research, at present, there is no “standardized”
approach used to assess ENM toxicity in the research community. Of particular interest is
occupational exposure to tungsten carbide cobalt (WC-Co) “dusts”, composed of nano- and
micro-sized particles, in hard metal manufacturing facilities and mining and drilling industries.
Inhalation of WC-Co dust is known to cause “hard metal lung disease” and an increased risk of
lung cancer; however, the mechanisms underlying WC-Co toxicity, the inflammatory disease
state and progression to cancer are poorly understood. Herein, a discussion of ENM toxicity is
followed by a review of the known literature regarding the effects of WC-Co particle exposure
and an original dissertation research project, focusing on the mechanisms of WC-Co mediated
toxicity in vitro and in vivo, is proposed.

Keywords: engineered nanomaterial, nanotoxicity, nanoparticle, occupational exposure, hard
metal, lung disease, cancer
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ENGINEERED NANOMATERIALS, NANOTOXICITY & MEANS of EXPOSURE
Due to recent technological and manufacturing advancements, the production and use of
engineered nanomaterials (ENMs) is increasing at a rapid pace. The term ENM broadly
encompasses a number of nano-sized materials that vary in shape, such as nanotubes, nanowires,
or nanoparticles (NPs), which are generally defined as “any material having at least one
dimension smaller than 100 nm” [1, 2]. Due to their extremely small size and high surface area,
NPs offer a number of advantages over traditional “bulk” materials and are suitable for a wide
variety of applications in consumer goods [3-5], medical devices and diagnostics [6-9],
pharmaceutical products [8, 10-14], fuel additives [15-17] and other industrial uses [18]. As a
result, the number of manufactured goods containing NPs is continually rising; in 2006,
manufacturers reported that NPs were incorporated in over 600 consumer products worth $50
billion in market value [3], a number which more than doubled to greater than 1600 NPcontaining consumer products in 2013 [19].
With the increased use of NPs in such diverse applications, a concomitant risk of
exposure exists across consumer households and in commercial occupational settings. NPs exist
in our daily environments and are often referred to as “contaminants” of important air, water and
soil resources [20-24]. Because these NPs are all around us, exposure can occur via mechanisms
such as inhalation, ingestion and dermal exposure [25]. Additionally, emerging evidence
suggests that humans may also be exposed to NPs internally, which may be generated in situ due
to orthopedic surgical implant wear [26-29]. These potential routes of NP exposure are
summarized graphically in Figure 1. Importantly, the route of exposure ultimately determines
which body system or specific tissues the NPs interact with which in turn, determines the effects
of NP exposure such as toxicity [30-32] or alterations in physiological function [33, 34].
3

Figure 1. Routes and potential detrimental effects of NP exposure.

The effects of NP exposure can be divided into primary and secondary categories (Figure
1), depending upon the extent of exposure. Primary effects resulting from direct cellular NP
contact may include toxicity, oxidative stress, DNA damage and inflammation [1, 2, 35]. Due to
their small size, NPs may translocate through tissue barriers into the blood, where they can
circulate and eventually deposit in other organs, thereby generating a secondary NP exposure.
Secondary effects may include toxicity at the site of NP deposition, in organs such as the liver,
spleen or kidneys, systemic inflammation or alterations in systemic function [1, 2, 33, 35-37].
The first three routes of exposure occur via external NP sources, but there is emerging evidence
which indicates that humans may also be exposed internally, when orthopedic or surgical implant
wear NPs are released locally from the implant site [26, 38, 39]. Most commonly, humans are
exposed to NPs in their environments through the pulmonary route, by inhaling airborne NPs
during normal breathing [33, 34, 40, 41].
4

Despite their potential toxic properties, it is worth mentioning that certain NPs have
distinct advantages which outweigh the risk of use and have greatly improved a consumer
products on the market today such as sunscreens and cosmetics [25]. For example, titanium
dioxide NPs present in sunscreens and cosmetic products are highly beneficial, offering excellent
protection from sun exposure, therefore protecting the skin against UV damage and preventing
sunburn. NPs have been approved for use under these conditions; however, the long-term effects
of titanium dioxide NPs on aquatic life in contaminated water sources (lakes, oceans, etc) remain
an important concern for future research.

Table 1. Important components of NP toxicity testing.
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As a direct result of the increased use of NPs and likelihood of exposure, the study of the
acute and chronic effects of NP exposure has recently emerged as the field of ‘nanotoxicology’
[42]. Currently, there is no standard approach for NP toxicity testing and a number of arguments
support the implementation of a standard testing procedure, so that results and outcomes can be
directly comparable amongst all NPs tested. However, this remains a difficult task because the
route and realistic amount of exposure (dose) vary greatly depending on the particular NP in
question [43]. In order to define the toxic potential of NPs, several key factors must be addressed
(summarized in Table 1) [1, 2, 42]. First, it is imperative to characterize NPs in terms of size,
shape and properties, so that the observed effects can be attributed to a particular property or
characteristic [44, 45]. Next, an appropriate dosage metric must be selected for the NPs to be
examined. In the literature, NP dosages have been reported as concentration per volume or mass
(mg/mL or mg/kg), as reactive surface area (cm2) or as particle number in solution, calculated
based on NP size [43].
In addition to particle characterization and selection of the dosing metric, an appropriate
model must be selected for toxicity testing [32, 41, 46]. Typically, in vitro cell-based models are
the starting point due to lower cost and relative ease of execution compared to in vivo animalbased model systems [47]. In vitro systems require small amounts of NP for testing and allow for
dose-response testing and sample collection over time in a variety of systems such as cells or
tissues [47]. Primary or commercial cells are commonly used for ENM toxicity testing and cell
selection for a given assay is frequently based on the potential route of NP exposure; some
examples of in vitro models are summarized in Table 2. Aside from the advantage of being “fast
and cheap”, in vitro models can be used to estimate toxico-kinetic parameters, target organ
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toxicity and help define appropriate NP dosages for in vivo studies, which helps to reduce the
number of experimental animals required for nanotoxicity research.

Table 2: Examples of In Vitro Cell Models used for Nanotoxicity Testing
Cell Type

NPs Studied

NP Size

Human lung carcinoma (A549)

Cerium Dioxide
(CeO2)

10 nm

Human hepatocyte (C3A), human
colon adenocarcinoma (CaCo-2),
primary trout hepatocytes

Gold (Au)

35 nm

Cerium Dioxide
(CeO2)

25 nm

Human fibroblasts, peripheral
blood mononuclear cells,
macrophages

Cobalt Chromium
(CoCr)

30 nm

Hepatocellular carcinoma (HepG2)

Silicon Dioxide
(SiO2)

43 nm

Human lung epithelial cells
(BEAS-2B)

Titanium Dioxide
(TiO2)

25 nm

Rat alveolar macrophages (RAW
264.7)

Crystalline Silica
Zinc Oxide
Magnesium Oxide
(DQ12, ZnO, MgO)

960 nm

3 μm

10 nm

NP Dose

[Ref]

6.25, 25 or 100
μg/mL

[17]

0-1000 μg/mL

[24]

1-5000 μm3/well

[4850]

25, 50, 100, 200
μg/mL

[51]

5, 10, 20, 40 μg/mL

[52]

1, 5, 10, 40 μg/cm2

[53]

8 nm

Table 2. Examples of in vitro models used in NP toxicity testing.

Although in vitro models and toxicity assays are reliable and used frequently, several
groups have reported NP interference with commonly used cell-based assays [54-57], bringing
into question whether the results are accurate or if they are simply artifacts generated due to NP
interference with the assay mechanism [57, 58]. To address this issue, a number of control
7

experiments are required to identify any potential NP assay interference and these effects must
be considered when interpreting the final results.
Although they offer a number of advantages, cell-based systems are limited and generally
demonstrate the effects of NPs within a very specific and small compartment compared to
whole-animal in vivo models [59-61]. Animal models may offer more realistic insights as to the
effects of NP exposure in humans because the body systems can be utilized as a whole, with all
of its cells, tissues and organs interacting with the NPs as would be encountered in a realistic
exposure scenario [59-61].
Since there are a number of NP exposure routes for humans, a number of in vivo
exposure approaches must be used such that the effects of the NP on the appropriate tissue or
organ system can be identified. Commonly used in vivo NP exposure routes are summarized
Table 3, including NP inhalation, intra-tracheal instillation (IT), injection and ingestion or
gavage. As mentioned earlier, NP inhalation and pulmonary exposure is the most common in
humans and is therefore the most frequent route by which experimental animals are exposed in
nanotoxicity studies. However, not all NPs are suitable for aerosolization for the purposes of an
inhalation chamber, so alternatively, pulmonary NP exposure can be achieved via intra-tracheal
instillation (IT) [62]. IT is a highly reproducible, direct method for depositing NP within the
lungs and NP delivered in this manner have very similar lung distribution to NP inhalation [62];
therefore, IT is considered an excellent approach for the pulmonary delivery of NP. In addition
to pulmonary routes of exposure, animals may also be exposed to NP via injection for the
purposes of systemic or local NP exposure. Intra-peritoneal (IP) or intravenous (IV) NP
injections can be used to achieve systemic NP exposure, as the NP will circulate through the
vasculature and may deposit in organs such as the liver, spleen or kidneys. Injection may also be
8

used to achieve localized NP exposure within articular locations, such as the knee or hip, or may
be used to target subcutaneous tumors.

Table 3: Examples of In Vivo Animal Models Used for Nanotoxicity Testing
NP Delivery
Method

Inhalation

Intra-tracheal
Instillation (IT)

Animal Model

Mouse

(via GI tract)

NP Dose

[Ref]

15 nm

250 μg/m3 for 3 hr/
day × 7 days

[63]

[64]

Rat

Magnetite
(Fe3O4)

1.3 μm

Rat

Cerium Dioxide
(CeO2)

191 nm

10, 100, 400 μg per
rat

[65]

Mouse

Chitosan

633 nm

2 mg/kg

[66]

Cobalt
Chromium
(CoCr)

32 nm

(periarticular
injection)

Rats (articular
injection)

Ingestion

Cadmium
Oxide (CdO)

NP Size

4.7, 16.6, 52.1
μg/m3 for 6 hr/ day ×
5 days/week × 13
weeks

Mouse
Injection

NPs Studied

Daphnia magna,
Cyprius carpo
(fish species)

Cobalt
Chromium
(CoCr)

Gold (Au)
Cerium Dioxide
(CeO2)

2.9 μm

1 injection/week × 2
weeks

[67]

0.05, 0.25, 1.25
μg/mL
60 nm

[68]
1 injection/week ×
10 weeks

35 nm
0-10 μg/mL
25 nm

Table 3. Examples of in vivo exposure models used in NP toxicity testing.
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1.2 × 106 μm3/25 g

[24,
69]

INDUSTRIAL HARD METAL (WC-Co) APPLICATIONS & EXPOSURE
Among the plethora of NPs gaining industrial use and popularity is tungsten carbide
cobalt (WC-Co), which is a hard composite metal known for its extreme hardness, stability and
sharpness [70, 71]. The use of WC-Co NPs as a spray coating on heavy machinery, drill bits and
saw blades substantially increases strength, durability and resistance to wear, which drastically
improves the operating lifetimes in industrial applications [70, 71]. In particular, WC-Co
coatings are popular in the mining and drilling industries, where maintenance of sharp saw
blades and drills is of critical importance.
Despite the improved durability and strength of WC-Co NP coatings compared to other
conventional materials, these coatings do not last forever and eventually wear over extended use
and time. As a result, airborne WC-Co dusts containing particles of varying size can be
generated during use [72]. These airborne WC-Co “dusts” present an occupational exposure
hazard not only in hard metal manufacturing facilities, but also in mining and drilling industries
where these WC-Co coated implements are used extensively in enclosed environments [73-78].
Typical WC-Co dusts encountered in industrial environments have a reported size range of
several microns down to highly respirable particles in the nano-size range [78, 79].
While exposure to WC-Co containing dusts has been identified as an occupational
workplace hazard by the National Institutes of Occupational Safety and Health (NIOSH) [80],
exposure limits for WC-Co dusts and powders remain undefined. Existing exposure limits for
cobalt metal and ionic cobalt [81-83] are difficult to translate to WC-Co exposure, as cobalt
content can vary, depending on the application, and generated dusts may not have uniform
composition between multiple industrial sites [77]. More importantly, the combination of WCCo is more toxic than Co, W or WC particles alone (see page 11). Therefore, understanding the
10

toxic effects of hard metal WC-Co particles is crucial so that occupational exposure guidelines
can be developed.

RISK OF WC-Co EXPOSURE: HARD METAL LUNG DISEASE (HMLD) PROGNOSIS
& CANCER RISK
Exposure to “hard metal dust” containing WC-Co is well associated with the occurrence
of occupational asthma and is a known prerequisite for the development of hard metal lung
disease (HMLD) [70, 72, 81, 84-109]. Diagnosis of HMLD is a challenge, as symptoms are
general and often mistaken for other respiratory ailments: patients often report difficulty
breathing and present with reduced lung capacity, progressive lung inflammation and eventual
fibrosis [101, 102, 105, 110, 111]. HMLD has been reported in hard metal manufacturing, oil
and mining/drilling industries, where workers were exposed to WC-Co dusts or fumes on a daily
basis for a number of years prior to diagnosis [72, 84, 101, 105, 112-118]. Currently, treatments
are limited and no disease-specific therapy or diagnostic tool exists. There has been some
success in treating HMLD with corticosteroids or immuno-suppressive therapies [119-122], but
in most cases, avoidance of further hard metal exposure is the recommended course of action.
It has recently been established that the defining characteristic of HMLD is the presence
of “bizarre, cannibalistic, multinucleated giant cells” in lung biopsy specimens of workers
exposed to WC-Co [102, 111, 114, 117, 123-127]. These giant cell complexes are thought to
originate from macrophages which have engulfed WC-Co particles, which then stimulate
inflammatory and fibrotic processes in the surrounding lung tissue [99, 102, 114, 124, 125]. In
some cases, WC-Co particle “deposits” have been found in biopsy specimens, confirming
causative exposure to WC-Co dust and HMLD diagnosis [113, 114, 124, 126]. It has been
11

hypothesized that there may be an allergic reaction or a genetic predisposition which may
contribute to the development of HMLD in certain individuals [89, 128, 129].
There is also accumulating evidence that patients with HMLD are at a two-fold increased
risk of developing lung cancer [95, 97, 100, 101]. It has been argued that the generation of
reactive oxygen species by WC-Co particles, which may directly cause DNA damage, along with
the ability of cobalt ions to inhibit DNA repair mechanisms, may play a synergistic role in the
development of lung cancer in HMLD patients [100]. However, this hypothesis has yet to be
verified in vivo and the relationship between the inflammatory disease state and development of
lung cancer remains unclear.

DEFINING HARD METAL (WC-Co) TOXICITY: In Vitro and In Vivo STUDIES
Early data concerning the effects of inhaled WC-Co dusts first emerged in the 1960s and
continued through the 1980s, providing researchers the foundation to further explore the toxic
effects of hard metal exposure using in vitro [128, 130-153] and in vivo [130, 154-161] models.
Although cobalt itself was originally considered the causative agent of HMLD, several studies
demonstrated that this is not the case and the disease is mainly developed due to the
simultaneous presence of WC with Co [128, 132, 134-136, 138, 140, 141, 145, 146, 155, 156,
162, 163]. It is currently understood that the combination of WC-Co is more toxic than Co, W or
WC particles alone, both in vitro and in vivo [128, 130, 132, 134, 138-149, 152, 153, 155-160],
but the reason for this enhanced toxicity is still not well defined.
On the in vitro side, the effects of direct WC-Co particle exposure were examined by a
number of research groups in terms of cell viability, apoptogenic potential, genotoxicity,
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oxidative stress and DNA damage in multiple cell lines of various origins. The major outcomes
of these early in vitro studies are summarized in Table 4, where the cell type, particle size and
dosage parameter is noted for each study. In alveolar macrophages, 2 μm WC-Co particles
caused significant toxicity after 24 hr of exposure at concentrations ranging from 50 to 1667
μg/mL, but were less toxic toward type II pneumocytes under these conditions [130, 152],
confirming pulmonary WC-Co toxicity in a relevant in vitro model. Toxicity has also been
reported in mouse peritoneal macrophages, where WC-Co particles ranging from 2-4 μm caused
toxicity after as little as 6 hr of exposure at concentrations ranging 50 to 300 μg/mL [140-146].
In human peripheral blood mononuclear cells, exposure to micron-sized WC-Co particles caused
apoptosis, DNA damage, genotoxicity and alterations in gene expression after exposure times as
short as 15 min and up to 6 hr [147-149, 157]. Additionally, a number of these studies compared
the toxicity of WC-Co, WC or Co particles and determined that the interaction of WC with Co
significantly enhances the toxicity of the composite compared to either component alone [128,
132, 134, 140, 141, 146, 148].
There are fewer studies which have examined the effects of nano-WC-Co particles;
however, nano-WC-Co toxicity has been reported in human keratinocytes, liver carcinoma cells,
oligodendroglial precursor cells and neurons, at concentrations ranging from 3 to 30 μg/mL and
exposure times from 1 hr up to 3 days [132, 133, 138]. Internalization of nano-WC-Co has been
reported in the keratinocytes (epidermal cells) after 2 days of exposure, which suggested that
nano-WC-Co could potentially be absorbed through the skin [132, 133]. Nano-WC-Co toxicity
has also been reported in rainbow trout gill cells, murine epidermal cells and fibroblasts at
concentrations < 100 μg/mL for 3 hr and up to 3 days [137, 150, 151]. Nano-WC-Co has also
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been shown to exert genotoxic effects by affecting the expression of genes involved in cellular
apoptosis and stress responses [133, 134].
While the effects of WC-Co particles have been established in multiple cell lines of
varying origin, these studies used mono-culture systems in their examination of WC-Co particle
toxicity, which may not provide an accurate assessment of what happens during/after WC-Co
exposure since the local environment of the lung is highly dynamic and contains more than a
single cell type. Additionally, amongst these studies, there was little information regarding the
effects of WC-Co exposure in lung epithelial cells (non-carcinoma), which line the airway and
are highly likely to directly encounter WC-Co particles or dust during an occupational exposure.
Despite these limitations, this body of research clearly demonstrates that WC-Co particles are
highly toxic and are capable of inducing oxidative stress and genotoxicity following exposure,
highlighting the need for further investigation into the relationship between acute WC-Co
toxicity and development of HMLD.

Table 4: Summary of In Vitro Studies Regarding WC-Co Particle Toxicity

Cell Type

Primary rat type II
pneumocytes
Human colon
adenocarcinoma
(CaCo-2), human
keratinocytes
(HaCaT), human lung
carcinoma (A549),
OLN-93 oligodendroglial precursor cells,
rat neurons, astrocytes

Particle Size

Major Outcome(s)

[Ref]

2 μm
50 μg/mL WCCo

No changes in the levels of TNFα, IL-1, fibronectin or
cystatin-C (compared to control) were observed after
WC-Co exposure for 12 or 24 hr in isolated rat type II
pneumocytes.

[130]

145 nm
3.3, 6.6, 8.25,
11, 16.5 or 33
μg/mL WC-Co

WC-Co particles exhibited significant toxicity at a
concentration of 33 μg/mL after 3 days exposure to
CaCo-2, HaCaT and A549 cells. Significant toxicity
was also observed in astrocytes after exposure to
3.3 μg/mL and higher WC-Co concentration after 1
and 3 days. Primary rat neurons were not sensitive
to WC-Co toxicity. Additionally, WC-Co particles
were internalized into the cytoplasm of HaCaT, A549
and OLN-93 cells after 2 days.

[132]

& Dosage
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Table 4. Summary of in vitro WC-Co toxicity studies.
Table 4: Summary of In Vitro Studies Regarding WC-Co Particle Toxicity (continued)
Particle Size
Cell Type

Major Outcome(s)

[Ref]

After 15 min exposure to WC-Co, PMBC
demonstrated 1.5-fold increase in DNA damage,
marked by increased formation of micronuclei due to
oxidative stress, compared to control and Co particle
treatment alone.

[134]

& Dosage
1 μm
Human peripheral
blood mononucleated
cells (PMBC)

10, 50 or 100
μg/mL WC-Co
or Co
145 nm

Rainbow trout gill cells
(RTgill-W1)

Human keratinocyte
(HaCaT) and hepatocellular liver
carcinoma (HepG2)
cells

8.25, 16.5 or
33 μg/mL WCCo

145 nm
7.5, 15 or 30
μg/mL

2 μm
Mouse peritoneal
macrophages

50, 100, 200
or 300 μg/mL
of WC-Co, Co
or WC
62 nm

Human keratinocytes
(HaCaT)

33 μg/mL WCCo
2-4 μm

Mouse peritoneal
macrophages

0-500 μg/mL
of carbides:
WC, TaC, SiC,
NbC, Fe, TiC,
Mo2C; all plus
6% Co

WC-Co caused significant reduction in cell viability
after 3 hr and 3 day of exposure in RT gill cells. WCCo particles were also found to be internalized into
the cytoplasm after 2 days.

[137]

WC-Co internalization in HaCaT was confirmed;
however, WC-Co did not cause significant toxicity at
the concentrations studied after 1 hr, 3 hr or 3 days.
WC-Co particles did not induce reactive oxygen
species (ROS) or DNA micronuclei under the
conditions tested.

[138]

After 18-24 hr of exposure, WC-Co caused
significant toxicity, marked by increased LDH release
and significant induction of oxidative stress
compared to control. Activated oxygen species were
implicated in associated DNA damage (micronuclei)
in macrophages.

[140144]

WC-Co exposure caused significant changes in gene
expression, such as HIF1, after 3 hr and 3 days of
exposure. WC-Co responsive genes were involved
in cellular death and stress responses.

[133]

The addition of 6% Co particles to each of the
“carbide” particles significantly enhanced the toxicity
of WC, TiC and NbC in macrophages after 18 hr
exposure, marked by increased levels of LDH
release compared to control and the various carbide
particles alone. Enhanced toxicity was attributed to
the interaction of Co with the carbides.

15

[146]

Table 4: Summary of In Vitro Studies Regarding WC-Co Particle Toxicity (continued)
Particle Size
Cell Type

Major Outcome(s)

[Ref]

& Dosage

Human peripheral
blood mononuclear
cells (PMBC)

< 1 μm
100 μg/mL WCCo

< 1 μm
Human peripheral
blood mononuclear
cells (PMBC)

Human peripheral
blood mononuclear
cells (PMBC) and
human monocytes

Human peripheral
lymphocytes and
mouse fibroblast (3T3)

33.3, 45 or 100
μg/mL WC-Co
or WC

< 1 μm
100 μg/mL WCCo or WC

2 μm
100 μg/mL WCCo, WC or Co

80 nm, 4 μm
Mouse epidermal cells
(JB6)

Rat alveolar
macrophages (AM)
and type II
pneumocytes

25, 37.5, 50, 75
or 150 μg/mL
WC-Co

2 μm
83, 417 or 1667
μg/mL WC-Co
or Co

Exposure to WC-Co particles for 15 min caused
altered gene expression after 6 and up to 24 hr
post-exposure in PMBC, including activation of
HIF-1α, p53 and altered expression of HMOX1
which is involved in oxidative stress response
mechanisms.

[147]

WC-Co particles caused cellular apoptosis, marked
by annexin-V staining, after 15 min and 6 hr of
exposure. Apoptosis was induced via the caspase9 pathway and DNA fragmentation was significantly
elevated in WC-Co exposed cells compared to WC
alone.

[148]

A 24 hr exposure to WC-Co caused significant upregulation of apoptosis and stress response genes
in both PMBC and monocytes, namely BNIP3,
which is involved in mitochondrial mediated cell
death.

[149]

In lymphocytes, WC-Co caused significant
induction of DNA strand breaks after 15 min of
exposure, attributed to oxidative stress damage,
and caused extensive DNA damage in isolated 3T3
cellular DNA compared to WC or Co particles
alone.

[150]

Nano-WC-Co induced greater oxidative stress and
hydroxyl radicals, marked by significantly
decreased cellular GSH levels, in JB6 cells
compared to micro-WC-Co. Nano-WC-Co also
stimulated induction of AP-1 and NF-kappaB and
increased cellular proliferation in JB6 cells
compared to micro-WC-Co under identical
conditions.

[151]

After 24 hr exposure to WC-Co, significant toxicity
was observed in AM, but not in type II
pneumocytes, compared to controls. However, type
II cells were more sensitive toward Co toxicity than
AM, in the absence of WC components.

[152]
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The large majority of previous WC-Co animal studies summarized in Table 5 employed
the intra-tracheal installation (IT) exposure model, as the preferred means of delivery for hard
metal particles and ‘dust’ in vivo [130, 154-157, 159, 161]. Inhalation studies regarding pure Co
dust have been published [160], but to our knowledge, an in vivo study which employs inhalation
as the means of delivery for WC-Co particles has yet to be reported. As noted in Table 5, the
previous in vivo studies examined the effects of WC-Co particles in the micron-size range, using
the mass-per-body weight dosing scheme (i.e. mg/kg or mg/g), although some variation in
particle size was noted in most cases (overall, WC-Co size ranging from 0.1 to 6 μm).
Specifically, micro-sized WC-Co particle exposure caused significant pulmonary inflammation
in rats, marked by increased broncho-alveolar lavage (BAL) fluid parameters such as lactate
dehydrogenase (LDH) and albumin content, compared to control animals, as little as 24 hr after
delivery of the WC-Co IT bolus [130, 156, 157, 161]. Significant pulmonary edema, interstitial
lung fibrosis, alveolar congestion and alveolitis were also reported in micro-sized WC-Co
exposed animals at 1 and 6 months following a single IT exposure [154, 155, 161]. Given this
body of literature, the local effects of micro-sized WC-Co following pulmonary exposure have
been well characterized and it is understood that micro-sized WC-Co exerts both acute and
chronic effects in vivo.
However, since it is now understood that inhaled particulate matter can exert extrapulmonary effects and alter systemic functions [37, 66, 164-175], these studies provide limited
insight as to the potential systemic effects of WC-Co after pulmonary exposure. The overall lack
of in vivo toxicity data regarding nano-sized WC-Co is also concerning, since nano-sized WC-Co
particles are likely to penetrate deeper into the lungs and cause more tissue damage than microsized WC-Co particles. Further, the pathology of HMLD and presence of the “hallmark”
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multinucleated giant cells have yet to be successfully reproduced in an animal model, so the
mechanism underlying WC-Co mediated toxicity and progression to HMLD in exposed workers
needs further investigation.

Table 5: Summary of In Vivo Studies Regarding WC-Co Particle Toxicity

Method of
Delivery

Intratracheal
Instillation
(IT)

Animal Model &
Particle Size
Rat
Mixed WC-Co
dusts ~ 0.1 to 6
μm

Rat
IT
5 μm WC-Co

Rat
IT
5 μm WC-Co

Rat
IT
2 μm WC-Co

WC-Co
Dosage

Major Outcome(s)

[Ref]

Single IT
bolus at high
dose (≥ 1
mg/kg body
weight)

At 6 months following single IT WCCo exposure, rats presented with
pulmonary edema, alveolar
congestion and lung fibrosis in
regions of deposited WC-Co dusts.

[154]

Single IT
bolus at 1
mg/100 g
body weight

WC-Co caused high mortality with
massive pulmonary edema,
increased macrophage counts,
LDH, albumin and total protein
content at 24 hr post-exposure.

[155]

Single and
repeated IT
bolus at 1, 5
or 10 mg/kg
body weight

Single IT WC-Co exposure caused
acute alveolitis which persisted for
about 1 month following the IT
bolus. Repeated weekly exposure
(4x/1 month) caused interstitial lung
fibrosis and increased lung
hydroxyproline levels in exposed
rats.

[156]

Single IT
bolus at 16.6
mg/kg body
weight

WC-Co exposure caused significant
elevation of LDH, total protein &
albumin in BAL fluids after 12 hr
and up to 72 hr following exposure.
In rat type II pneumocytes isolated
after IT exposure, increased
induction of micronuclei were
observed, indicating genotoxicity
and DNA damage.

[157]
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Table 5: Summary of In Vivo Studies Regarding WC-Co Particle Toxicity

Method
of
Delivery

Animal Model &
Particle Size

Rat
IT
2 μm WC-Co

Rat
IT

3 μm WC-Co

Rat
IT

1 μm WC-Co

WC-Co
Dosage

Major Outcome(s)

[Ref]

Single IT
bolus at 1
mg/100 g
body weight

24 hr after single IT WC-Co
exposure, significant increases in
LDH, total protein and albumin were
found in BAL fluids. WC-Co did not
exert any effects on the levels of IL1, TNFα, fibronectin or cystatin-C in
BAL fluids of exposed animals.

[130]

Single IT
bolus at 2.5, 5
or 10 mg/100
g body weight

Pulmonary edema, fibrin formation
and increased number of
inflammatory cells were observed in
WC-Co exposed rat lungs, along
with decreased reactivity to
methacholine, increased levels of
nitric oxide synthase (NOS), LDH,
total protein and albumin in BAL
fluids.

[159]

Single IT
bolus at 1 or 3
mg per rat

A significant increase in LDH was
observed after 1, 4, 7 and 30 days
of WC-Co exposure and fibrosing
alveolitis was developed in rats after
30 days post-IT exposure.

[161]

Table 5. Summary of in vivo WC-Co toxicity studies.
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SPECIFIC AIMS of DISSERTATION RESEARCH
The long-term goal of this dissertation research project is to identify the mechanisms by
which NPs exert their toxic effects and how these effects may contribute toward the development
of respiratory diseases, such as HMLD. Since our focus is hard metal NP exposure in particular,
the overall objective of this research project was to identify the mechanism underlying nanoWC-Co toxicity in vitro and to establish an in vivo model to assess the potential systemic effects
caused by pulmonary exposure to nano-WC-Co.
Our central hypothesis is that nano-WC-Co particle exposure causes toxicity in vitro via
induction of oxidative stress and activation of apoptosis, induces inflammation and exerts
systemic effects in vivo which may be contributing factors in the progression of HMLD in
patients. This hypothesis was generated upon review of the existing literature regarding hard
metal toxicity and emerging data highlighting the potential extra-pulmonary (systemic) effects of
inhaled NPs. Our rationale is that this dissertation research will improve our knowledge
regarding the mechanism of nano-WC-Co toxicity at the cellular level, which may offer new
insights into the progression of HMLD and direct us toward improved disease diagnosis,
therapeutic treatments or potential prophylactic strategies in the future.
In pursuit of our long-term goal and to systematically test our central hypothesis, the
proposed research was divided into three attainable specific aims, presented graphically in
Figure 2:
Specific Aim 1: Determine the toxicity and identify the internalization mechanism of nanoand micro-sized tungsten carbide cobalt (WC-Co) particles in lung epithelial cells (BEAS-2B).
Our working hypothesis for Aim 1 is that nano-WC-Co causes dose-dependent toxicity via
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induction of oxidative stress and stimulation of cellular apoptosis due to particle internalization
in vitro.
Specific Aim 2: Determine the inflammatory response to tungsten-carbide cobalt (WC-Co)
NPs using a co-culture model composed of lung epithelial cells (BEAS-2B) and macrophages
(THP-1). Our working hypothesis for Aim 2 is that exposure to nano-WC-Co stimulates the
release of pro-inflammatory cytokines and induces M2 macrophage polarization in a co-culture
model using lung epithelial cells and macrophages.
Specific Aim 3: Design and conduct an in vivo pilot study to determine the systemic effects of
pulmonary tungsten carbide-cobalt (WC-Co) exposure in rats. Our working hypothesis for Aim
3 is that, in addition to local toxic effects in the lung tissue, acute nano-WC-Co exposure induces
a systemic response marked by increased levels of inflammatory markers in the blood plasma.
Our proposed research is of importance because we will address the weaknesses of
previous studies by examining the effects of WC-Co exposure on lung epithelial cells and
macrophages using co-culture in vitro and establish an in vivo model for the assessment of
systemic effects caused by pulmonary nano-WC-Co exposure. This research will have a positive
impact on the realm of hard metal toxicity research, which may facilitate the discovery of
molecular markers which could be used for improved diagnostic and treatment strategies which,
in turn, could greatly reduce the impact of HMLD on healthcare costs and improve long-term
patient outcomes. Additionally, the approach described herein could be further applied to other
NPs or ENMs; therefore, this research may contribute toward the development of a standard
model and approach for nanotoxicity and safety testing.
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Figure 2. Schematic representation of the proposed WC-Co dissertation research project.
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CHAPTER 2:

Exploring the Potential Role of Tungsten Carbide Cobalt (WC-Co)
Nanoparticle Internalization in Observed Toxicity toward Lung
Epithelial Cells in vitro

First-Author manuscript published in fulfillment of
Specific Aim #1

Armstead, A.L; Arena, C.B; Li, B. 2014. Exploring the potential role of tungsten carbide cobalt
(WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial cells in vitro.
Tox App Pharmacol 278, 1-8. http://dx.doi.org/10.1016/j.taap.2014.04.008
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ABSTRACT
Tungsten carbide cobalt (WC-Co) has been recognized as a workplace inhalation hazard
in the manufacturing, mining and drilling industries by the National Institute of Occupational
Safety and Health. Exposure to WC-Co is known to cause “hard metal lung disease” but the
relationship between exposure, toxicity and development of disease remain poorly understood.
To better understand this relationship, the present study examined the role of WC-Co particle
size and internalization on toxicity using lung epithelial cells. We demonstrated that nano- and
micro-WC-Co particles exerted toxicity in a dose- and time-dependent manner and that nanoWC-Co particles caused significantly greater toxicity at lower concentrations and shorter
exposure times compared to micro-WC-Co particles. WC-Co particles in the nano-size range
(not micron-sized) were internalized by lung epithelial cells, which suggested that internalization
may play a key role in the enhanced toxicity of nano-WC-Co particles over micro-WC-Co
particles. Further exploration of the internalization process indicated that there may be multiple
mechanisms involved in WC-Co internalization such as actin and microtubule based cytoskeletal
rearrangements. These findings support our hypothesis that WC-Co particle internalization
contributes to cellular toxicity and suggests that therapeutic treatments inhibiting particle
internalization may serve as prophylactic approaches for those at risk of WC-Co particle
exposure.

Keywords: nanotoxicity, nanoparticle, hard metal, lung disease, pulmonary exposure, particle
internalization
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INTRODUCTION
The effects of nanomaterial inhalation and pulmonary exposure are intense areas of
research, as this is one of the most common routes by which humans are exposed to
nanomaterials or nanoparticles in their environments [30, 37]. Although the effects of exposure
vary due to the material and composition of the particles, pulmonary effects of nanoparticle
exposure are known to include lung toxicity, inflammation, asthma, pleural effusion, pulmonary
fibrosis, granuloma formation, etc [40, 176]. Inhalation of nanoparticles is a concern not only for
the casual consumer, but also as an occupational hazard for industry workers whose daily tasks
include the manufacture, production or repeated use of nanoparticle-containing goods, tools and
equipment.
In particular, occupational exposure to tungsten carbide cobalt (WC-Co), a hard
composite metal commonly used as a material or coating for tools and machinery in mining and
drilling industries [70] is a concern. Exposure typically occurs via inhalation in the workplace, as
WC-Co “dusts” are released into the air upon extensive and repeated use of these tools, such as
drills, in a closed environment. Inhalation of WC-Co “dusts”, composed of various-sized WC-Co
particles, is well-documented to cause occupational asthma, hard metal lung disease (HMLD)
and an increased (e.g. two-fold) risk for lung cancer [70, 73, 75, 77, 85, 97, 100, 101, 114, 124,
163, 177]. Among pulmonary diseases, HMLD is difficult to diagnose as its symptoms are
similar to other respiratory ailments. HMLD usually manifests as progressive inflammation and
fibrosis of the lung, with some cases progressing to lung cancer [101, 102, 104, 107, 114, 124].
At present, the relationship between WC-Co exposure, toxicity and development of HMLD
remains poorly understood.
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Since the first recognition of adverse health effects from WC-Co exposure in the 1960s
[178-182], there have been a number of reports regarding the toxicity of WC-Co in the literature
both in vitro [131-135, 137, 140, 141, 143, 144, 147, 149-153, 158] and in vivo [130, 154-157,
159-161]. While it is well established that composite WC-Co particles are more toxic than
tungsten (W), tungsten carbide (WC) or cobalt (Co) alone, the potential contribution of WC-Co
particle internalization toward observed toxicity and the mechanism by which WC-Co particles
could be internalized by relevant cells has not been well-addressed. The present study examined
the toxic effects and explored potential internalization mechanism(s) of nano- and micro-sized
WC-Co particles in lung epithelial cells.

MATERIALS and METHODS
Materials and Reagents: Micro-sized WC-Co particles (micro-WC-Co; 4 μm) were purchased
from Alfa Aesar (Ward Hill, MA) and nano-sized WC-Co particles (nano-WC-Co; 80 nm) were
purchased from Inframat Advanced Materials (Manchester, CT). BEAS-2B lung epithelial cells
were obtained from the laboratory of Yon Rojansakul. Dulbecco’s Modified Eagle Media
(DMEM), sterile phosphate buffered saline (PBS), 0.25% trypsin/ethylenediaminetetraacetic acid
(EDTA), fetal bovine serum (FBS) and penicillin/streptomycin were purchased from Lonza
(Allendale, NJ). The MTT cell viability kit (TOX-1), 2’,7’-dichlorofluorescein diacetate (DCF),
dihydroethidium (DHE), monodansylcadaverine (MDC), colchicine and cytochalasin-D,
glutaraldehyde, paraformaldehyde, agarose and osmium tetroxide were purchased from SigmaAldrich (St. Louis, MO). ApoScreen flow cytometry kit, including annexin-V-FITC (AV-FITC)
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and propidium iodide (PI), was purchased from Southern Biotech Inc. (Birmingham, AL). SPIPON 812 for electron microscopy was purchased from SPI Supplies (West Chester, PA).
Particle Preparation: For cell culture experiments, stock WC-Co particle suspensions (5
mg/mL) were prepared in sterile PBS containing 10% FBS and sonicated using an Omni
International Sonic Ruptor 250 Ultrasonic Homogenizer (Kennesaw, GA). Stock particle
suspensions were sonicated under 120 watts power output, at a frequency of 20 kHz, in two 30second intervals to ensure particle dispersion. Sonication was performed in 30 mL plastic vials
immobilized in an ice bath to minimize heating of the suspension during the sonication process.
Dilute particle suspensions (0.1 to 1000 μg/mL) were prepared in DMEM containing 10% FBS
from the 5 mg/mL stock particle suspension on the day of each experiment.
Particle Characterization: Micro- and nano-WC-Co particles were characterized after
preparation in suspension for cell culture, described above, via dynamic light scattering (DLS,
Malvern Zetasizer version 7.01, Malvern Instruments Ltd, Malvern, UK), transmission electron
microscopy (TEM; Zeiss Libra 120 electron microscope, Carl Zeiss Microscopy, Jena,
Germany), scanning electron microscopy and energy-dispersive x-ray for the determination of
elemental composition (SEM/EDX; JEOL JSM 7600F, Jeol USA, Inc, Peabody, MA). Further
detail provided in Supplementary Material.
Cell Culture and Exposure to WC-Co Particles: BEAS-2B cells were cultured in DMEM
supplemented with 10% FBS and 1% penicillin-streptomycin and maintained at 37°C and 5%
CO2. Briefly, confluent monolayers were rinsed with PBS, trypsinized, transferred to 5 mL
polystyrene tubes and centrifuged at 1200 rpm for 7 min to pellet. The cell pellet was resuspended at the desired plating density, transferred to a tissue culture plate and allowed to
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adhere overnight. 96 well plates were seeded at 1.5 × 105 cells/mL for viability, oxidative stress
and inhibitor assays; 24 well plates were seeded at 2 × 105 cells/mL for apoptosis and TEM
examination of particle internalization.
Cell Viability Assay: For the viability assay, cells were exposed to either nano- or micro-WCCo particles at concentrations of 0.1, 1, 10, 100 and 1000 μg/mL for exposure periods of 0.5, 1,
2, 6, 12 and 48 hr. Following particle treatment, cells were rinsed once with sterile PBS to
remove traces of media and excess particles. The MTT cell viability assay was performed per kit
instructions (TOX-1, Sigma-Aldrich) in a 96 well cell culture plate.The absorbance of each well
was recorded at 570 nm using a Bio-Tek μQuant microplate reader (Winooski, VT). Blank
values were subtracted from absorbance readings. Cell viability was calculated by dividing the
absorbance of particle treated cells (AbsExptl) by the absorbance of the negative control cells
(media treatment only; AbsControl) and converted to percentage according to the following
equation: Cell Viability (%) = (AbsExptl ∕AbsControl) × 100%.
Oxidative Stress Assay: Oxidative stress was examined at select nano- and micro-WC-Co
particle concentrations of 0.1, 10 and 1000 μg/mL after exposure periods of 0.5, 1, 2, 6, 12 and
48 hr. Following particle treatment, cells were rinsed once with sterile PBS to remove traces of
media and excess particles. Oxidative stress was then determined by the addition of 10 μM DCF
or DHE in PBS following particle treatment. Plates were incubated for 15 min in the dark and
then fluorescence intensity of each well was quantified at 520 nm for DCF or 620 nm for DHE.
The relative fluorescence of particle-treated cells was calculated as fold over control.
Annexin-V Apoptosis Assay: Cells were treated with WC-Co particles at select concentrations
of 10, 100 and 1000 μg/mL for 12 hr. Positive control (apoptotic) cells were prepared by heat28

shock for 5 min at 56°C to induce apoptosis. Following particle exposure/heat treatment, cells
were rinsed once with PBS, trypsinized, transferred to 5 mL polystyrene tubes and centrifuged at
1200 rpm for 7 min to pellet. Cell pellets were re-suspended and rinsed twice with 1 mL of PBS
to remove traces of media that may interfere with staining. After rinsing, cells were re-suspended
in ice-cold binding buffer and stained with AV-FITC and PI according to manufacturer
instructions. Samples were analyzed immediately by flow cytometry using a BD FACSCalibur
flow cytometer (Franklin Lakes, NJ).
Particle Internalization and Inhibition Assay: Three cytoskeletal inhibitors, each affecting a
specific pathway, were studied to explore the potential mechanism(s) by which WC-Co particles
could be internalized: 1) MDC; an inhibitor of clathrin-coated pit endocytosis [183], 2)
colchicine; an inhibitor of microtubule polymerization [184] and 3) cytochalasin-D; an inhibitor
of actin filament polymerization [185]. WC-Co particle suspensions were prepared as described
above with the addition of 10 μg/mL MDC, colchicine or cytochalasin-D. Cell viability was
calculated as described above; in this case, control cells received inhibitor treatment only (media
+ 10 μg/mL inhibitor) such that any background toxicity of the inhibitor itself was accounted for
in the resulting cell viability calculation.
Transmission Electron Microscopy (TEM): Following 12 hr, 100 μg/mL WC-Co particle
exposure, cells were washed once with PBS, detached using trypsin/EDTA and collected by
centrifugation at 1200 rpm. Cell pellets were washed twice with PBS and fixed with 2% paraformaldehyde and 2.5% glutaraldehyde in PBS for 0.5 hr at room temperature. Fixed cell
samples were transferred to the West Virginia University Tissue Processing & Imaging Core
Facility for additional processing. Briefly, fixed cell pellets were washed 3 times with PBS, resuspended in warm 2% low-melting point agarose solution and centrifuged at 2000 × g for 5
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min. The resulting gelled pellet was post-fixed in a 1% osmium tetroxide for 2 hr at room
temperature. Post-fixation, the cell pellet was washed 3 times with PBS and dehydrated in a
graded ethanol series followed by propylene oxide. Next, the cells were embedded in SPI-PON
812 solution and polymerized at 60°C for 48 hr. Thin sections (50 nm) were cut and mounted on
copper grids and subsequently imaged using a Zeiss Libra 120 electron microscope at
120 kV(Carl Zeiss Microscopy, Jena, Germany). A minimum of 200 cells were examined for the
presence of WC-Co particles per mounted sample, with at least 20 sample grids examined per
treatment group. The presence of tungsten (W) in cells showing internalized WC-Co particles
was confirmed using electron energy loss spectroscopy (EELS; see Supplementary Material).
Statistical Analyses: All experiments were performed in triplicate and data are presented as
mean ± standard deviation. Statistical analysis was carried out by 2-way analysis of variance
(ANOVA) using GraphPad Prism software (La Jolla, CA). P values < 0.05 were considered
significant.

RESULTS
WC-Co Particle Characterization: Dynamic light scattering analysis of WC-Co particles in
suspension revealed a narrow nano-WC-Co particle size distribution, with a calculated average
particle size of 98 nm verified by TEM imaging (Figure 1A and C). For the micro-WC-Co
particles, size distribution was slightly larger with a calculated average particle size of 3.4 μm,
also confirmed by TEM imaging (Figure 1B and D). EDX analysis of raw WC-Co powder
showed that nano-WC-Co contained oxygen in addition to tungsten and cobalt (Table 1 and
Figure S1, S2).
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WC-Co Effects on Cell Viability and Oxidative Stress: Lung epithelial BEAS-2B cells were
exposed to WC-Co particles at concentrations of 0.1, 1, 10, 100 and 1000 μg/mL for durations of
0.5, 1, 2, 6, 12 and 48 hr. In cells exposed to nano-WC-Co particles (Figure 2A), a significant
reduction in viability (compared to control) was observed at concentrations of 10, 100 and 1000
μg/mL for all the exposure time periods studied. Significant reduction in viability was also
observed at concentrations of 0.1 and 1 μg/mL after 48 hr of exposure. In cells exposed to micro-

Figure 2.1. WC-Co particle characterization via dynamic light scattering (DLS) of A) nano-WC-Co and
B) micro-WC-Co particles suspended in cell culture media (average size = 98 nm and 3.4 μm,
respectively) and representative TEM images of C) nano-WC-Co (scale bar = 500 nm) and D) micro-WCCo (scale bar = 2 μm) particles.
Table 1: Elemental Composition of WC-Co Particles by EDX (Weight %)
Particle Sample
Tungsten (W)
Cobalt (Co)
Carbon (C)
Oxygen (O)
Nano-WC-Co
72.13
13.42
7.63
6.81
(avg. size 98 nm)
Micro-WC-Co
86.53
5.06
8.40
0.00
(avg. size 3.4 μm)
Table 1.1. Elemental composition of nano- and micro-WC-Co particles by weight percentage determined
using energy-dispersive X-ray (EDX).
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Figure 2.2. Cell viability after A) nano-WC-Co and B) micro-WC-Co particle exposure and C) oxidative
stress indicated by DCF fluorescence after exposure to 1000 μg/mL nano- and micro-WC-Co particles.
(*P < 0.05, †P < 0.001 compared to control, ‡P < 0.05 compared to micro-WC-Co)
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WC-Co (Figure 2B), significant reduction in viability (compared to control) was observed at
concentrations of 100 and 1000 μg/mL at 2, 6, 12 and 48 hr of exposure. Significant reduction in
viability was also observed at 1 and 10 μg/mL after 48 hr of exposure. Moreover, nano-WC-Co
particle exposure resulted in significantly higher reduction in cell viability overall compared to
micro-WC-Co particles (Figure S3). For instance, the cell viability following nano-WC-Co
exposure was significantly lower than the viability following micro-WC-Co exposure (Figure
S3) at 1000 μg/mL for all exposure periods studied except at 48 hr, where the cell viability for
both particle exposures was very low (Figure S3F). Significantly lower cell viability was also
observed in nano-WC-Co compared to micro-WC-Co particle exposure at 0.5 hr from 10 to 1000
μg/mL (Figure S3A).
Oxidative stress was measured in the form of DCF/DHE fluorescence after exposure to
WC-Co particles at 0.1, 10, 1000 μg/mL at representative low, moderate and highly toxic particle
concentrations determined in Figure 2A, B. Compared to control, there was a significant
increase in DCF fluorescence in cells exposed to 1000 μg/mL nano- and micro-WC-Co particles
over the exposure periods studied (0.5, 1, 2, 6, 12, and 48 hr) and no significant difference when
exposed to 0.1 and 10 μg/mL (Figure 2C and S4A). Maximal DCF fluorescence was observed
for 1000 μg/mL nano- and micro-WC-Co after 1 hr of exposure, where DCF fluorescence due to
nano-WC-Co exposure was significantly higher than micro-WC-Co (Figure 2C). Compared to
control, there were no significant differences in DHE fluorescence observed for cells exposed to
nano- or micro-WC-Co at any concentration or exposure period tested (Figure S4B).
Induction of Apoptosis in WC-Co Exposed Cells: The total percentage of apoptotic, necrotic
or viable BEAS-2B cells determined by flow cytometry after exposure to WC-Co is shown in

33

Figure 3. Cells stimulated to undergo apoptosis by heat treatments at 56°C were included as a
positive control for reference.

Figure 2.3. Summary of flow cytometry staining profiles after 12 hr WC-Co particle exposure: A) total
percentage of apoptotic cells (AV+/PI+ and AV+/PI-; sum total of upper and lower right quadrants), B)
total percentage of viable cells (AV-/PI-; lower left quadrant) and C) total percentage of necrotic cells
(PI+/AV-; upper left quadrant) (*P < 0.05 compared to control, ‡P < 0.05 compared to micro-WC-Co)
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A dose-dependent increase in the total percentage of apoptotic cells was observed with
increasing WC-Co particle concentration for nano- and micro-WC-Co particles (Figure 3A).
Compared to negative control, a significantly higher percentage of apoptotic cells was observed
at 1000 μg/mL for both nano- and micro-WC-Co particles (Figure 3A). A corresponding dosedependent decrease in the percentage of viable cells was also observed and a significantly lower
percentage of viable cells, compared to control, was found at 1000 μg/mL for both nano- and
micro-WC-Co particles (Figure 3B). The percentage of necrotic cells remained low, less than
1% for cells exposed to nano- and micro-WC-Co (Figure 3C). A significant difference in the
percentage of apoptotic cells was observed at the highest particle concentration of 1000 μg/mL,
where nano-WC-Co treatment showed significantly higher apoptosis than micro-WC-Co
treatment (Figure 3A) and the percentage of viable cells after nano-WC-Co treatment was
significantly lower than micro-WC-Co treatment (Figure 3B).

Particle Internalization and Inhibition: After 6 hr of nano-WC-Co exposure, there was a
significant increase in cell viability compared to control (cells receiving particle treatment only,
no inhibitor) in the presence of MDC, colchicine and cytochalasin D at WC-Co concentrations of
10, 100 and 1000 μg/mL (Figure 4A). After 12 hr, significant increases in cell viability were
observed in the presence MDC and colchicine at 100 μg/mL nano-WC-Co and in the presence of
cytochalasin D at 10, 100 and 1000 μg/mL nano-WC-Co (Figure 4B). After 48 hr, significant
increases in cell viability were observed for MDC and colchicine at 10 and 100 μg/mL whereas
cytochalasin D caused a significant increase in viability for 10, 100 and 1000 μg/mL nano-WCCo (Figure 4C).
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Figure 2.4. Cell viability after exposure to nano- or micro-WC-Co particles in the presence of 10 μg/mL
cytoskeletal inhibitors MDC, colchicine or cytochalasin D after A) 6 hr, B) 12 hr and C) 48 hr. [*P < 0.05,
†
P < 0.001 compared to control (particles only)]
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For cells exposed to micro-WC-Co particles, a significant increase in cell viability was
observed after 6 and 12 hr in the presence of MDC and colchicine at 100 μg/mL WC-Co (Figure
4A and B). In the presence of cytochalasin D, significant increases in cell viability were
observed after 6 hr for 100 and 1000 μg/mL WC-Co and after 12 hr at 10, 100 and 1000 μg/mL
micro-WC-Co (Figure 4A and B). After 48 hr, significant increases in cell viability were
observed for MDC and colchicine at 10 and 100 μg/mL and in the presence of cytochalasin D at
10, 100 and 1000 μg/mL micro-WC-Co (Figure 4C).
Compared to micro-WC-Co exposure, nano-WC-Co particle exposure led to significantly
lower cell viability after 6 hr in the presence of MDC and cytochalasin D at 100 and 1000 μg/mL
and in the presence of colchicine at 1000 μg/mL (Figure S6A, S7A, S8A). After 12 hr of
exposure, nano-WC-Co particles resulted in significantly lower cell viability than micro-WC-Co
particles in the presence of all 3 inhibitors at particle concentration of 1000 μg/mL (Figure S6B,
S7B, S8B). After 48 hr, the cell viability after nano-WC-Co exposure was significantly lower
than that of micro-WC-Co exposure in the presence of MDC at 10 and 100 μg/mL, colchicine at
10 μg/mL and cytochalasin D at 1000 μg/mL (Figure S6C, S7C, S8C).
Representative TEM images of BEAS-2B cells exposed to 100 μg/mL WC-Co particles
for 12 hr are shown in Figure 5. We found that nano-WC-Co particles had been internalized
(visible as distinct black dots, denoted by arrows) and were localized in the cytoplasm within the
outer cell membrane (Figure 5B). For cells exposed to micro-WC-Co, no particles of micron
size were detected within the cells; however, several particles with diameter of approximately
500 nm were found localized in the cytoplasm (Figure 5C). In the presence of cytochalasin D,
no particles were found within the cytoplasm of nano-WC-Co exposed cells (Figure 5D). The
presence of tungsten in representative particle-treated cells (Figure 5) was confirmed using
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EELS, where a definite tungsten peak was identified at ~ 1850 eV (Figure S9) which confirmed
the presence of WC-Co particles within the cytoplasm shown in Figure 5.

Figure 2.5. Representative TEM images of A) non-exposed control cells, B) cells exposed to 100 μg/mL
nano-WC-Co for 12 hr, C) cells exposed to 100 μg/mL micro-WC-Co for 12 hr and D) cells exposed to
100 μg/mL nano-WC-Co plus 10 μg/mL cytochalasin D for 12 hr. Arrows denote WC-Co particles; scale
bars = 0.5 μm.

DISCUSSION
While workplace exposure limits are defined for hard metal manufacturing facilities [7779], it is difficult to predict the resulting lung burden of inhaled WC-Co per person [124] and
challenging to define a relevant dosing scheme for experimental studies. Since exposure limits
are frequently defined on a mass-per-volume basis (i.e. mg per m3), we elected to deliver our
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nano- and micro-WC-Co particles at equivalent mass-per-volume doses and intentionally
encompassed a large concentration range, 0.1 to 1000 μg/mL, to cover the range in total lung
particle mass burden that would be observed in workers exposed through occupational settings.
As shown in Figure 2, nano-WC-Co was significantly more toxic than micro-WC-Co at
concentrations ≥ 10 μg/mL. These data are consistent with our expectations and similar to
toxicity reported in the literature (Bastian et al., 2009, De Boeck et al., 2003, Lombaert et al.,
2012, Lombaert et al., 2004, Lombaert et al., 2008, Busch et al., 2010, Kuhnel et al., 2009,
Kuhnel et al., 2012, Anard et al., 1997). Since reasonable measures were taken to address the
potential artifacts (Figures S10-16) due to particle interference with our in vitro assays [53-56,
186], the differences in our observed toxicity were probably to the smaller size, higher resulting
particle number and increased surface area of the nano-WC-Co compared to the micro-WC-Co
particles. These factors are known to play a critical role in particle toxicity and uptake regardless
of material composition [10, 187-191].
The role of apoptosis in hard metal lung disease remains unclear; however, earlier studies
have demonstrated the apoptogenic potential of WC-Co particles in vitro [148]. Since there are
known roles for the regulation/dysregulation of apoptotic processes in cancer progression [192194] and it is reported that HMLD patients are at a two-fold increased risk of developing lung
cancer [97, 100], it seemed appropriate to examine the effects of WC-Co exposure on the
induction of apoptosis in our lung epithelial cell model [195]. We confirmed that WC-Co
exposure induces apoptosis in exposed cell populations after 12 hr in the present study (Figure 3,
S5). We believe in the possibility that WC-Co induced apoptosis may play a role in HMLD
progression and contribute to the increased risk of lung cancer; however, the exact mechanism
and contribution of these factors remains to be elucidated.
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Interestingly, our apoptosis findings (Figure 3) did not correlate directly with our
viability data shown in Figure 2; greater toxicity was determined in the MTT viability assay than
was observed by quantification of annexin-V-positive (apoptotic/dead) cells in our flow
cytometry assay. We attributed the variance in observed WC-Co toxicity to the differences in
assay methodology and approach: while the MTT assay relies on the conversion of the
tetrazolinium substrate to formazan by live cells, the annexin-V flow cytometry assay relies on
membrane surface staining of exposed phosphatidyl serine (PS) residues, a known marker for
apoptotic cells. In this case, we believe that after WC-Co treatment, some of the cells may have
reduced metabolic function but are not yet undergoing apoptosis, which would be reflected in the
MTT assay as a reduction in viability; however, these same cells would not be quantified as
apoptotic (dead) by the AV-FITC apoptosis assay since they may not yet have externalized PS
residues available for staining. However, our data confirmed that WC-Co is capable of inducing
apoptosis. Additionally, our data regarding the limited capacity of WC-Co particle exposure to
stimulate oxidative stress at low concentrations (<1000 μg/mL, Figure S4) appears to be
consistent with earlier in vitro studies in other cells [138, 140, 143, 144, 153]. Although
oxidative stress has been implicated as the toxic mechanism for other nanomaterials such as
silica or titanium dioxide [51, 52], our data suggest that oxidative stress is probably not a primary
mechanism of WC-Co toxicity.
Hard metal WC-Co particle internalization is of particular interest because hard metal
deposits have been found in lung biopsy specimens from patients with hard metal lung disease
[85, 95, 101, 113, 114, 196-199] which may suggest a potential role for particle internalization
and/or deposition in the disease state. Studying how WC-Co particle internalization occurs in
vitro may offer a better understanding of how these deposits may form in vivo, which may allow
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for the development of improved HMLD treatment strategies or new prophylactic approaches
[200-202] for those at risk of exposure. It has been reported that alveolar epithelial cells are
capable of internalizing nanoparticles (Stearns et al., 2001) and we confirmed in this study that
WC-Co particles are capable of being internalized [132] in our lung epithelial cell model as
shown in Figure 5. Based on our findings from the cytoskeletal inhibitor assay shown in Figure
4, we believe that WC-Co particle internalization plays a role in WC-Co mediated toxicity
because a significant increase in cell viability was observed for all three inhibitors tested when
compared to cells treated with WC-Co particles only.
The extent of this “rescue” effect varied amongst the inhibitors; however, cytochalasin D
appeared to have the most significant effect of the three inhibitors (Figure 4C), so we
hypothesized that actin dynamics and polymerization, inhibited by the presence of cytochalasin
D [185, 203], may play a major role in the internalization of WC-Co particles. Additionally, we
did not find any internalized WC-Co particles in cells treated with cytochalasin D shown in
Figure 5. A significant increase in cell viability was also observed in the presence of colchicine
and MDC, so the potential for multiple mechanisms of internalization cannot be excluded from
this study. Colchicine, known to inhibit microtubule polymerization [184, 204], can interrupt the
formation of endocytic vesicles which may also play a role in WC-Co internalization as indicated
by the increase in cell viability observed in Figure 4. However, colchicine was ineffective at
reducing WC-Co toxicity at the highest concentration of particles after 48 hr (Figure 4C), so we
believe that microtubule-dependent internalization processes are likely secondary to actinmediated processes affected by cytochalasin D. MDC is an inhibitor of clathrin [183, 204] and
specifically blocks clathrin-mediated endocytosis. In our study, MDC caused the least significant
increase in cell viability following WC-Co exposure so we do not believe that clathrin-pit
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mediated endocytosis is a primary mechanism for WC-Co particle internalization. Taken
together, these initial findings suggest a potential role for WC-Co particle internalization in
observed toxicity toward lung epithelial cells.

CONCLUSION
This study examined the toxicity of nano- and micro-sized WC-Co particles and explored
the potential role of particle internalization in observed toxicity toward lung epithelial cells.
Nano-WC-Co was found to be more toxic than micro-WC-Co as expected and we determined
that WC-Co particles are capable of being internalized (via TEM). The presence of cytochalasin
D, colchicine and MDC all caused a reduced toxicity, which suggests that there may be multiple
mechanisms involved in WC-Co internalization and toxicity. Therefore, internalization of WCCo particles by cells lining the respiratory tract and lung is possible and may be a potential
source of hard metal deposits found in HMLD biopsy specimens.
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SUPPLEMENTARY MATERIAL
MATERIALS and METHODS
S1.1 WC-Co Particle Characterization: Micro-WC-Co and nano-WC-Co particles were
analyzed using dynamic light scattering (DLS), transmission electron microscopy (TEM) and
scanning electron microscopy with energy-dispersive x-ray (SEM/EDX) to determine the
average particle/aggregate size in suspension, morphology and elemental composition.
For DLS, stock particle suspensions (5 mg/mL) were prepared by adding 25 mg dry
particle powder to a 20 mL vial containing 5 mL sterile PBS with 10% FBS. The particles were
then sonicated using an Omni International Sonic Ruptor (Kennesaw, GA) for two intervals of
30 sec each to ensure particle dispersion. Dilute particle suspension was then prepared in DMEM
supplemented with 10% FBS and analyzed via DLS using a Malvern Zetasizer 7.01 (Malvern
Instruments Ltd, Malvern, UK). Background absorbance of DMEM containing 10% FBS only
was used to ‘blank’ the instrument prior to measurement of the WC-Co particle suspensions.
For TEM, WC-Co particles were re-suspended in distilled water and vortexed for 60 sec
to remove traces of salt and protein from the culture media which could interfere with TEM
imaging. Five microliters of the resulting suspension was transferred to a carbon-coated copper
grid. Excess liquid was wicked away using filter paper after 30 sec and grids were allowed to
dry for at least 30 min before imaging on a Zeiss Libra 120 electron microscope at 120 kV (Carl
Zeiss Microscopy, Jena, Germany).
For SEM/EDX, raw particle powder was imaged on a JEOL JSM 7600F setup equipped
with an Oxford Instruments energy dispersive x-ray (EDX) system for chemical analysis. EDX
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measurements were carried out in the Point & ID mode with spectrum acquisition time of 120 s
and spectrum range of 0-10 keV.
S1.2 WC-Co Nanoparticle Compatibility with In Vitro Assays: To eliminate potential
artifacts due to the presence of WC-Co particles in the absorbance measurement for the MTT
cell viability assay, nano- and micro-WC-Co suspensions ranging from 0.1 to 1000 μg/mL in
PBS and supplemented DMEM were tested for background absorbance, with and without the
addition of the MTT tetrazolinium dye solution, at 570 nm (primary MTT absorbance
wavelength) and 590 nm (background wavelength). The WC-Co particles did not exhibit any
absorbance in the presence of the MTT dye solution after 2 hr of incubation under assay
conditions (Figure S10).
Similarly, for the oxidative stress assays using DCF and DHE dye solutions, nano- and
micro-WC-Co particles were tested for background fluorescence and interference with the dye
solutions. The WC-Co particles did not exhibit any auto-fluorescence at either of the primary
fluorescence wavelengths for DCF (520 nm) or DHE (620 nm) and did not affect the background
fluorescence of the dye solutions themselves (Figure S11). Additionally, we tested whether WCCo particle addition caused increased fluorescence of DCF/DHE in dye-loaded cells. In a
separate experiment, cells were loaded with dye solution for 30 minutes, spiked with particle
suspensions and resulting fluorescence was read immediately at each wavelength. No changes in
DCF/DHE fluorescence were observed in intact cells under these conditions (Figure S12). After
initial measurement, cells spiked with WC-Co particles were then lysed by the addition of 0.1 %
Triton-X, in order to release the fluorescent DCF/DHE into solution. Resulting fluorescence was
read after 15 min at each wavelength to determine if WC-Co caused changes in fluorescence
under this condition. No changes in fluorescent DCF/DHE intensity were observed, indicating
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that WC-Co particle are inert toward DCF/DHE and there are no artifacts present as the result of
particle-dye interactions (Figure S13).
S1.3 Inhibitor Concentration and Background Toxicity: The selection of inhibitors for this
study was based on the existing literature regarding nanoparticle internalization. Inherent toxicity
of the inhibitors alone was tested over a concentration range of 2-50 μg/mL and a 48 hr exposure
period for colchicine, cytochalasin-D and monodansylcadaverine (MDC). Each inhibitor
exhibited varying effects on cell viability over the course of 48 hr (Figure S14); however, all
three inhibitors maintained reasonable cell viability (80 % of control, un-treated cells) at a
concentration of 10 μg/mL which was further selected for our studies regarding WC-Co particle
internalization. Importantly, for each WC-Co particle internalization experiment, the negative
control (non-particle treated) cells were treated with inhibitor only, so that the background
toxicity of the inhibitors was considered and did not affect our final viability results.
S1.4 WC-Co Nanoparticle Compatibility with Apoptosis Assay: Prior to examining AV/PI
stained cell populations following WC-Co particle exposure, several control tests were
performed on the FACs Calibur to confirm that the particles did not bind the stains or otherwise
interfere with the determination of cell staining profiles. Experiment parameters were set on the
machine using live, unstained cells, positive control (dead, heat-shock) and negative control
(live, untreated) AV/PI stained cells (Figure S15). Gating and laser intensity were set and saved
for further experiments. Once stain and instrument parameters were finalized, nano- and microWC-Co particles were prepared in assay binding buffer at the maximum concentration tested
(1000 μg/mL) and run through the instrument to exclude any potential background or
interference of the particles with various assay components (Figure S16).
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S1.5 Electron Energy Loss Spectroscopy (EELS): To confirm the presence of WC-Co
nano/micro-particles in cell samples imaged via TEM, EELS measurements were obtained on a
Zeiss Libra 120 Transmission Electron Microscope equipped with a Gatan Imaging Filter (GIF)
Tridiem spectrometer with an UltraScan 1000 FT detector. Cumulative M5 edge spectra were
collected, centered at an energy loss of 1970 eV with a collection time of 10s. The resulting
tungsten (W) peak appears at ~1850 eV. The power law background model in Digital
Micrograph software (Gatan, Inc., Pleasanton, CA, USA) was used to model the energydependence of the background signal.
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FIGURES

Figure S1. EDX spectra for elemental composition by weight (%) for A) nano-WC-Co and B)
micro-WC-Co; insets depict scanned powder area.
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Figure S2. Representative SEM images of raw A) nano-WC-Co and B) micro-WC-Co powders
used for EDX compositional analysis; scale bars = 1 μm.
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Figure S3. Comparison of cell viability after exposure to nano- and micro-WC-Co for A) 0.5 hr,
B) 1 hr, C) 2 hr, D) 6 hr, E) 12 hr and F) 48 hr. (*P < 0.05, †P < 0.001 compared to control, ‡P <
0.05 compared to micro-WC-Co)
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Figure S4. Relative fluorescence of A) DCF and B) DHE as markers of oxidative stress
following exposure to nano- and micro-WC-Co particles. (*P < 0.05 compared to control, ‡P <
0.05 compared to micro-WC-Co at the same exposure time)
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Figure S5. Representative flow cytometry plots illustrating annexin-V (AV) and propdium
iodide (PI) stained cell populations following 12 hr exposure to A) 1000 μg/mL nano-WC-Co
and B) 1000 μg/mL micro-WC-Co. Percentages of stained cells are listed in each respective
quadrant: lower left (PI‒/AV‒; viable), lower right (PI‒/AV+; early apoptotic), upper right
(PI+/AV+; late apoptotic), upper left (PI+/AV‒; necrotic).
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Figure S6. Comparison of cell viability in presence of nano- and micro-WC-Co plus 10 μg/mL
MDC after A) 6 hr, B) 12 hr and C) 48 hr of exposure. [*P < 0.05, †P < 0.001 compared to
control (WC-Co only), ‡P < 0.05 compared to micro-WC-Co + MDC]
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Figure S7. Comparison of cell viability in presence of nano- and micro-WC-Co plus 10 μg/mL
colchicine after A) 6 hr, B) 12 hr and C) 48 hr of exposure. [*P < 0.05, †P < 0.001 compared to
control (WC-Co only), ‡P < 0.05 compared to micro-WC-Co + colchicine]
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Figure S8. Comparison of cell viability in presence of nano- and micro-WC-Co plus 10 μg/mL
cytochalasin D after A) 6 hr, B) 12 hr and C) 48 hr of exposure. [*P < 0.05, †P < 0.001 compared
to control (WC-Co only), ‡P < 0.05 compared to micro-WC-Co + cytochalasin D]
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Figure S9. Electron energy loss spectra (EELS) for cell samples scanned for the presence of
internalized WC-Co particles using TEM, confirming the presence of tungsten (W) ~1850 cV in
the A) cumulative and B) power law fitted curves.
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Figure S10. Background absorbance of DMEM containing MTT reagent (tetrazolinium salt)
under assay conditions in the absence (blank/0) and presence of WC-Co particles to confirm the
absence of artifacts at 570 nm, the primary absorbance wavelength for formazan detection.
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Figure S11. Background fluorescence of blank (PBS + dye only) and WC-Co particle
suspensions in the absence of cells to confirm the absence of artifacts at the primary emission
wavelengths for A) DCF at 520 nm and B) DHE at 620 nm.
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Figure S12. Background fluorescence in dye-loaded cells after being spiked with WC-Co
particle suspensions to confirm the absence of artifacts at the primary emission wavelengths for
A) DCF at 520 nm and B) DHE at 620 nm.
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Figure S13. Background fluorescence in dye-loaded cells after being spiked with WC-Co
particle suspensions and lysed, releasing fluorescent dyes into solution in order to confirm the
absence of artifacts due to particle interference at the primary emission wavelengths for A) DCF
at 520 nm and B) DHE at 620 nm.
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Figure S14. Cell viability in the presence of colchicine, monodansylcadaverine (MDC) and
cytochalasin D after 48 hr of exposure. Cell viability in presence of inhibitor calculated based on
absorbance of untreated control cells (no inhibitor).
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Figure S15: Representative flow cytometry dot plots illustrating gating parameters set for A)
live, unstained cells, B) live, stained cells (neg. control; AV + PI) and C) heat-shocked dead cells
(pos. control; AV + PI).
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Figure S16: Representative scatter and dot plots showing the background of WC-Co particles in
the flow cytometry apoptosis assay in the presence of assay binding buffer, AV-FITC and PI for
A-B) nano-WC-Co and C-D) micro-WC-Co. Gates in B, D set based on control parameters
shown above in Figure S14.
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CHAPTER 3:

The Inflammatory Effects of Hard Metal (WC-Co) Nanoparticle
Exposure in vitro: Mono-culture vs. Co-culture Models

Original dissertation research completed in fulfillment of
Specific Aim #2
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ABSTRACT
Identifying the toxicity of nanoparticles is an important area of research as the number of
nanomaterial-based consumer and industrial products continually rises. In addition, the potential
inflammatory effects resulting from pulmonary nanoparticle exposure are emerging as an
important aspect of nano-toxicity. In this study, we examined the toxicity and inflammatory state
resulting from tungsten carbide cobalt (WC-Co) nanoparticle exposure in macrophages and a coculture of lung epithelial cells (BEAS-2B) and macrophages (THP-1) at a 3:1 ratio. We found
that the toxicity of nano-WC-Co was cell dependent; significantly less toxicity was observed in
THP-1 compared to BEAS-2B cells. We demonstrated that nano-WC-Co caused reduced toxicity
in our co-culture model compared to lung epithelial cell mono-culture, which suggested that
macrophages may play a protective role against nano-WC-Co mediated toxicity in co-cultures.
Nano-WC-Co exposure in macrophages resulted in increased levels of interleukin-1beta (IL-1β)
and interleukin-12 (IL-12) secretion and decreased levels of tumor necrosis factor (TNFα). In
addition, the polarizing effects of nano-WC-Co exposure toward the M1 (pro-inflammatory) and
M2 (anti-inflammatory) macrophage phenotypes were investigated. The results of this assay
indicated that nano-WC-Co exposure stimulated the M1 phenotype, marked by high expression
of CD40 M1 macrophage surface markers.

Keywords: nanoparticle, nanotoxicity, inflammation, cytokine, macrophage, lung disease,
cancer
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INTRODUCTION
The majority of nanomaterial or nanoparticle (NP) exposure occurs via the pulmonary
route [30, 37] and, upon inhalation, macrophages are recruited to the area as part of the body’s
defense mechanism to promote particle clearance from the lungs [205, 206]. Phagocytic by
nature, macrophages will quickly identify and engulf the NPs as part of their inherent
physiological response mechanism [206, 207]. However, during this process, the macrophage
accumulates a large quantity of NPs. Depending on the NP, this accumulation within the cell
may cause toxicity or induce a secondary immune response and stimulate a local or systemic
inflammatory process [63, 170, 207-209]. Therefore, along with addressing the directly toxic
effects of the multitude of NPs currently used in consumer products today, it is important to
consider the inflammatory response which these materials may generate upon exposure [207].
Macrophage mediated inflammation typically occurs in response to bacterial or viral
infections and tissue injuries as a part of the normal healing process, but it can also occur as a
result of foreign particle inhalation [207, 210]. Depending on the stimulus, macrophages
differentiate into either a “classically” activated M1 or “alternatively” activated M2 phenotype,
which have signature characteristics that distinguish them from one other [211-217]. Classical
M1 macrophages play important roles in infection clearance, typically in response to
lipopolysaccharide (LPS), which stimulates a high level secretion of pro-inflammatory cytokines
such as tumor necrosis factor alpha (TNFα) and interleukin 12 (IL-12) and promotes a type 1 T
helper (Th1) immune response [211-213, 217]. Macrophages activated by other factors, such as
endogenous interleukin 4 (IL-4) or glucocorticoid hormones, fall under the alternatively
activated M2 phenotype. M2 macrophages generally secrete high levels of interleukin 10 (IL-10)
and interleukin 1-beta (IL-1β) to promote the type 2 T helper (Th2) immune response [211-213,
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217]. Additionally, emerging evidence indicates that macrophage activation/polarization toward
the M1 or M2 phenotype may play critical roles in tumor growth and cancer progression [210,
211, 218, 219]. It is thought that M1 macrophages promote tumor resistance, due to their highlevel secretion of pro-inflammatory cytokines and potent effector cell functions [212, 213]. In
contrast, M2 macrophages are believed to possess tumor promoting functions due to their
promotion of angiogenesis, tissue remodeling and repair mechanisms [212, 213]. Further, the
tumor microenvironment can influence tumor associated macrophages to undergo a “phenotypic
switching” from M1 to M2, and thus tumor-promoting, phenotype [212, 218].
Given this body of literature, it has been suggested that inflammation resulting from
pulmonary NP exposure may play a role in the toxicity associated with exposure [33, 40, 63, 66,
170, 176, 207-209, 220, 221] and that the inflammatory state resulting from particle exposure
may play a role in cancer progression [207, 210]. This is especially concerning in occupational
settings [18, 75, 78, 79] where workers undergo pulmonary exposure to NPs on a daily basis [98,
176]. In particular, exposure to tungsten carbide cobalt NPs (nano-WC-Co) in occupational
settings is known to cause hard metal lung disease (HMLD), characterized by progressive
inflammation and fibrosis of the lung [85, 101, 104, 105, 113, 114, 118, 129], which is further
associated with a two-fold increased risk of lung cancer [97, 100, 107]. While the toxicity of
WC-Co particles has been studied [128, 130-134, 137, 139, 141, 143, 147-153, 155-157, 159,
161, 222, 223], the relationship between WC-Co toxicity, inflammation and lung cancer remains
poorly understood.
Additionally, there is limited information regarding the interaction of multiple cell types
during WC-Co NP exposure (i.e. immune cells and epithelial cells), as the majority of previous
in vitro studies employed single cell (mono-culture) models in their examination of WC-Co
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toxicity [130, 132-134, 141-144, 146-149]. This design is a disadvantage, as co-culture models
may more closely represent the in vivo environment during a WC-Co NP exposure. To address
this gap in understanding, the present study examined the effects of nano-WC-Co particle
exposure in vitro using mono- and co-culture cell models composed of macrophages (THP-1)
and lung epithelial cells (BEAS-2B) to assess the toxicity, stimulation of inflammatory cytokine
secretion and M1/M2 macrophage polarization. We hypothesized that exposure to nano- WC-Co
stimulates inflammation in macrophages and may promote polarization toward the M1 proinflammatory macrophage phenotype.

MATERIALS and METHODS
Materials and Reagents: THP-1 (TIB-202) human monocyte cell line (TIB-202) was purchased
from American Type Culture Collection (ATCC; Manassas, VA) and BEAS-2B cells (originally
purchased from ATCC) were obtained from the laboratory of Yon Rojanasakul. Nano-WC-Co
(tungsten carbide cobalt) composite particles were purchased from Inframat Advanced Materials
(Manchester, CT). RPMI-1640 media for THP-1 cell culture was purchased from ATCC.
Phosphate buffered saline (PBS), Dulbecco’s Modified Eagle Media (DMEM), 0.25%
trypsin/ethylenediaminetetraacetic acid (EDTA), versene (EDTA-based cell detachment
reagent), penicillin/streptomycin, beta-mercaptoethanol and fetal bovine serum (FBS) were
purchased from Lonza (Allendale, NJ). Isopropanol, hydrochloric acid, Triton-X-100, thiazolyl
blue

tetrazolinium

bromide

(MTT

reagent),

phorbol-12-mystirate-13-acetate

(PMA),

lipopolysaccharide (LPS) and enzyme-linked immunosorbent assay (ELISA) kits for human IL12p70 (#RAB0252), IL-10 (#RAB0244), IL-1β (#RAB0273) and TNFα (#RAB0476) were
purchased from Sigma-Aldrich (St. Louis, MO). Flow cytometry staining buffer (containing
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0.2% bovine serum albumin and sodium azide), recombinant human IL-4, human IgG, antihuman CD-40-APC and anti-human CD-206-FITC antibodies were purchased from BD
Biosciences (Franklin Lakes, NJ).
Nano-WC-Co Particle Preparation: Nano-WC-Co stock particle suspensions (5 mg/mL) were
prepared in sterile PBS (containing 10% FBS to prevent agglomeration) by sonication under 120
watts power output, frequency 20 kHz, for 1 min with an Omni International Sonic Ruptor
(Kennesaw, GA). Sonication was performed in 30 mL plastic vials immobilized in an ice bath to
prevent heating during particle dispersion. Dilute nano-WC-Co particle suspensions (1 to 1000
μg/mL) were prepared on the day of each experiment in DMEM containing 10 % FBS from the 5
mg/mL stock particle suspension.
Cell Culture and THP-1 Macrophage (M0) Activation: BEAS-2B cells were maintained and
passaged

upon

confluence

in

DMEM

supplemented

with

10%

FBS

and

1%

penicillin/streptomycin. THP-1 cells were maintained and passaged upon confluence in RPMI1640 supplemented with 10% FBS, 1% penicillin/streptomycin and 0.5 mM betamercaptoethanol. All cells were maintained in an incubator at 37° C and 5% CO2. Differentiation
of THP-1 cells to macrophages (M0) was achieved through the addition of 10 ng/mL PMA. After
48hr, THP-1 to M0 differentiation was confirmed via examination of cell morphology using a
light microscope [215, 224], where M0 cells underwent a signature change in morphology and
became adherent to the culture dish. For co-culture, M0 cells were rinsed once with PBS and
incubated with versene (EDTA-based cell dissociation reagent) for 15 min. M0 were then
pipetted gently to ensure detachment from the culture dish and re-suspended in DMEM at the
desired concentration for co-culture seeding.
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Macrophage and Epithelial Cell Co-Culture: To establish the co-culture (CC) at a ratio of 3:1
(lung epithelial cell: macrophage), BEAS-2B cells were trypsinized, re-suspended in DMEM and
seeded in a 96-well plate at a density of 1.5 × 105 cells/mL and allowed to adhere for 1 hr.
BEAS-2B attachment was confirmed using light microscopy prior to the addition of M0 cells.
M0 cells were seeded directly on top of the BEAS-2B monolayer at a density of 5 × 104 cells/mL
in DMEM and co-cultured for 24 hr to allow attachment and cellular interaction prior to nanoWC-Co exposure.
Nano-WC-Co Particle Exposure: Nano-WC-Co particle exposure was achieved by aspirating
the media from each well and replacing immediately with an equivalent volume of nano-WC-Co
particle suspension at a concentration of 1, 10, 100 or 1000 μg/mL and incubated at 37° C and
5% CO2 for exposure periods of 2, 6, 12, 24 and 48 hr; controls were treated with LPS (100
ng/mL) or IL-4 (20 ng/mL). For the M1/M2 flow cytometery experiments, M0 cells were treated
with either control LPS, IL-4 or 0, 1, 10 and 100 μg/mL nano-WC-Co for exposure periods of 1,
2 and 5 days.
Cell Viability after Nano-WC-Co Exposure: Following nano-WC-Co exposure, the media
containing nano-WC-Co was aspirated from each well and cells were rinsed once with PBS to
remove excess particles. Then, 100 μL un-supplemented DMEM was added to each well,
followed by the addition of 10 μL MTT reagent to achieve a final concentration of 0.5 mg/mL
MTT per well. Cells were incubated for 2 hr at 37° C and 5% CO2 to allow conversion of the
soluble tetrazolinium salt (yellow) to formazan crystals (purple). Crystal formation was
confirmed using light microscopy. Next, 100 μL of solubilization solution (0.1 M HCl in
isopropanol containing 10% Triton-X) was added to each well to dissolve the formazan crystals
and the absorbance of each well was recorded immediately at 570 nm using a Bio-Tek μQuant
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microplate reader (Winooski, VT). Blank values were subtracted from all absorbance readings.
Cell viability was calculated by dividing the absorbance of nano-WC-Co treated cells by the
absorbance of control cells receiving media treatment only and converted to a percentage.
Macrophage Polarization Assay: THP-1 cells were seeded at a density of 5 × 105 cells/mL in
RPMI-1640 containing 10 ng/mL PMA in a 12-well culture dish and incubated for 48 hr to
stimulate M0 cell differentiation. Media were then aspirated from each well and replaced with
DMEM containing 100 ng/mL LPS (M1 stimulus/positive control), 20 ng/mL IL-4 (M2
stimulus/positive control) and 0, 1, 10 or 100 μg/mL nano-WC-Co particles. M0 cells were
incubated with the M1, M2 or nano-WC-Co stimulus for 1, 2 and 5 days at 37° C and 5% CO2.
Flow Cytometry: Following M1/M2/WC-Co exposure, M0 cells were rinsed once with PBS,
detached with versene (described above) and transferred to 15 mL polystyrene tubes. Cells were
centrifuged at 1200 rpm for 7 min to pellet and re-suspended in 1 mL ice-cold flow cytometry
staining buffer. M0 cells were counted on a hemocytometer and a total of 3 × 105 cells per
sample were transferred to 5 mL polystyrene tubes for subsequent staining. After centrifugation,
cell pellets were re-suspended in 100 μL staining buffer containing 10 μg human IgG and
incubated for 30 min over ice to block macrophage Fc receptors and minimize non-specific
antibody binding. Next, cells were rinsed with 1 mL cold staining buffer to remove excess IgG
and re-suspended in 80 μL buffer. 10 μL of each antibody (anti-CD-40-APC or anti-CD-206FITC) was added to each appropriate tube, including positive/negative and single-stain controls
and incubated for 1 hr over ice. After staining, cells were rinsed 3 times with 1 mL cold staining
buffer to remove unbound antibodies. After the final rinse, cell pellets were re-suspended in 100
μL 0.4% paraformaldehyde to fix and stored overnight at 4° C. The next day, fixed cells were
centrifuged, re-suspended in 300 μL staining buffer and analyzed immediately on a BD LSR
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FORTESSA flow cytometer. Instrument settings were defined at the beginning of each
experiment using the cells only (no stain) and single-stain controls (CD40-APC only and
CD206-FITC only) and applied for all subsequent experimental samples.
Inflammatory Cytokine Secretion in response to Nano-WC-Co Exposure: The concentration
of IL-12, IL-10, IL-1β and TNFα in cell culture supernatants was determined using an enzymelinked immunosorbent assay (ELISA) kit. Following nano-WC-Co exposure, cell culture
supernatants were collected after 6, 12, 24 and 48 hr in 150 μL aliquots in a 96-well plate and
preserved immediately at -80° C for later analysis. Once all supernatant samples had been
collected, the 96-well plates were quickly thawed at room temperature and centrifuged briefly
(500 rpm for 5 min) to pellet any cell debris or nano-WC-Co particles which may interfere with
the assay. The ELISA assays were then carried out according to manufacturer instructions.
Briefly, 100 μL supernatant or cytokine standard (prepared according to instructions) was
transferred to the appropriate well(s) of the 96-well ELISA plate and incubated at room
temperature for 2.5 hr with gentle shaking. Next, the solutions were discarded and each well was
rinsed 4 times with prepared 1x wash buffer according to instructions. Following the rinse step,
100 μL of biotinylated antibody was added to each well and incubated for 1 hr with gentle
shaking. Next, solutions were discarded, the rinse step was repeated, followed by the addition of
100 μL streptavidin solution to each well and incubated for 45 min with gentle shaking. Then,
solutions were discarded, the rinse step was repeated and 100 μL of TMB one-step substrate
reagent was added to each well. Plates were incubated in the dark for an additional 30 min with
gentle shaking, followed by the addition of 50 μL stop solution to each well. Plate absorbance
was read immediately at 450nm. Standard curves were prepared in duplicate for each ELISA
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plate. The concentration of cytokine(s) in each supernatant sample was then calculated based on
the sample absorbance at 450 nm and the slope of the standard curve according to instructions.
Statistical analyses: All experiments were performed in triplicate and data are presented as
mean ± standard deviation. Statistical analysis was carried out by 2-way analysis of variance
(ANOVA) using GraphPad Prism software (La Jolla, CA). P values < 0.05 were considered
significant.

RESULTS
Nano-WC-Co Characterization: Nano-WC-Co particles were prepared and characterized as
previously described [222]. Briefly, nano-WC-Co particles averaged 98 nm in diameter in
suspension determined by dynamic light scattering and transmission electron microscopy.
Compositional analysis by energy-dispersive x-ray (EDX) determined that nano-WC-Co
contained 72.13% tungsten, 13.42% cobalt, 7.63% carbon and 6.81% oxygen.
Co-Culture Viability: Macrophages (THP-1), lung epithelial cells (BEAS-2B) and a 3:1 coculture of BEAS-2B and THP-1 cells were exposed to nano-WC-Co at concentrations of 1, 10,
100 and 1000 μg/mL for durations of 2, 6, 12, 24 and 48 hr. In macrophage mono-culture (THP1), nano-WC-Co exposure did not induce significant changes in cell viability (compared to
control) at 1 μg/mL but did induce a significant reduction in cell viability at 10 μg/mL after 48
hr, at 100 μg/mL after 6, 12, 24 and 48 hr and at 1000 μg/mL after 2, 6, 12, 24 and 48 hr of
exposure (Figure 1). Consistent with our previous report [222], nano-WC-Co exposure caused a
significant reduction in cell viability in lung epithelial cells (BEAS-2B) at 1 μg/mL after 24 and
48 hr and at ≥ 10 μg/mL after 2, 6, 12, 24 and 48 hr of exposure (Figure 1). The viability in
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THP-1 cells was significantly higher compared to BEAS-2B mono-culture at 1 μg/mL after 2, 6
and 48 hr and at 10, 100 and 1000 μg/mL after 2, 6, 12, 24 and 48 hr nano-WC-Co exposure
(Figure 1).
In the co-culture of BEAS-2B and THP-1 cells, nano-WC-Co exposure did not lead to
significant changes in cell viability at 1 μg/mL but caused a significant reduction in cell viability
(compared to control) at 10 μg/mL after 24 and 48 hr and at 100 and 1000 μg/mL after 2, 6, 12,
24 and 48 hr of exposure (Figure 1). Compared to BEAS-2B mono-culture, an increased cell
viability was observed in the co-culture model at 1 μg/mL after 24 and 48 hr, at 10 μg/mL after
2, 6, 12, 24 and 48 hr, at 100 μg/mL after 2, 24 and 48 hr and at 1000 μg/mL after 2 and 6 hr of
exposure (Figure 1).

Figure 3.1. Cell viability after exposure to A) 1 μg/mL, B) 10 μg/mL, C) 100 μg/mL and D) 1000 μg/mL
nano-WC-Co particles in macrophages (THP-1), lung epithelial cells (BEAS-2B) and 3:1 co-culture
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(BEAS-2B:THP-1). (*P < 0.05, †P < 0.01 compared to control; ‡P < 0.05 compared to BEAS-2B
monoculture)

Macrophage Polarization: Macrophage polarization toward the M1 and M2 phenotypes
was examined after exposure to LPS (M1 positive control), IL-4 (M2 positive control) and 0, 1,
10 or 100 μg/mL nano-WC-Co for 1, 2 and 5 days. Cells staining positive for CD40-APC were
considered M1-type macrophages and cells staining positive for CD206-FITC were considered
M2-type macrophages. A summary of M1 and M2 flow cytometry staining is presented
graphically in Figure 2. Representative dot plots depicting M1/M2 macrophage staining after
exposure to nano-WC-Co for 1, 2 and 5 days are shown in Figure 3 (1 μg/mL), Figure 4 (10
μg/mL) and Figure 5 (100 μg/mL). Compared to the control group (0 μg/mL nano-WC-Co), for
the staining control samples used to set the instrument gating parameters, a significant increase
in CD40+ stained cells was observed following LPS exposure for 1, 2 and 5 days; IL-4 exposure
caused a significant increase in CD206+ cells after 2 and 5 day exposure (Figure S2).
In general, CD40+ staining was dominant in all the samples at the exposure periods
studied (Figure 2). Compared to the control group (0 μg/mL WC-Co), cells exposed to 1 and 10
μg/mL nano-WC-Co had significantly higher CD40+ staining after 5 days of exposure. Exposure
to 10 μg/mL nano-WC-Co also caused a significant increase in CD40+ cells after 1 day and cells
exposed to 100 μg/mL demonstrated significantly lower numbers of CD40+ cells after 2 and 5
days of exposure (Figure 2A). Further, cells exposed to 1, 10 and 100 µg/mL nano-WC-Co had
significantly less CD206+ cells after 5 days of exposure compared to the control group (0 μg/mL
WC-Co) (Figure 2B). With increasing nano-WC-Co exposure time from day 1 to day 2 and day
5, an increase in the ratio of M2/M1 was found; the ratio of M2/M1 was significantly higher after
5 days compared to 1 day for 1, 10 and 100 100 µg/mL nano-WC-Co (Figure 2C).
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Figure 3.2. Summary of macrophage flow cytometry staining as total percentage of A) CD40+/M1, B)
CD206+/M2 and C) M2/M1 ratio after exposure to nano-WC-Co particles for 1, 2 and 5 days. (*P < 0.05
compared to 0 μg/mL (M0) control (2A, B) and †P < 0.01 compared to 1 day (2C))
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Figure 3.3. Representative flow cytometry dot plots depicting macrophage staining after exposure to 1
μg/mL nano-WC-Co particles for A) 1 day, B) 2 days and C) 5 days. CD40-APC as surface marker of
M1-type macrophages and CD206-FITC as surface marker of M2-type macrophages.
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Figure 3.4. Representative flow cytometry dot plots depicting macrophage staining after exposure to 10
μg/mL nano-WC-Co particles for A) 1 day, B) 2 days and C) 5 days. CD40-APC as surface marker of
M1-type macrophages and CD206-FITC as surface marker of M2-type macrophages.
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Figure 3.5. Representative flow cytometry dot plots depicting macrophage staining after exposure to 100
μg/mL nano-WC-Co particles for A) 1 day, B) 2 days and C) 5 days. CD40-APC as surface marker of
M1-type macrophages and CD206-FITC as surface marker of M2-type macrophages.
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Inflammatory Cytokine Secretion: The levels of inflammatory cytokines were quantified in the
cell culture supernatant via ELISA after 6, 12, 24 and 48 hr of exposure to 0, 1, 10 or 100 μg/mL
nano-WC-Co (Figure 6) and either LPS (M1 stimulus) or IL-4 (M2 stimulus) (Figure S3).
Nano-WC-Co treatment caused varying effects on TNFα secretion (Figure 6A); 1 μg/mL nanoWC-Co caused a significant increase in TNFα after 6 hr of exposure, compared to control (0
μg/mL), but the levels were significantly lower after 12, 24 and 48 hr of exposure. A decrease in
TNFα, compared to control (0 μg/mL), was also observed at 10 μg/mL after 24 and 48 hr and at
100 μg/mL after 12, 24 and 48 hr exposure to nano-WC-Co (Figure 6A).
In the IL-1β assay (Figure 6B), 1 μg/mL nano-WC-Co treatment caused a significant
increase in IL-1β levels, compared to control (0 μg/mL), after 12 and 24 hr of exposure. In the 10
μg/mL nano-WC-Co group, a significant increase in IL-1β was found at exposures of 12, 24 and
48 hr. Compared to control (0 μg/mL), 100 μg/mL nano-WC-Co exposure led to a significant
decrease in IL-1β after 6 and 12 hr and a significant increase after 24 hr followed by a significant
decrease after 48 hr of exposure (Figure 6B).
For IL-12 (Figure 6C), exposure to 1 μg/mL nano-WC-Co caused a significant increase
compared to control (0 μg/mL) after 12 hr exposure.

10 μg/mL nano-WC-Co caused a

significant increase in IL-12 after 12 and 48 hr of exposure and 100 μg/mL nano-WC-Co also
caused a significant increase in IL-12 (compared to control) after 6, 12 and 48 hr of exposure
(Figure 6C).
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Figure 3.6. Secretion of pro-inflammatory cytokines A) TNFα, B) IL-1β and C) IL-12 in cell culture
supernatant as markers of inflammation following nano-WC-Co exposure. (*P < 0.05, †P < 0.01
compared to 0 μg/mL (M0) control)
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DISCUSSION
Due to the increased use of nanoparticles (NP) in consumer and industrial applications
[3], there is a critical need to clearly define the toxic and inflammatory effects of NP which occur
after exposure. We recently reported that commercially prepared nano-WC-Co particles induced
a time- and dose-dependent toxicity in human lung epithelial cells (BEAS-2B) and were capable
of being internalized, inducing oxidative stress and stimulating apoptotic cell death in vitro
[222]. Since macrophages play a critical role in promoting natural pulmonary particle clearance
mechanisms, an important aspect of the current study was to define the toxic effects of nanoWC-Co particle exposure on macrophages in both mono- and co-culture settings. To test the
effects of nano-WC-Co particle exposure on macrophage-mediated inflammation and M1/M2
polarization, we selected monocyte-derived THP-1 cells as our macrophage model due to their
prevalence in the literature and the ease with which THP-1 cells are differentiated toward a
macrophage (M0) phenotype with PMA [215, 217, 224, 225]. Here, a 3:1 co-culture ratio of
BEAS-2B to THP-1 M0 was selected to represent the dynamic tissue environment within the
lung during a particle inhalation scenario [226, 227]; the viability was compared between THP-1
and BEAS-2B mono-cultures and the 3:1 co-culture system.
Due to the inherent phagocytic nature of macrophages, we hypothesized that the presence
of THP-1 M0 in the co-culture model would offer a “protective effect” against nano-WC-Co
toxicity; therefore, increased viability would be observed in the co-culture system compared to
BEAS-2B cells alone. In this case, the results of our cell viability study (Figure 1) are consistent
with our hypothesis and we believe that macrophage engulfment of nano-WC-Co isolated the
particles and prevented direct contact with the BEAS-2B cells, effectively attenuating nano-WCCo toxicity to the extent reported previously in BEAS-2B cells [222]. In fact, the toxicity of
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nano-WC-Co was found to be cell dependent and significantly less toxicity was observed in
macrophages compared to BEAS-2B cells (Figure 2). While the 1000 μg/mL dose is very high,
we believe that it is relevant because the resulting lifetime accumulation of nano-WC-Co
particles in the lung from occupational settings could be substantial. This idea is supported by
histological findings in HMLD patients, where large deposits of WC-Co are often visible in lung
specimens [113, 114, 123, 124].
Macrophage polarization following exposure to other metal NPs has been reported
elsewhere [228], so we explored the effects of nano-WC-Co exposure on macrophage
polarization toward the M1 or M2 phenotype using flow cytometry by staining for two wellknown macrophage cell membrane markers: CD40 as an M1 surface marker and for CD206
(mannose receptor), as an M2 macrophage surface marker [214, 215, 217]. Overall, high levels
of CD40+/M1 staining were observed in nano-WC-Co particle exposed groups (Figure 2A) and
in the LPS-stimulated M1 positive control group (Figure S2A). The prevalence of CD40+/M1
staining was much higher in nano-WC-Co exposed groups than CD206+/M2 staining; while a
slight increase in CD206+/M2 staining was observed at 5 days compared to 1 and 2 days after
nano-WC-Co exposure, overall, the levels of CD206+/M2 macrophages were significantly lower
than the control (0 μg/mL) group (Figure 2B). It seems that the ratio of M2/M1 increased with
increasing exposure time (Figure 2C).
Therefore, at least in terms of surface marker expression, nano-WC-Co particles appear
to induce strong CD40 expression, typical of an M1 classically activated phenotype, rather than
increased levels of CD206 expression associated with M2 alternatively activated macrophages.
However, there are a few potential limitations which may have contributed to the lack of
CD206+ macrophages in our cell populations. Upon stimulation with PMA, THP-1 macrophages
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became extremely adherent to the culture dish and were difficult to detach for membrane surface
staining, so it is possible that CD206 membrane receptors may have been damaged during the
detachment process, causing low numbers of CD206+ cells overall. Additionally, in our control
(0 μg/mL) group, receiving PMA treatment only, a high level of CD40+/M1 staining was
observed, which may indicate a predisposition toward the M1 surface markers in our control
cells.
Next, we examined the secretion of pro-inflammatory cytokines including TNFα, IL-1β
and IL-12 over an exposure period ranging from 6 to 48 hr to determine the effects of nano-WCCo exposure on cytokine expression over time (Figure 6). Given the strong CD40+/M1-type
inflammatory macrophage surface marker expression in our flow cytometry assay, we expected
to see complimentary induction of pro-inflammatory cytokines in our ELISA assay. Typically,
TNFα is secreted by activated macrophages and plays a primary role in the inflammatory
immune response associated with infections due to bacterial or viral pathogens, such as
promoting neutrophil chemotaxis and inducing acute phase proteins (C-reactive protein) [229].
A mixed TNFα response was observed in nano-WC-Co macrophages compared to the control
group, with higher levels after 6 hr exposure to low concentration (1 μg/mL) but similar or lower
levels of TNFα compared to control at 10 and 100 μg/mL (Figure 6A).
IL-1β is a potent inflammatory cytokine that plays a critical role in the immune response
to infection by promoting adhesion factors on endothelial cells, which allows for migration of
macrophages and neutrophils to the site of infection [230]. IL-1β is known to enhance systemic
inflammation and mediate auto-immune disorders, such as rheumatoid arthritis [230, 231]. In
contrast to TNFα, significantly higher levels of IL-1β, compared to control, were observed in all
three nano-WC-Co treatment groups after 24 hr of exposure and for the 1 and 10 μg/mL groups
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after 12 hr (Figure 6B). Since IL-1β is produced largely by activated macrophages, the induction
of high levels of IL-1β secretion may indicate a pro-inflammatory response and increased
activation in macrophages exposed to nano-WC-Co particles.
IL-12 is known to induce phagocytic activation of macrophages, natural killer cells and
cytotoxic T-lymphocytes as part of the innate immune response to bacterial, parasitic or
intracellular infections [232-237]. IL-12 also acts as an inducer of other cytokines, such as
interferon-gamma (IFNγ). Like IL-1β, IL-12 may also contribute to chronic inflammation in
rheumatoid arthritis, psoriasis and other immune disorders [232]. In our THP-1 macrophage
model, nano-WC-Co exposure also stimulated IL-12 secretion, since significantly higher IL-12
levels were found in nano-WC-Co treated cells, compared to control, after 12 hr of exposure
(Figure 6C).
Additionally, it is worth considering how the toxic effects of nano-WC-Co particles
toward THP-1 macrophages (Figure 1) may have impacted the results of our inflammatory
cytokine assay. In general, the 1 μg/mL nano-WC-Co dose was non-toxic up to 48 hr in our
viability assay, so higher observed levels of TNFα, IL-1β and IL-12 at this concentration are
likely to reflect increased inflammatory cytokine secretion overall in nano-WC-Co exposed
macrophage populations. In contrast, significant toxicity was observed after 48 hr exposure to 10
μg/mL nano-WC-Co, so the lower levels of secreted inflammatory cytokines at this
concentration seem consistent with increased nano-WC-Co toxicity at this time point. 100 μg/mL
nano-WC-Co was toxic toward THP-1 macrophages at 6 hr and beyond, so the secretion of
increased levels of IL-12 (compared to control) at this concentration are especially significant,
indicating that the remaining live macrophages (< 80% compared to control) are stimulated to
undergo a very strong IL-12 mediated inflammatory response. Taken together, these results are
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consistent with our hypothesis and demonstrate that nano-WC-Co particles are capable of
inducing a pro-inflammatory response in macrophages marked by high levels of IL-1β and IL-12
secretion and high expression of CD40 M1 surface markers.

CONCLUSION
This study examined the toxicity of nano-WC-Co in a co-culture of macrophages and
lung epithelial cells and explored the effects of nano-WC-Co exposure on M1/M2 polarization
and inflammatory cytokine secretion in THP-1 macrophages. The presence of THP-1 cells in the
co-culture model was found to reduce the toxicity of nano-WC-Co compared to a mono-culture
of BEAS-2B, which suggested a protective role of macrophages against nano-WC-Co particle
toxicity. In macrophages, nano-WC-Co exposure induced increased secretion of IL-1β and IL12, which are indicators of a pro-inflammatory response. The M1/M2 polarization assay
indicated a strong M1 phenotype (CD40+) in nano-WC-Co treated macrophages after 1, 2 and 5
days of exposure. Overall, the outcomes of our cytokine ELISA and flow cytometry assay
indicated that exposure to nano-WC-Co particles in vitro stimulates a pro-inflammatory cytokine
response and polarization toward the M1 phenotype in macrophages.
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SUPPLEMENTARY MATERIAL
FIGURES

Figure S1. Representative flow cytometry dot plots depicting macrophage staining controls used to set
flow cytometer experimental parameters: A) no stain/M0 cells only, B) M1 positive control (LPS) stained
with CD40-APC only, C) M2 positive control (IL-4) stained with CD206-FITC only and D) M0 negative
control cells stained with both CD40-APC and CD206-FITC. CD40-APC as a surface marker of M1-type
macrophages and CD206-FITC as a surface marker of M2-type macrophages.

88

Figure S2. Summary of A) CD40+ M1-type and B) CD206+ M2-type macrophage flow cytometry
staining controls. M0 cells received PMA treatment only, M1 positive control received 100 ng/mL LPS
and M2 positive control received 20 ng/mL IL-4 for 1, 2 or 5 days. (*P < 0.05, †P < 0.01 compared M0
control)

89

Figure S3. Levels of A) TNFα, B) IL-1β and C) IL-12 inflammatory markers in cell culture supernatant
for the M0 (negative control), LPS (100 ng/mL) and IL-4 (20ng/mL) control groups. (*P < 0.05, †P <
0.01 compared to M0 control)
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Figure S4. Levels of IL-10 in cell culture supernatants following A) nano-WC-Co exposure and B) M0
(negative control), LPS (100 ng/mL) and IL-4 (20ng/mL) control treatments. (*P < 0.05, †P < 0.01
compared to M0 control)
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ABSTRACT
Exposure to hard metal tungsten carbide cobalt (WC-Co) “dusts” in enclosed industrial
environments is known to contribute to the development of hard metal lung disease and an
increased risk for lung cancer. Currently, the influence of local and systemic inflammation on
disease progression following WC-Co exposure remains unclear. To better understand the
relationship between WC-Co nanoparticle (NP) exposure and its resultant effects, the acute local
pulmonary and systemic inflammatory responses caused by WC-Co NPs were explored using an
intra-tracheal instillation (IT) model and compared to those of CeO2 (another occupational
hazard) NP exposure. Sprague-Dawley rats were given an IT dose (0-500 μg per rat) of WC-Co
or CeO2 NPs. Following 24-hr exposure, broncho-alveolar lavage fluid and whole blood were
collected and analyzed. A consistent lack of acute local pulmonary inflammation was observed
in terms of the broncho-alveolar lavage fluid parameters examined (i.e. LDH, albumin,
macrophage activation); however, significant acute pulmonary inflammation was observed in the
CeO2 NP group. The lack of acute inflammation following WC-Co NP exposure contrasts with
earlier in vivo reports regarding WC-Co toxicity in rats, illuminating the critical role of NP dose
and exposure time and bringing into question the potential role of impurities in particle samples.
Further, we demonstrated that WC-Co NP exposure does not induce acute systemic effects since
no significant increase in circulating inflammatory cytokines were observed. Taken together, the
results of this in vivo study illustrate the distinct differences in acute local pulmonary and
systemic inflammatory responses to NPs composed of WC-Co and CeO2; therefore, it is
important that the outcomes of pulmonary exposure to one type of NPs may not be implicitly
extrapolated to other types of NPs.
Keywords: nanoparticle exposure; particle inhalation; pulmonary exposure; inflammation
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INTRODUCTION
The increased use of engineered nanomaterials (ENMs) in commercial manufacturing
and consumer products presents an important toxicological concern. As the ENMs are used
repetitively and wear over time, nanoparticles (NPs) are generated and released into the
environment, thereby creating a NP exposure hazard. Currently, there are no definitive
“standards” for evaluating the toxic effects of NPs, so identifying NP exposure effects remain a
challenge for researchers world-wide [32]. It is evident from the literature that the effects of NP
exposure effect vary greatly, ranging from non-toxic to carcinogenic, depending upon the
particle size, composition, dose, length, and route of exposure [1, 2, 31, 32, 37, 58]. The
pulmonary effects of NPs are particularly important, as airborne NPs are inhaled and inhalation
is the most frequent route by which workers are exposed in occupational settings [42, 176, 238].
Recently, it has been reported that inhaled NPs are capable of depositing in the lung and
causing systemic effects at sites distant from that of exposure [37, 168, 169]. Translocation of
NPs across the lung and into the bloodstream may result NP deposition in other organs (liver,
spleen, kidney), with subsequent organ damage or toxicity, and may cause changes in vascular
function or permeability [34, 37, 65, 164, 165, 168, 171, 172, 239, 240]. It is difficult to predict
the long-term impact of these systemic effects, so the extent by which systemic effects of NP
exposure may contribute to or alter specific disease states remains unknown.
As mentioned above, occupational inhalation of NPs is of particular concern; specifically,
exposure to tungsten carbide cobalt (WC-Co) dusts and particles. WC-Co is a hard composite
metal commonly used as a material and coating for equipment used in mining and drilling
industries [70]. As these tools are used extensively in a closed environment, WC-Co dusts
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containing particles of respirable range are released, thereby creating an occupational inhalation
hazard [78, 79]. Inhalation of WC-Co containing dusts and particles is known to cause hard
metal lung disease (HMLD) and a two-fold increased risk for lung cancer [73, 77, 101, 102,
177]; however, the relationship between acute WC-Co toxicity and the potential role of
inflammation on HMLD progression remains unknown. The toxicity of WC-Co particles toward
a number of cell types in vitro has been reported in the literature [131, 132, 134, 135, 141, 143,
144, 148-150, 152, 153, 158, 222, 241]. Specifically, we recently found that WC-Co particles in
the nano-size range were internalized by epithelial cells and that exposure to WC-Co NPs
resulted in significant toxicity toward lung epithelial cells at concentrations as low as 10 μg/mL
for exposure periods as short as 0.5 hr, significant toxicity at concentrations of 0.1 and 1 μg/mL
after 48 hr exposure and that overall, WC-Co NPs caused significantly greater toxicity compared
to WC-Co micro-particles [222].
Additionally, there have been several studies regarding the toxicity of WC-Co particles in
vivo [130, 154-157, 159-161]. These early in vivo studies focused on the local pulmonary
responses to WC-Co exposure and confirmed that the composite material of WC-Co was
responsible for the observed toxic effects when compared to tungsten (W), carbide (C), or cobalt
(Co) exposure alone [154, 160, 161]. The WC-Co particles used for these studies were within the
2-4 μm size range and reported toxicity following single IT exposure was marked by severe
alveolitis, pulmonary edema and increased levels of lactate dehydrogenase (LDH), which were
observed after 24 hr and up to 72 hr post-exposure [154-156]. While the findings regarding the
pulmonary toxicity of WC-Co micro-particles were fairly consistent among these studies, there is
a lack of information regarding the toxicity of WC-Co particles in the nano-size range in vivo.
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Given the gap in knowledge regarding nano-sized WC-Co toxicity in vivo and our recent
findings demonstrating the enhanced toxicity of nano-sized WC-Co compared to micro-sized
WC-Co in vitro, we conducted a pilot study to examine the acute pulmonary and systemic
inflammatory effects of WC-Co NP exposure, which have not yet been reported, using an intratracheal instillation rat model and compared the outcomes with cerium dioxide (CeO2) NPs. The
Nurkiewicz laboratory, including Minarchick, Porter, and Nurkiewicz whom are coauthors of
this study, previously reported that CeO2 NPs induced microvascular dysfunction following
pulmonary exposure in vivo, characterized by impaired endothelium-dependent and endotheliumindependent dilation and speculated that such microvascular changes may likely contribute to
cardiovascular dysfunction associated with particle exposure [65]. In this case, we hypothesized
that WC-Co NPs would induce dose-dependent acute pulmonary inflammation, similar to CeO2
NPs [65, 170, 242] and may cause systemic inflammation marked by increased levels of
inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6).

MATERIALS and METHODS
WC-Co and CeO2 NPs: Tungsten carbide cobalt (WC-Co) NPs (80 nm) were purchased from
Inframat Advanced Materials (Manchester, CT). Cerium dioxide (CeO2) NPs were synthesized
and characterized as previously described [65]. The chemical composition of WC-Co NPs
included 72.1 wt.% W, 13.4 wt.% Co, 7.6 wt.% C, and 6.8 wt.% O [222]. Stock solutions of
WC-Co and CeO2 NPs were prepared as previously reported [65]. Briefly, dry WC-Co or CeO2
NPs were weighed and added to 10 mL of saline (Normosol) with 10% fetal bovine serum
(FBS). Previous studies showed that saline and FBS reduced particle aggregation and did not
induce mechanical artifacts in terms of broncho-alveolar lavage (BAL) and systemic responses in
96

rats [33, 36, 65]. The average size of WC-Co and CeO2 NPs in Normosol (isotonic saline) plus
10% FBS was determined via dynamic light scattering (DLS) using a Malvern Zetasizer version
7.01 (Malvern Instruments Ltd, Malvern, UK). The average sizes of WC-Co and CeO2 NPs were
found to be approximately 100 nm and 190 nm, respectively.
Animals: Male Sprague-Dawley rats (8-9 weeks old) were purchased from Hilltop Laboratories
(Scottdale, PA). The rats were housed at the West Virginia University animal facility in
ventilated cages, under controlled humidity and temperature, with a 12 hr light/dark cycle with
food and water provided ad libitum. Animals were acclimated for at least 2 days prior to use.
Rats were divided randomly into groups (six animals per group) and assigned to either the 0, 50,
250 or 500 μg WC-Co or 400 μg CeO2 NP group. All procedures were approved by the West
Virginia University Animal Care and Use Committee (Permit Number 12-0414) and carried out
in accordance with recommendations set forth in the Guide for the Care and Use of Laboratory
Animals by the National Institutes of Health. All efforts were made to ensure minimal suffering
during stated procedures.
Intra-tracheal Instillation Rat Model and NP Exposure: The NP stock solutions were
sonicated for 5 min on ice to ensure particle dispersion and used immediately for intra-tracheal
(IT) instillation. Rats were lightly sedated with isofluorane gas (5% induction) and intratracheally instilled with a 300 μL bolus dose of the stock NP solutions to achieve final doses of
0, 50, 250, and 500 μg WC-Co NPs or 400 μg CeO2 NPs. Rats were monitored after instillation
until consciousness was regained. After a 24-hr recovery period, rats were euthanized with
thiobutabarbital sodium salt hydrate (Inactin®; Sigma-Aldrich, MO) at a dose of 1 mg/kg via
intra-peritoneal (i.p.) injection. Anesthesia was confirmed by testing the toe-pinch reflex. Upon
euthanization, the rat abdomen was opened and whole blood was collected in anti-coagulant
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(ethylenediaminetetraacetic acid, EDTA) vacuum tubes via the abdominal aorta until a minimum
of 6 mL blood was obtained. Following blood collection, the aorta was cut for complete
exsanguination and broncho-alveolar lavage (BAL) was performed immediately thereafter.
Blood Plasma Isolation: Whole blood samples were kept on ice until all samples were collected
and then centrifuged at 2000 × g for 15 min to separate the plasma from the cellular blood
components. The plasma (supernatant) was drawn off using a pipet, transferred to a cryogenic
vial in 0.5 mL aliquots, and flash frozen in liquid nitrogen for later cytokine analysis.
Assessment of Pulmonary Inflammation at 24-hr Post-Exposure: Pulmonary inflammation
was assessed in the BAL fluid after NP exposure by evaluating several parameters. First, BAL
fluid samples were assessed for cytotoxicity using the LDH assay and second, albumin protein
concentration in the BAL fluid was determined to evaluate the integrity of the epithelialendothelial (blood-gas exchange) barrier in the lung. Third, inflammatory cells were isolated
from the BAL fluid and differential cell counts performed to identify the number of alveolar
macrophages (AM) and polymorphonuclear leukocytes (PMN) present in the lung following NP
exposure. Further, isolated macrophage (AM) activation states were examined using a standard
chemiluminescence assay. Then, the concentration of inflammatory cytokines (i.e. TNF-α, IL-6,
and IFN-) were determined in BAL fluid samples using ELISA.
BAL Procedure and BAL Fluid Collection: Broncho-alveolar lavage (BAL) was
performed with Ca2+/Mg2+-free phosphate buffered saline (PBS, pH 7.4) plus 5.5 mM D-glucose
as previously described [240]. Briefly, a tracheal cannula was inserted and BAL was performed
through the cannula using ice-cold PBS. The first BAL fluid, totaling 6 mL of PBS, was
collected and immediately centrifuged (650 x g, 10 min, 4°C). The resulting first BAL fluid
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supernatant was then divided for later analysis: two 0.5 mL aliquots were flash-frozen in liquid
nitrogen for cytokine determination by ELISA and the remaining 5 mL was kept on ice for
analysis of LDH and albumin. After the first BAL was collected, BAL was repeated using 8 mL
of PBS until a total of 40 mL BAL fluid was collected. Next, the 40 mL of BAL fluid was
centrifuged (650 x g, 10 min, 4°C) and the resulting cell pellet was pooled with the cell pellet
from the first BAL fluid. The pooled cells were re-suspended in HEPES-buffered medium (10
mM N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid], 145 mM NaCl, 5 mM KCl, 1 mM
CaCl2, 5.5 mM D-glucose, pH 7.4) and centrifuged a second time (650 x g, 10 min, 4°C). The
resulting supernatant was decanted and a final suspension of the isolated BAL cells was prepared
in HEPES-buffered medium.
Albumin Protein Assay and LDH Activity: LDH and albumin assays were performed as
previously described [65, 243] on the same day as BAL fluid collection using a Roche Cobas
c111 (Roche Diagnostic Systems, Indianapolis, IN). In brief, LDH activity was used as a marker
of cytotoxicity. A commercial assay kit was purchased from Roche Diagnostic Systems
(Indianapolis, IN) and used to measure LDH activity based on the LDH-driven oxidation of
pyruvate coupled with the reduction of nictoinamide adenine dinucleotide at 340 nm. Albumin
concentration was monitored as an indicator of cellular integrity using a commercially available
kit from Sigma Chemical Co (St. Louis, MO) based on albumin binding to bromcresol green and
measuring the color change at 628 nm.
Histology: A total of 1.0 × 106 BAL cells were suspended in 200 μL HEPES-buffered
medium and transferred to microscope slides using the cytospin approach [244]. The resulting
cytospin preparations were stained with modified Wright-Giemsa stain and cell differentials
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were determined using light microscopy. Differential cell counts were calculated by multiplying
the total cell count by the cell differential percentage obtained from the cytospin preparations.
Macrophage Chemiluminescence: The activation state of alveolar macrophages (AM),
previously isolated from the BAL fluid (above), was determined in a total volume of 0.5 mL
HEPES-buffered medium as previously described using a chemiluminescence assay [245]. First,
chemiluminescence of resting AM (non-stimulated) was determined by incubating 1.0 × 106
AM/mL at 37°C for 20 min, followed by the addition of 5-amino-2,3-dihydro-1,4phthalazinedione (luminol) to a final concentration of 0.08 μg/mL. The resulting
chemiluminescence was measured with an automated luminometer (Berthold Autolumat Plus LB
953, Oakridge, TN) at 390-620 nm for 15 min, where the integral of counts per minute (cpm)
versus time was calculated. Next, zymosan-stimulated chemiluminescence was determined by
adding 2 mg/mL of un-opsonized zymosan just prior to the measurement of chemiluminescence.
The use of un-opsonized zymosan in this assay allows for the determination of AM
chemiluminescence, which is a reflection of the macrophage activation state, because unopsonized zymosan stimulates AM chemiluminescence [246] but does not stimulate
polymorphonuclear leukocyte (PMN) chemiluminescence [62, 247]. Stimulated macrophage
chemiluminescence was then calculated by subtracting the cpm from the resting AM
measurement from the cpm of the zymosan-stimulated measurement.
Inflammatory Cytokine ELISA: Standard curves for cytokines including TNF-α, IL-6, and
Interferon  (IFN-γ) were prepared using a dilution series with a commercial ELISA kit
(Signosis, Inc, Santa Clara, CA). Previously frozen plasma and BAL fluid samples were thawed
and used to determine the cytokine concentrations in each sample. Briefly, 100 μL of BAL fluid
or plasma sample was added to each well of the 96-well ELISA plate and incubated for 2 hr to
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allow sufficient binding to the immobilized antibodies within each well. Samples were then
aspirated and wells were rinsed three times with 200 μL buffer per wash. Next, 100 μL biotinlabeled detection antibody was added to each well and incubated for 1 hr. The washing step was
repeated followed by the addition of 100 μL streptavidin-horseradish peroxidase (HRP)
conjugate to each well. After 45 min, the washing step was repeated and 100 μL substrate was
added to each well. The plate was further incubated for 30 min in the dark, followed by the
addition of 50 μL stop solution to each well. The absorbance of each sample was immediately
measured at 450 nm. BAL fluid and plasma samples were run in triplicate and the cytokine
concentration of each sample was calculated based on the sample absorbance and the slope of the
standard curve for each respective cytokine.
Statistical Analysis All data were presented as the mean ± standard deviation. Statistical
significance between experimental groups was determined using one-way analysis of variance
(ANOVA) and Dunnett’s post-hoc analysis in GraphPad Prism 6 software (San Diego, CA).

RESULTS
Pulmonary Inflammation: BAL fluid was collected and analyzed to assess pulmonary
inflammation following 24-hr exposure to WC-Co or CeO2 NPs. Compared to the vehicle control
group, there were no significant differences in LDH activity for WC-Co NP exposed animals at
the doses studied. A significant increase in LDH activity was observed in the CeO2 NP group
compared to the vehicle control and all of the WC-Co NP exposed groups (Figure 1A). This
indicated a lack of cytotoxicity in the WC-Co NP exposed groups at the doses studied while the
exposure to CeO2 NPs caused significant cytotoxicity. Similarly, there were no significant
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differences found in the albumin content in WC-Co NP exposed animals compared to vehicle
control, although relatively higher albumin content was observed at the exposure dose of 500 µg
compared to the other doses (i.e. 50 and 250 µg) (Figure 1B). A significant increase in albumin
was found in the CeO2 NP exposed group compared to the vehicle control and all of the WC-Co
NP exposed groups (Figure 1B). This indicated that the epithelial-endothelial barrier remained
undisrupted in WC-Co NP exposed animals but was affected in the CeO2 NP exposed group.

Figure 4.1. Pulmonary inflammation parameters assessed in the BAL fluid following 24-hr exposure to
WC-Co and CeO2 NPs: A) LDH activity, B) albumin and C) AM chemiluminescence. Values presented
as mean ± SD. (*P < 0.05, ‡P < 0.001 compared to the vehicle control and †P < 0.01 compared to WC-Co
NP exposed groups)
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The activation state of AM was determined via zymogen-stimulated chemiluminescence
assay, where no significant differences were found in AM activation in WC-Co NP exposed
animals at all the doses studied compared to the vehicle control group. A significant increase in
AM activation was observed when the CeO2 NP exposed group was compared to the vehicle
control and to all of the WC-Co NP exposed groups (Figure 1C). Moreover, the number of AMs
in the BAL fluid samples was similar across the vehicle control and all WC-Co NP exposed
animals, where a relatively higher number of AMs was found in the CeO2 NP exposed group
compared to the vehicle control and WC-Co NP exposed groups; however, the differences were
not significant (Figure 2A). Additionally, no significant differences in the number of PMNs
were found between the WC-Co NP exposed groups and the vehicle control group; however, a
significant increase in the number of PMNs was detected in the CeO2 NP exposed group
compared to the vehicle control and the WC-Co NP exposed groups (Figure 2B).
Further, no significant differences were detected in the levels of inflammatory cytokines
(i.e. TNF-α and IFN-γ) in BAL fluid among the WC-Co, CeO2, and vehicle control groups
(Figure 3A) with the exception of IL-6, where a significant increase in IL-6 was observed for the
CeO2 NP group compared to the vehicle control and WC-Co NP exposed groups (Figure 3A).
Systemic Inflammation: The levels of inflammatory cytokines including TNF-α, IL-6, and IFNγ were determined in blood plasma samples to examine the potential systemic inflammatory
response to WC-Co and CeO2 NP exposures. No significant differences were observed in TNF-α
and IFN-γ levels among all the animal groups studied (i.e. Control, WC-Co NP, and CeO2 NP
groups), but significantly higher IL-6 was found in the CeO2 NP exposed group compared to the
vehicle control and WC-Co NP exposed groups (Figure 3B).
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Figure 4.2. Inflammatory cells quantified in BAL fluid samples following 24-hr exposure to WC-Co and
CeO2 NPs: A) alveolar macrophages (AM) and B) polymorphonuclear leukocytes (PMN), represented as
the total number of AM/PMN per 106 isolated BAL cells per rat. Values presented as mean ± SD. (†P <
0.01 compared to the vehicle control and WC-Co NP exposed groups)

Isolated BAL Cell Histology: Histological examination of the cytospin cell preparations
revealed a population of AMs present in both the vehicle control (Figure 4A) and WC-Co NP
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exposed groups (Figure 4B) and AM containing NPs were visible in WC-Co exposed groups
(Figure 4B). These data suggest that AM were capable of phagocytizing the WC-Co NP;
however, the overall lack of inflammation observed in the other pulmonary parameters suggests
that the WC-Co NPs were recognized as ‘inert’ by the AM and did not cause significant AM
activation.

Figure 4.3. Inflammatory cytokine concentrations in A) BAL fluid and B) blood plasma. (†P < 0.01
compared to the vehicle control and WC-Co NP exposed groups)
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Figure 4.4. Histology of isolated BAL fluid cells from a representative A) control (vehicle only) rat and
B) 500 μg WC-Co NP exposed rat. Scale bars = 20 μm. (black arrow = alveolar macrophage, AM; arrow
head = erythrocyte; dotted arrow = polymorphonuclear leukocyte, PMN; wide arrow = AM with WC-Co
NPs)
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DISCUSSION
In this study, we determined the acute inflammatory effects of WC-Co and CeO2 NP
exposure in terms of local pulmonary responses via assessment of BAL fluid and the acute
systemic effects via quantification of important inflammatory mediators in the blood.
In general, the presence of particles in the lungs, including NPs, is thought to promote the
recruitment of macrophages, increase macrophage phagocytic activity and thereby stimulate
particle clearance from the lung [41, 205-207] as part of the normal physiological response.
Macrophage recruitment and phagocytosis of deposited particles is rapid, usually occurring
within 24 hr of exposure for most animal species [205]. In this study, WC-Co NPs were
phagocytized by AMs after 24 hr, evidenced by histological examination, which is consistent
with reports demonstrating the uptake of other NPs such as graphene [41], titanium dioxide [248,
249] and magnetite [250] by AMs in vivo. Interestingly, WC-Co NPs were also “phagocytized”
by lung bronchial epithelial cells in vitro [222], which suggests that NP internalization may not
be exclusive to macrophages and is of particular interest, since hard metal (WC-Co) deposits
have been found in workers diagnosed with HMLD [113, 114, 124]. In the present study, WCCo NPs did not induce significant acute pulmonary inflammation, compared to the vehicle
control, in the assessment of LDH activity and albumin content in the BAL fluid following 24-hr
exposure at doses of 50-500 μg per rat. The lack of acute pulmonary inflammation is further
supported by the observation that WC-Co NP exposure caused little change in the number of AM
and PMN cells and did not increase macrophage activation following 24-hr WC-Co NP
exposure. This outcome is similar to that reported for instilled titanium dioxide NPs, which do
not cause any substantial acute pulmonary inflammation after 24 hr at a dose up to 200 μg per rat
[248, 249].
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It is known that particle size may play a major role in the depth of tissue penetration and
toxicity. Compared to micron-sized particles, NPs are smaller and have higher surface area (that
is available for tissue interaction) and are thereby capable of deeper penetration and possessing
higher toxicity [238, 251-256]. However, no significant alterations in LDH activity and albumin
levels were observed in this study following WC-Co NP exposure, while significant increases in
LDH and albumin were reported in a similar IT rat model following 24-hr exposure of WC-Co in
the 2 μm size range [155-157]. Two factors may have contributed to the differences observed
between this study and the previous ones: particle dose and chemical composition. In this study,
we elected to dose our animals (50-500 μg per rat) based on total lung burden in the microgram
range, which were identified in vitro to be significantly toxic against lung epithelial cells [222]
and are known to cause significant inflammation in CeO2 NP exposed animals [65]. This is in
stark contrast to the previous WC-Co NP studies [155-157], which used a mg per 100 g body
weight dosing scheme with total WC-Co NP doses ranging from 3-30 mg per rat in a single IT
exposure. As a result, the previous studies most likely overloaded the lung and led to significant
inflammation. Moreover, the WC-Co NPs in the previous studies were obtained from a hard
metal manufacturing facility and contained a significant amount of iron [155-157], which is not
found in our WC-Co NPs. Iron has recently been identified as a pulmonary irritant [64, 174, 257]
and could have contributed to the observed inflammatory responses in the previous studies.
In this study, no significant differences in inflammatory cytokines (i.e. TNF-α, IL-6, IFNγ) were found in plasma or BAL fluid samples for WC-Co NP exposed animals compared to the
vehicle control. These findings indicate that WC-Co NPs did not induce acute systemic
inflammation after 24-hr pulmonary exposure at the doses studied. By contrast, within the
emerging body of literature regarding NP toxicity in vivo, it is reported that cadmium oxide [63],
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titanium dioxide [220] and silver [221] NPs are capable of inducing systemic inflammation after
acute pulmonary exposure, marked by increased inflammatory cytokine levels. For example, a
three-fold increase in the pulmonary levels of TNF-α and IFN-γ were observed in mice exposed
to cadmium oxide NPs for 24 hr [63]. Similarly, a significant increase in pulmonary IL-6 was
reported in rats exposed to silver NPs for 24 hr [221]. While cadmium oxide and silver NPs
increased the pulmonary levels of these inflammatory cytokines, titanium dioxide is capable of
inducing a significant increase in both the pulmonary and systemic levels of IL-6 and IFN-γ after
24-48 hr of exposure in a rat IT model [220]. Together, these reports demonstrate the capacity of
pulmonary NP exposure to initiate systemic inflammation and highlights the potential influence
that systemic inflammatory cascades may have on the outcomes of pulmonary NP exposure.
In contrast to the WC-Co NPs, CeO2 NPs induced significant acute pulmonary and
systemic responses in our intra-tracheal instillation rat model. After 24-hr exposure, we observed
significant acute inflammation in our CeO2 NP exposed group compared to the vehicle control in
terms of LDH activity, albumin content, and macrophage activation state. These findings are
consistent with a previous study in Nurkiewicz’s laboratory [65], where significantly higher
LDH, albumin, and number of activated AMs were observed after 24-hr exposure to 100-400 µg
CeO2 NPs, which might have contributed to microvascular dysfunction [65]. The significant
increases in AM activation and number of PMNs in this study indicated that CeO2 NPs
stimulated the activation of macrophages and promoted the recruitment of PMNs. Furthermore,
in this study we found a significant increase in IL-6 levels in both the plasma and BAL fluid of
CeO2 NP exposed animals compared to the vehicle control. This is most likely because IL-6 is
primarily secreted by activated macrophages to stimulate inflammation in response to pulmonary
tissue damage caused by the presence of NPs in the lung [207]. Overall, the outcomes reported
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here for CeO2 NPs are consistent with the earlier studies regarding the systemic effects of
exposure [65] and other in vivo [164, 170, 242] and in vitro [24, 258-262] reports concerning
CeO2 NP toxicity in the literature.
In the current in vivo study, WC-Co NPs did not induce significant acute pulmonary and
systemic inflammation, which is likely because we limited our investigation to a single IT dose
(i.e. 50-500 μg per rat) and a short exposure time (i.e. 24 hr). It is possible that multiple doses of
WC-Co NP could cause significant inflammation in a delayed response (beyond 24 hr). Future
studies that explore multiple WC-Co NP doses and/or longer exposure times are warranted to
further examine the pulmonary and systemic inflammatory response to WC-Co NPs in vivo.

CONCLUSIONS
In this study, we examined the acute local pulmonary and systemic inflammatory
responses to WC-Co NPs using an intra-tracheal instillation rat model. No significant differences
between WC-Co exposed animals and vehicle control were observed in terms of LDH activity,
albumin concentration, or cell differentials. Macrophages isolated from WC-Co animals also did
not show significant activation when compared to macrophages from vehicle control animals. In
addition, no significant differences in inflammatory cytokines were observed for WC-Co
exposed animals. These findings indicated a lack of acute local pulmonary and systemic
inflammatory responses after 24-hr exposure to WC-Co NPs in an IT dose in the range of 0-500
μg per rat.
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CHAPTER 5:

Toxicity of Cobalt Chromium Molybdenum (CoCrMo) Particles Toward
Lung Epithelial Cells in vitro

A Summary of Original Research Findings
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ABSTRACT

Metal-on-metal (MoM) joint implants are used routinely during total hip and knee
replacement surgeries and are typically composed of cobalt chromium molybdenum (CoCrMo)
alloy. While these implants are more successful than previous technologies, recent evidence
indicates that CoCrMo “wear particles”, in the nano- and micro-size range, can be generated in
situ and may cause toxicity and inflammation in patients. Meanwhile, occupational exposure to
CoCrMo particles has been associated with the development of industrial dental worker’s
pneumoconiosis and pulmonary exposure to CoCrMo particles is therefore a relevant concern in
the manufacturing of MoM implant devices. In this study, we examined the pulmonary toxicity
of nano- and micro-CoCrMo particles in vitro using a lung epithelial cell model and compared
the outcomes with tungsten carbide cobalt (WC-Co) particles, which are known to cause toxicity
and lung disease in exposed workers. We found that CoCrMo particles induced a time and dosedependent toxicity. There was no significant increase in the toxicity of nano-CoCrMo compared
to micro-CoCrMo particles; however, nano-CoCrMo caused significantly greater levels of
oxidative stress than micro-CoCrMo particles. Compared to WC-Co, CoCrMo particles caused
significantly less cellular toxicity and oxidative stress under the conditions tested. These in vitro
findings suggest that the pulmonary toxicity and oxidative stress associated with CoCrMo
particle exposure in occupational settings may contribute to the development of lung disease.

Keywords: implant wear, joint replacement, cobalt chromium, occupational lung disease,
pulmonary exposure, nanoparticle, nanotoxicity
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INTRODUCTION
Over a million total hip replacement procedures are performed each year; one-third of
these surgeries use metal-on-metal (MoM) implant devices composed of cobalt chromium
molybdenum (CoCrMo) alloys [263]. While MoM implant devices offer advantages, such as
increased strength and resistance to wear over previous implants composed of polymeric and/or
ceramic articulating surfaces, they are not without their faults or risks [28, 39]. In particular, new
evidence is emerging that these MoM CoCrMo implants generate particles in situ, within the
micro- and nano-size range, as a result of wear between the articulating joint surfaces [26, 28, 29,
38, 39, 264-266]. The generation of wear particles increases when the implant is improperly
aligned, causing aseptic loosening of the joint, uneven wear and damage to the implant area [26,
28]. The current literature suggests that CoCrMo wear particles released locally within the joint
area and surrounding tissues may cause toxicity and a subsequent inflammatory response [26, 28,
39, 266].
Given this evidence and emerging concerns regarding the long term effects of CoCrMo
particle exposure in joint replacement patients, the toxicity of CoCrMo wear particles has
recently been explored in vitro [29, 39, 48-50, 263-278] and in vivo [67, 279, 280]. CoCrMo
toxicity has been reported in osteoblasts, osteoclasts, fibroblasts, leukocytes and macrophages,
where oxidative stress and DNA damage are cited as common mechanisms of toxicity amongst
these studies [29, 48-50, 264, 267, 268, 271, 272, 274, 276-278]. Additionally, CoCrMo particle
exposure has been found to cause reproductive toxicity [68, 281], genotoxicity and inflammatory
immune reactions in exposed mice [38, 67, 279]. Together, these studies demonstrate that
CoCrMo particles possess toxic properties under in vitro and in vivo conditions.
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In addition to “internal” CoCrMo particle exposure via MoM implant wear, it is
important to consider alternative routes of exposure such as inhalation, which could occur during
the manufacturing and production of MoM implants. Industrial exposures to cobalt-containing
metal “dusts” have been well-associated with the development of pneumoconiosis, occupational
asthma and lung disease in a number of settings [86, 88, 96, 178, 181, 182, 282-289]. Although
occupational exposure to CoCrMo particles has not been directly reported in orthopedic implant
manufacturing settings, pulmonary exposure to CoCrMo “dusts”, similar in composition to
orthopedic implant materials, have been reported in dental implant manufacturing settings [290].
Inhalation of CoCrMo particles has been attributed as the cause of “dental technician’s
pneumoconiosis” (DTP) [290-296], which has a similar clinical presentation to hard metal lung
disease resulting from tungsten carbide cobalt (WC-Co) exposure [26, 296, 297].
Given the risk of CoCrMo pulmonary exposure through inhalation of CoCrMo dusts in
manufacturing settings and the lack of data regarding CoCrMo pulmonary toxicity, the goal of
the current study was to determine the toxicity and oxidative stress response to nano- and microCoCrMo particle exposure in a lung epithelial cell culture model recently established in our lab
[222]. Based on the literature, we hypothesized that nano- and micro-CoCrMo particles would
exert time and dose-dependent toxicity and induce high levels of oxidative stress in BEAS-2B
lung epithelial cells.

MATERIALS and METHODS
Materials and Reagents: CoCrMo particles were obtained as a gift from T.A. Simoes
(University of Leeds, Institute for Materials Research, Leeds, UK). BEAS-2B lung epithelial
cells were obtained from the laboratory of Yon Rojansakul (West Virginia University,
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Morgantown, WV, USA). Dulbecco’s Modified Eagle Media (DMEM), sterile phosphate
buffered saline (PBS), 0.25% trypsin/ethylenediaminetetraacetic acid (EDTA), fetal bovine
serum (FBS) and penicillin/streptomycin were purchased from Lonza (Allendale, NJ). The MTT
cell viability kit (TOX-1), 2’,7’-dichlorofluorescein diacetate (DCF) and dihydroethidium (DHE)
were purchased from Sigma-Aldrich (St. Louis, MO).
Particle Preparation: Briefly, CoCrMo nanoparticles were prepared from micro-sized ASTM
F75 cobalt chromium atomized powder for surgical implants using mechanochemical milling in
a high energy SPEX mill (Metuchen, NJ) [298]. For cell-based assays, CoCrMo particles were
prepared in a phosphate buffered saline (PBS) solution containing 10% fetal bovine serum (FBS)
as a stabilization agent and sonicated using an Omni International Sonic Ruptor 250 Ultrasonic
Homogenizer (Kennesaw, GA). A stock concentration of 5 mg/mL CoCrMo particles was
prepared by sonication (2 min, 120 watts power output, frequency 20 kHz) in an ice bath, to
minimize heating of the sample during particle dispersion. Dilute particle suspensions, ranging
from 0.1 to 1000 μg/mL, were prepared in DMEM containing 10% FBS and used immediately
on the day of each experiment.
Particle Characterization: Micro- and nano-CoCrMo particles were characterized for size and
morphology by scanning electron microscopy and elemental composition was determined via
energy-dispersive x-ray (SEM/EDX; JEOL JSM 7600F, Jeol USA, Inc., Peabody, MA). The
average size of CoCrMo particles in suspension for cell culture was determined using dynamic
light scattering (DLS). Additional details provided in the Supplementary Material.
CoCrMo Particle Assay Interference: Prior to execution of the cell viability and oxidative
stress assays, the potential interference of CoCrMo particles was examined under the
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experimental conditions. To test compatibility with the MTT-based cell viability assay, 200 μL
of CoCrMo suspensions (0.1 to 1000 ug/mL in DMEM) was added to duplicate wells in a 96well plate. The plate was briefly centrifuged (500 × g, 5 min) to pellet the particles at the bottom
of the wells. The supernatant was then aspirated and 100 μL of plain (un-supplemented) DMEM
was added to each well containing CoCrMo particles, along with 10 μL of MTT dye reagent.
After 2 hr incubation at 37°C, 100 μL of solubilization solution was added to each well and the
absorbance was determined at 570 nm. Any auto-reduction of the MTT dye reagent to formazan
by the CoCrMo particles themselves would have been detected as an increase in absorbance
compared to the blank wells, containing only media, MTT dye reagent and solubilization
solution. Similarly, for the oxidative stress assay, we tested whether the CoCrMo particles
caused increased fluorescence of either DCF or DHE dye under our assay conditions. CoCrMo
particle suspensions were plated and centrifuged in duplicate wells of a 96-well plate as
described above. The supernatant was then aspirated and replaced with 100 μL of 10 μM DCF or
DHE working solution prepared in PBS. Plates were incubated for 15 min in the dark and then
fluorescence intensity of each well was quantified every 5 min, up to one hour, at 520 nm for
DCF or 620 nm for DHE, to identify any potential particle/dye interference compared to the
blank (dye solution only) wells.
Cell Culture and Exposure to CoCrMo Particles: BEAS-2B cells were cultured in DMEM
supplemented with 10% FBS and 1% penicillin-streptomycin and maintained at 37°C and 5%
CO2. Briefly, confluent monolayers were rinsed with PBS, trypsinized, transferred to 5 mL
polystyrene tubes and centrifuged at 1200 rpm for 7 min to pellet. The cell pellet was resuspended at the desired plating density of 1.5 × 105 cells/mL, transferred to a 96-well tissue
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culture plate and allowed to adhere overnight prior to conducting the cell viability and oxidative
stress assays.
Cell Viability Assay: For the viability assay, cells were exposed to either nano- or microCoCrMo particles at concentrations of 0.1, 1, 10, 100 and 1000 μg/mL for exposure periods of 6,
12, 24 and 48 hr. Following particle treatment, cells were rinsed once with sterile PBS to remove
traces of media and excess particles. The MTT cell viability assay was performed per kit
instructions (TOX-1, Sigma-Aldrich). The absorbance of each well was recorded at 570 nm
using a Bio-Tek μQuant microplate reader (Winooski, VT). Blank values were subtracted from
absorbance readings. Cell viability was calculated by dividing the absorbance of particle treated
cells (AbsExptl) by the absorbance of the negative control cells (media treatment only; AbsControl)
and converted to percentage according to the following equation: Cell Viability (%) = (AbsExptl
∕AbsControl) × 100%.
Oxidative Stress Assay: Oxidative stress was examined at the same concentration and exposure
range described for the viability assay (above). Following particle treatment, cells were rinsed
once with sterile PBS to remove traces of media and excess particles. Oxidative stress was then
determined by the addition of 10 μM DCF or DHE in PBS following particle treatment. Plates
were incubated for 15 min in the dark and then fluorescence intensity of each well was quantified
at 520 nm for DCF or 620 nm for DHE. The relative fluorescence of particle-treated cells was
calculated as fold over control.
Statistical Analyses: All experiments were performed in triplicate and data are presented as
mean ± standard deviation. Statistical analysis was carried out by 2-way analysis of variance
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(ANOVA) using GraphPad Prism software (La Jolla, CA). P values < 0.05 were considered
significant.

RESULTS
CoCrMo Particle Characterization and Assay Interference: Morphological examination of
nano- and micro-CoCrMo particles by SEM revealed distinct differences between the two
particle types (Figure 1). Micro-CoCrMo particles demonstrated spherical morphology sized in
the 5-6 μm range (Figure 1B) whereas nano-CoCrMo particles demonstrated a more irregular
particle shape and size range, from a half-micron down to 100-200 nm (Figure 1A). DLS
analysis indicated that nano-CoCrMo averaged 54 nm and micro-CoCrMo particles averaged
5.04 μm in in suspension, similar to our WC-Co particles characterized previously [222]. We did
not find any CoCrMo particle interference in our assay tests; no auto-reduction of the MTT dye
was identified and no changes in DCF/DHE fluorescence were observed under the assay
conditions tested (see Supplementary Material).

Figure 5.1. SEM images showing size and morphology of A) nano-CoCrMo and B) micro-CoCrMo
particles.
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CoCrMo Effects on Cell Viability: BEAS-2B cells were exposed to nano- and micro-CoCrMo
particles at concentrations of 0.1, 1, 10, 100 and 1000 μg/mL for durations of 6, 12, 24 and 48 hr.
BEAS-2B average cell viability was about 90-98% (vs. control of 100%) for all cells exposed at
concentrations of 0.1, 1 and 10 μg/mL for durations of 6-48 hr; the cell viability tended to
decrease with increasing particle exposure time from 6 hr to 48 hr at concentrations of both 100
and 1000 μg/mL (Figure 2).
In cells exposed to nano-CoCrMo particles (Figure 2A), a significant reduction in
viability (compared to control) was only observed at the highest concentration of 1000 μg/mL for
24 and 48 hr exposure periods; the other concentrations and exposures tested did not cause a
statistically significant change in cell viability for nano-CoCrMo.
In cells exposed to micro-CoCrMo particles (Figure 2B), a significant reduction in
viability (compared to control) was observed at a concentration of 1000 μg/mL at 12, 24 and 48
hr of exposure. There were no significant differences observed in toxicity between the nano- and
micro-CoCrMo; however, when we compared the viability after CoCrMo treatment with our
previous study on WC-Co particles [222], significant differences in toxicity were noted. We
identified that nano-CoCrMo caused significantly less toxicity than nano-WC-Co at 1, 10, 100
and 1000 μg/mL after 48 hr of exposure (Figure 3). Similarly, we observed that micro-CoCrMo
caused significantly less toxicity than micro-WC-Co at 1, 10, 100 and 1000 μg/mL after 48 hr of
exposure (Figure 3). At a low particle concentration (i.e. 0.1 μg/mL), no significant differences
in cell viability were found between nano-CoCrMo and nano-WC-Co or between micro-CoCrMo
and micro-WC-Co particles (Figure 3).
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Figure 5.2. Cell viability measured by the MTT assay after exposure to A) Nano-CoCrMo and B) MicroCoCrMo particles. (†P < 0.01 compared to controls with 100% viability)

CoCrMo Effects on Oxidative Stress: Oxidative stress was measured in the form of DCF/DHE
fluorescence after exposure to nano- and micro-CoCrMo particles at 0.1, 1, 10, 100 and 1000
μg/mL under identical exposure conditions in the viability assay. Compared to control, there was
a significant increase in DCF fluorescence in cells exposed to 100 μg/mL nano-CoCrMo after 6,
12 and 24 hr of exposure and at 1000 μg/mL after 6, 12, 24 and 48 hr of exposure; a 3.5 fold
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Figure 5.3. Comparison of cell viability after 48 hr exposure to nano-CoCrMo, nano-WC-Co, microCoCrMo and micro-WC-Co. (°P < 0.001 vs. WC-Co)

increase in DCF fluorescence was observed in cells exposed to 1000 μg/mL nano-CoCrMo after
6 hr of exposure and after which DCF fluorescence decreased with increasing exposure time
(Figure 4A). In cells exposed to micro-CoCrMo, a significant increase in DCF fluorescence was
observed after 6 hr exposure to 10 and 100 μg/mL and after 6, 12, 24 and 48 hr exposure to 1000
μg/mL micro-CoCrMo; a 2.3 fold increase in DCF fluorescence was observed in cells exposed to
1000 μg/mL micro-CoCrMo after 6 hr of exposure (Figure 4B). In addition, nano-CoCrMo
particles caused a significantly higher change in DCF fluorescence compared to micro-CoCrMo
particles after 6, 12 and 24 hr exposure to 100 μg/mL and after 6, 12, 24 and 48 hr at 1000
μg/mL (Figure 4).
For DHE, no significant differences, compared to control, were observed in fluorescence
after exposure to nano-CoCrMo (Figure 5A) or micro-CoCrMo (Figure 5B) particles, and the
DHE fluorescences in cells exposed to both nano- and micro-CoCrMo particles were about the
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same as the controls at all concentrations (0.1-1000 μg/mL) and exposure times (i.e. 6-48 hr)
studied.

Figure 5.4. Oxidative stress measured via fluorescence intensity of DCF after exposure to A) nanoCoCrMo and B) micro-CoCrMo particles. (†P < 0.01 compared to control; ‡P < 0.05 vs. micro-CoCrMo)

Compared to nano-WC-Co particles, nano-CoCrMo particles caused significantly less
DCF fluorescence at 6 and 12 hr of exposure but significantly higher DCF fluorescence at 24 and
48 hr of exposure at the 1000 μg/mL concentration (Figure 6A). Compared to micro-WC-Co
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particles, micro-CoCrMo particles caused significantly higher levels of DCF fluorescence at 6 hr
exposure but significantly lower DCF fluorescence at 12 hr of exposure at the 1000 μg/mL
(Figure 6B). Compared to WC-Co particles, there was a significant increase in DHE
fluorescence after exposure to both nano- and micro-CoCrMo at 1000 μg/mL after 6, 12, 24 and
48 hr of exposure (Figure 6B).

Figure 5.5. Oxidative stress measured via fluorescence intensity of DHE after exposure to A) nanoCoCrMo and B) micro-CoCrMo particles.
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Figure 5.6. Comparison of oxidative stress measured via fluorescence intensity of A) DCF and B) DHE
after 48 hr exposure to nano-CoCrMo, nano-WC-Co, micro-CoCrMo and micro-WC-Co particles at 1000
μg/mL. (°P < 0.001 vs. WC-Co)

DISCUSSION
Inhalation of cobalt-containing metal particles is a known occupational risk in certain
industries and has been associated with the development of hard metal lung disease following
exposure to WC-Co particles [85, 93, 125, 199, 282, 299] and dental technician’s
pneumoconiosis after exposure to CoCrMo particles [290-292, 294, 296, 297]. Exposure to
CoCrMo particles may also occur under other conditions, such as orthopedic joint implant wear
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[26, 39, 265]; advancements in our understanding of nanoparticle toxicity [35, 37, 168] lead us to
question the potential impacts of CoCrMo implant wear particles on tissues and organs beyond
the affected joint area. Due to their small size, nanoparticles have the capacity to enter the
circulatory system and deposit in secondary tissues such as the liver, spleen, kidney, lymph
nodes or lungs [26, 27, 31, 32, 238]. In humans whom have undergone MoM joint replacement
surgery, translocation and deposition of CoCrMo wear particles has been reported in lymph
nodes, liver and spleen [26, 38, 265, 300]; therefore, the potential secondary, systemic effects of
CoCrMo particle exposure cannot be ignored [175, 295, 301].
In the current study, we focused on the pulmonary toxicity associated with CoCrMo
inhalation in industrial settings using an in vitro lung epithelial cell model. Here, the toxicity of
nano- and micro-sized CoCrMo particles, originating from ASTM F75 orthopedic implant
material, was compared with the toxicity of nano- and micro-WC-Co particles in BEAS-2B cells.
Pulmonary exposure to WC-Co particles is known to cause “hard metal lung disease”, with
characteristic multi-nucleated giant cells, reduced lung function, progressive inflammation and
fibrosis of the lung in exposed workers [99-101, 107, 113, 114, 117, 124, 129, 302]. Therefore,
the pulmonary toxicity of WC-Co has been well studied in a number of relevant models
including bronchial epithelial cells, alveolar macrophages and lung carcinoma cells [132, 141143, 152, 222]. WC-Co nanoparticles are reported to cause significant cellular toxicity in
bronchial epithelial cells after as little as 2 hr of exposure to WC-Co concentrations ≥ 10 µg/mL
[222] and in A549 lung carcinoma cells after 3 days exposure to a low concentration of 8 µg/mL
WC-Co [132]. In alveolar macrophages, WC-Co exerts toxicity after as little as 2 hr exposure to
≥ 83 µg/mL [141, 142]. By contrast, very little is known about the pulmonary toxicity of
CoCrMo particles. Since occupational exposure to both CoCrMo and WC-Co particles is known
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to cause similar types of lung diseases, we hypothesized that the toxicity of CoCrMo particles
would be similar to that of WC-Co particles in our BEAS-2B cell model.
While a distinct dose- and time-dependent toxicity was observed for nano- and microCoCrMo particles (Figure 2), we did not note any significant increase in the toxicity of nanoCoCrMo compared to micro-CoCrMo. This outcome was somewhat surprising, as there is a clear
association between particle size and toxicity in the literature [25, 31, 35, 59, 187, 238, 295,
303]; nanoparticles typically exert greater toxic effects than microparticles of the same
composition, due to their smaller size and increased surface area available for cellular interaction
and chemical reactions. This result is in contrast to our findings regarding WC-Co particle
toxicity, where nano-WC-Co was significantly more toxic than micro-WC-Co in lung epithelial
cells at concentrations ≥ 10 μg/mL [222]. We speculate that there was little difference in nanoand micro-CoCrMo toxicity due to the fact that CoCrMo has caused significantly less toxicity
compared to WC-Co particles at doses of 1-1000 µg/mL under identical conditions (Figure 3),
and CoCrMo has been implemented as a “bio-compatible” material, hence its prevalent use in
the orthopedic community [26]. However, these results demonstrate that CoCrMo particles can
be toxic toward BEAS-2B cells.
Oxidative stress has been implicated in the reported toxicity of CoCrMo particles in other
cell types, such as fibroblasts [48, 50, 264, 274, 304]. Oxidative stress may also play a role in the
progression of lung diseases [305], such as those caused by cobalt-containing metal exposures
[139], so we examined the capacity of nano- and micro-CoCrMo particles to cause oxidative
stress in our BEAS-2B cell model.

The results of our DCF assay indicated that nano-CoCrMo

caused significantly higher levels of oxidative stress compared to micro-CoCrMo particles at
concentrations of 100 and 1000 μg/mL (Figure 4), which would be consistent with the expected
127

size-dependent effect due to the increased reactive surface area of nano-CoCrMo compared to
micro-CoCrMo. These results are consistent with fibroblast studies in the literature [48, 274],
which found high levels of oxidative stress, marked by increased levels of DCF fluorescence,
after as little as 2 hr of exposure [274] and increased levels of 8OHdG staining, a marker of
oxidative stress induced DNA damage, after 24 hr of exposure to nano-CoCrMo particles [48].
Although CoCrMo particles could cause high levels of oxidative stress compared to control, we
noted that nano-CoCrMo caused less oxidative stress than nano-WC-Co at 1000 μg/mL after 6
and 12 hr of exposure (Figure 6). Beyond 12 hr, nano-CoCrMo caused higher levels of oxidative
stress than nano-WC-Co; however, we attributed this phenomenon to the enhanced toxicity of
WC-Co over CoCrMo. At 24 hr exposure and beyond, nano-WC-Co caused such substantial
toxicity that no live cells remained to generate a signal in the oxidative stress assay. These data
indicated that, while less toxic than nano-WC-Co at high concentrations in the cell viability
assay, CoCrMo particles caused greater levels of oxidative stress upon long-term exposure (i.e.
48 hr), which could ultimately lead to downstream effects such as DNA damage and
genotoxicity upon long-term exposure [48-50, 271].
In the case of occupational WC-Co exposure, there is a two-fold increased risk of
developing lung cancer [97, 100]; however, no such link between CoCrMo particle exposure and
cancer has yet been identified [270]. It is worth noting, however, that only the relationship
between local implant wear particles and systemic cancer occurrence was examined during the
systematic review of in vitro and in vivo research regarding CoCrMo cancer occurrence [270].
Human clinical data pertaining to the occurrence and progression of DTP in CoCrMo exposed
technicians was not included in the study [290-294, 296, 297]. Currently, due to small sample
size and lack of clinical follow-up, there is little information regarding the long-term progression
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of DTP and occurrence of lung cancer in affected patients, so it remains unknown whether DTP
patients have an increased risk of lung cancer similar to that reported for HMLD patients.
Taken together, the results of our study demonstrated that CoCrMo particles cause
toxicity toward BEAS-2B cells at a high concentration (1000 μg/mL) but remain relatively nontoxic at concentrations ≤ 100 μg/mL, in stark contrast to WC-Co particles which exhibit high
toxicity at concentrations ≥ 10 μg/mL. These findings are intriguing, since both types of “dusts”
are reported to cause similar lung diseases following chronic occupational exposures. At least in
the case of WC-Co, the combination of WC with Co is highly toxic in vitro and in vivo, whereas
the components themselves are relatively non-toxic when administered alone [128, 140-144, 146,
154-156, 160, 161, 284]. It is thought that the release of cobalt ions from the composite particle
may enhance the toxicity of the constituent WC components [134, 140, 144, 146, 306, 307].
There is also some evidence which suggests that the speciation of cobalt released from MoM
CoCrMo hip implants plays a role in the associated toxicity and inflammation state [263], so it
seems plausible that similar mechanisms of toxicity may occur during CoCrMo and WC-Co
particle exposure. While the results of our preliminary study indicated that CoCrMo caused high
oxidative stress and toxicity toward lung epithelial cells, studies which further examine the
mechanism responsible for CoCrMo-mediated toxicity are warranted.
CONCLUSION
This study examined the toxicity of nano- and micro-CoCrMo particles and determined
whether their exposure caused oxidative stress in a lung epithelial cell model. Nano- and microCoCrMo caused significant toxicity at a high concentration (i.e. 1000 µg/mL), but there was no
enhancement of toxicity of the nano-CoCrMo compared to the micro-CoCrMo. However, nanoCoCrMo induced significantly higher levels of oxidative stress than micro-CoCrMo at high
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concentrations (i.e. 100 and 1000 µg/mL). The results presented here demonstrated, for the first
time, that CoCrMo particles cause pulmonary toxicity in vitro, which may contribute toward the
development of occupational dental technician’s pneumoconiosis (lung disease) in industrial
settings.
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SUPPLEMENTARY MATERIAL
MATERIALS and METHODS
S1.1 CoCrMo Particle Characterization: Milled nano- and micro-CoCrMo particles were
analyzed using scanning electron microscopy with energy-dispersive x-ray (SEM/EDX) to
determine the morphology and elemental composition. Dynamic light scattering (DLS) was used
to determine the average particle/aggregate size in suspension.
For DLS, stock particle suspensions (5 mg/mL) were prepared by adding 25 mg dry
particle powder to a 20 mL vial containing 5 mL sterile PBS with 10% FBS. The particles were
then sonicated using an Omni International Sonic Ruptor (Kennesaw, GA) for two intervals of
30 sec each to ensure particle dispersion. Dilute particle suspension was prepared in DMEM
supplemented with 10% FBS and analyzed via DLS using a Malvern Zetasizer 7.01 (Malvern
Instruments Ltd., Malvern, UK). Background absorbance of DMEM containing 10% FBS only
was used to ‘blank’ the instrument prior to measurement of the WC-Co particle suspensions.
For SEM/EDX, raw particle powder was imaged on a JEOL JSM 7600F setup equipped
with an Oxford Instruments energy dispersive x-ray (EDX) system for chemical analysis. EDX
measurements were carried out in the Point & ID mode with spectrum acquisition time of 120 s
and spectrum range of 0-10 keV.
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FIGURES

Figure S1. Background absorbance of DMEM containing MTT reagent (tetrazolinium salt)
under assay conditions in the presence of CoCrMo particles or blank (control) to confirm the
absence of artifacts at 570 nm, the primary absorbance wavelength for formazan detection used
in the MTT viability assay.
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Figure S2. Background fluorescence of blank (PBS + dye only) and WC-Co particle suspensions
in the absence of cells to confirm the absence of artifacts at the primary emission wavelengths
for A) DCF at 520 nm and B) DHE at 620 nm.
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CHAPTER 6:
Research Summary and General Discussion

A summary of our findings regarding nano-WC-Co toxicity and suggestions for future work
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SUMMARY & DISCUSSION
Occupational exposure to hard metals such as WC-Co is an important concern in the field
of nanotoxicology, since inhalation of WC-Co dusts and particles is known to cause hard metal
lung disease (HMLD), marked by progressive lung inflammation, fibrosis and an increased risk
of lung cancer [101, 102, 105, 110, 111]. Although WC-Co exposure is attributed as the cause of
HMLD, the relationship between acute WC-Co toxicity and disease progression remains poorly
understood. Previous in vitro studies focused on identifying the toxicity of micro-sized WC-Co
particles and determined that the combination of WC with Co is responsible for the observed
toxic effects, which are greater than that of the components (W, WC or Co) alone [128, 130153]; however, the mechanism underlying the enhanced toxicity of the WC-Co composite over
W, WC or Co alone has not been identified. Additionally, the toxicity of micro-sized WC-Co has
been verified in vivo, although these studies mainly focused on the local pulmonary effects of
WC-Co exposure [130, 154-161]. In general, there are fewer reports regarding the toxicity of
nano-sized WC-Co [132-134, 137, 138, 150, 151], especially in vivo, which is concerning since
nano-sized particles are generally thought to be more toxic and are capable of deeper airway
penetration than their micro-sized counterparts during inhalation.
Therefore, the goal of my dissertation research project was to examine the toxic effects of
nano-WC-Co, using relevant cell culture and animal models, to determine the toxicity of nanoWC-Co and shed light on potential mechanisms underlying disease progression. To achieve this
goal, we systematically examined the toxicity of WC-Co using a variety of in vitro and in vivo
models. In Specific Aim 1, we focused on the in vitro effects of nano-WC-Co particles on lung
epithelial cells which line the upper and middle respiratory tract. This model is highly relevant
due to the risk of pulmonary WC-Co exposure in industrial settings and the effects of WC-Co
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have yet to be reported in a non-carcinoma lung cell line. Here, we identified that nano-WC-Co
was capable of inducing greater cellular toxicity and higher levels of oxidative stress than microWC-Co particles of the same composition under identical conditions. These results were
consistent with the literature, where the enhanced toxicity of nano-sized over micro-sized
particles has been clearly established [25, 31, 32, 44, 205, 238]. Oxidative stress has been
reported in human cells after exposure to micro-sized WC-Co in vitro, so our findings here seem
consistent with earlier reports [132, 137, 140-144].
We further determined that cellular toxicity and death following WC-Co exposure occurs
via induction of cellular apoptosis rather than necrosis, using flow cytometry, which indicated
that WC-Co particles are capable of stimulating apoptotic signaling in lung epithelial cells. This
finding is consistent with a previous study, where apoptosis was reported in human peripheral
blood monocytes after as little as 6 hr of WC-Co exposure [148]. Determining the primary
apoptosis signaling cascade activated after exposure to WC-Co particles was beyond the scope of
our study and remains to be identified; however, since high levels of oxidative stress can cause
DNA damage, we speculate that apoptosis may occur in cells exposed to WC-Co due to reactive
oxygen species-induced DNA damage and subsequent activation of caspases involved in
apoptosis signaling [52, 136].
In HMLD patients, large deposits of WC-Co are often found in histological specimens,
but the origin of these deposits is unknown. One theory suggests that these WC-Co deposits are
due to macrophage phagocytosis of WC-Co particles [84, 299]: once the macrophage has
engulfed the WC-Co particle, the macrophage is unable to eliminate the WC-Co particle via its
normal lysosomal degradation process and as a result, WC-Co persists within the macrophage
thereby forming a ‘deposit’. Due to their small size, nano-WC-Co particles have been reportedly
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internalized by other non-phagocytic cell types such as neurons, colon and skin cells [132].
Consistent with this previous report, we found that lung epithelial cells are capable of
internalizing WC-Co particles up to 500 nm in diameter in our study; therefore, we speculate that
the origins of WC-Co deposits in HMLD patients may be multi-cellular in nature and could be
due to the interaction of WC-Co with both lung epithelial cells and alveolar macrophages.
Since one of the hallmarks of HMLD is pulmonary inflammation, in Specific Aim 2, we
examined the inflammatory response toward nano-WC-Co particles in macrophages and
determined the toxicity of WC-Co using a co-culture of lung epithelial cells and macrophages to
more closely represent the dynamic tissue environment of the lung. In our study, nano-WC-Co
exposure stimulated an inflammatory response in macrophages, marked by high levels of IL-12
and IL-1β secretion. In HMLD, lung inflammation and fibrosis occur in a progressive fashion, so
we speculate that the induction of a pro-inflammatory response in macrophages may be an
important factor in HMLD. This idea is supported by literature which indicates that IL-1 in
particular may play a role in pulmonary fibrosis [308], so it seems reasonable to suggest that
WC-Co may induce a similar type of pulmonary inflammatory response which promotes lung
fibrosis after inhalation.
Macrophages attenuated the toxicity of nano-WC-Co in our co-culture model compared
to lung epithelial cells alone. This “protective” effect was attributed to the engulfment of nanoWC-Co by the macrophages, which confined the WC-Co particles to the intracellular
environment of the macrophage itself, which thereby prevented direct interaction and toxicity of
the nano-WC-Co toward lung epithelial cells. Although phagocytosis of WC-Co particles is part
of the natural physiological macrophage response and seemed to play a protective role in our in
vitro study, the long-term effects of WC-Co internalization in macrophages have not yet been
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reported and could potentially have a more detrimental effect. As mentioned earlier, WC-Co may
not be degraded within the phago-lysosomal compartments inside the macrophage; the inability
to eliminate WC-Co may exacerbate the inflammatory response of the macrophage over long
term exposure and may play a role in the progressive inflammatory and fibrotic reaction due to
chronic secretion of cytokines such as IL-1 [308].
In addition to exerting local toxicity at the site of exposure, emerging evidence in the
field of nanotoxicology suggests that pulmonary NP exposure may cause systemic effects
beyond the site of exposure in the lung [37, 66, 164-175]. Animal studies regarding the toxicity
of WC-Co particles are limited, and in fact, the toxicity of nano-sized WC-Co has not yet been
reported in vivo. Therefore, in Specific Aim 3, we conducted a preliminary in vivo study to
investigate the local toxicity and potential systemic effects resulting from pulmonary nano-WCCo exposure in rats. Based on our in vitro outcomes in reported for Aims 1 and 2, we
hypothesized that exposure to nano-WC-Co would cause pulmonary toxicity, inflammation and
may cause an increase in the levels of circulating pro-inflammatory cytokines. However, we
found an overall lack of toxicity and pulmonary inflammation after 24 hr exposure to a single
dose of nano-WC-Co.
This outcome was perplexing, as all of the evidence regarding the effects of WC-Co
exposure thus far suggests that nano-WC-Co should cause acute toxicity both in vivo and in
vitro. In this case, we speculate that we may have missed the inflammatory response since only a
single exposure time (24 hr) was used. While we selected our dosages based on the toxicity of
WC-Co in vitro, it is possible that a single exposure at these concentrations in vivo simply did
not generate enough pulmonary toxicity/inflammation to be effectively detected via the bronchoalveolar lavage technique; toxicity and inflammation may have occurred but not at detectable
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levels after the 24 hr exposure time. It is also possible that the effects of nano-WC-Co exposure
may occur in a cumulative fashion (i.e. toxicity is observed after repeated or chronic exposures)
in vivo, so multiple/repeated exposure may be a prerequisite for WC-Co toxicity in whole
animals. The outcomes of our preliminary in vivo nano-WC-Co study highlight the need for
future studies to examine the systemic inflammatory effects of repeated or chronic nano-WC-Co
exposure, which would more closely represent an actual occupational WC-Co NP exposure.
Overall, the results of this dissertation project confirm the toxic potential of WC-Co
particles in the respiratory tract and highlight the importance of understanding the mechanism of
WC-Co toxicity as it relates to HMLD. Based on our findings reported herein, we speculate that
HMLD may be caused by the simultaneous acute toxicity of WC-Co in lung epithelial cells and
the rapid inflammatory response generated by macrophages upon WC-Co internalization. The
presence of apoptotic cells and secretion of inflammatory cytokines in the lung may stimulate an
immune response designed to promote tissue repair; however, the persistence of WC-Co in the
pulmonary region and likelihood for repeated exposures may shift this response toward a chronic
inflammatory state which, in turn, may promote the fibrosis and therefore lead to the
development of HMLD. This study, along with the existing body of literature regarding microWC-Co toxicity, highlights the detrimental effects of WC-Co NP exposure in occupational
settings, including hard metal manufacturing facilities and mining and drilling industries and
highlights the importance of defining occupational WC-Co exposure limits so that future
generations of workers are protected from this harmful disease. Studies which examine the
effects of chronic nano-WC-Co exposure in vitro and in vivo are warranted in the future, so that
the link between WC-Co acute toxicity and development of a chronic inflammatory state
observed in HMLD patients may be elucidated.
139

CHAPTER 7:

References for Chapters 1-6

140

REFERENCES
1.
2.
3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

Schrand, A.M., et al., Toxicity testing of nanomaterials. Adv Exp Med Biol, 2012. 745: p.
58-75.
Song, Y., et al., Nanomaterials in humans: identification, characteristics, and potential
damage. Toxicol Pathol, 2011. 39(5): p. 841-9.
Adlakha-Hutcheon, G., et al., NANOMATERIALS, NANOTECHNOLOGY Applications,
Consumer Products, and Benefits. Nanomaterials: Risks and Benefits, 2009: p. 195-207.
Hansen, S.F., et al., NANOMATERIALS IN CONSUMER PRODUCTS Categorization
and Exposure Assessment. Nanomaterials: Risks and Benefits, 2009: p. 359-367.
Stamm, H., N. Gibson, and E. Anklam, Detection of nanomaterials in food and consumer
products: bridging the gap from legislation to enforcement. Food Additives and
Contaminants Part a-Chemistry Analysis Control Exposure & Risk Assessment, 2012.
29(8): p. 1175-1182.
Chekman, I.S., et al., The prospects of medical application of metal-based nanoparticles
and nanomaterials. Lik Sprava, 2011(1-2): p. 3-21.
Cormode, D.P., et al., Nanotechnology in medical imaging: probe design and
applications. Arterioscler Thromb Vasc Biol, 2009. 29(7): p. 992-1000.
de Silva, M.N., Nanotechnology and nanomedicine: a new horizon for medical
diagnostics and treatment. Arch Soc Esp Oftalmol, 2007. 82(6): p. 331-4.
Lin, H. and R.H. Datar, Medical applications of nanotechnology. Natl Med J India, 2006.
19(1): p. 27-32.
Zhao, J. and V. Castranova, Toxicology of nanomaterials used in nanomedicine. J
Toxicol Environ Health B Crit Rev, 2011. 14(8): p. 593-632.
Blynskaya, E.V., K.V. Alekseev, and R.N. Alyautdin, Perspectives of the development of
pharmaceutical nanotechnology. Russian Journal of General Chemistry, 2012. 82(3): p.
519-526.
Chapman, P., Nanotechnology in the pharmaceutical industry. Expert Opinion on
Therapeutic Patents, 2005. 15(3): p. 249-251.
Crommelin, D.J.A., K. Park, and A. Florence, Pharmaceutical nanotechnology: Unmet
needs in drug delivery. Journal of Controlled Release, 2010. 141(3): p. 263-264.
Stolarczyka, E.U. and K. Stolarczyk, Perspectives of nanotechnology in medicine and
pharmacy and its influence on pharmaceutical industry. Przemysl Chemiczny, 2007.
86(8): p. 797-799.
Cassee, F.R., et al., Exposure, health and ecological effects review of engineered
nanoscale cerium and cerium oxide associated with its use as a fuel additive. Crit Rev
Toxicol, 2011. 41(3): p. 213-29.
Lynam, D.R., et al., Environmental assessment of MMT fuel additive. Sci Total Environ,
1990. 93: p. 107-14.
Park, B., et al., Hazard and risk assessment of a nanoparticulate cerium oxide-based
diesel fuel additive - a case study. Inhal Toxicol, 2008. 20(6): p. 547-66.
Madl, A.K., et al., Health Risk Ranking Framework for the Life Cycle of NanomaterialContaining Products: Comparison of Industrial Versus Consumer Application Settings.
International Journal of Toxicology, 2013. 32(1): p. 65-69.
http://www.nanotechproject.org/cpi/about/analysis/. 2014.
141

20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.

Arvidsson, R., S. Molander, and B.A. Sanden, Review of Potential Environmental and
Health Risks of the Nanomaterial Graphene. Human and Ecological Risk Assessment,
2013. 19(4): p. 873-887.
Hristovski, K.D., et al., Environmental releases of engineered nanomaterial resulting
from biosolids disposal to land and air. Abstracts of Papers of the American Chemical
Society, 2012. 244.
Luo, X.Z.J., Nanomaterial Registry A resource for biological and environmental
interactions of nanomaterials. 2012 Ieee International Conference on Bioinformatics and
Biomedicine Workshops (Bibmw), 2012.
Eckelman, M.J., et al., New perspectives on nanomaterial aquatic ecotoxicity: production
impacts exceed direct exposure impacts for carbon nanotoubes. Environ Sci Technol,
2012. 46(5): p. 2902-10.
Gaiser, B.K., et al., Assessing exposure, uptake and toxicity of silver and cerium dioxide
nanoparticles from contaminated environments. Environ Health, 2009. 8 Suppl 1( Suppl
1): p. S2.
Buzea, C., I.I. Pacheco, and K. Robbie, Nanomaterials and nanoparticles: Sources and
toxicity. Biointerphases, 2007. 2(4): p. Mr17-Mr71.
Keegan, G.M., I.D. Learmonth, and C.P. Case, A systematic comparison of the actual,
potential, and theoretical health effects of cobalt and chromium exposures from industry
and surgical implants. Crit Rev Toxicol, 2008. 38(8): p. 645-74.
Parry, M.C., et al., Blood levels of cobalt and chromium are inversely correlated to head
size after metal-on-metal resurfacing arthroplasty. Hip International, 2013. 23(6): p. 529534.
Pourzal, R., et al., Characterization of Wear Particles Generated from CoCrMo Alloy
under Sliding Wear Conditions. Wear, 2011. 271(9-10): p. 1658-1666.
Sansone, V., D. Pagani, and M. Melato, The effects on bone cells of metal ions released
from orthopaedic implants. A review. Clin Cases Miner Bone Metab, 2013. 10(1): p. 3440.
Simeonova, P.P. and A. Erdely, Engineered nanoparticle respiratory exposure and
potential risks for cardiovascular toxicity: predictive tests and biomarkers. Inhal Toxicol,
2009. 21 Suppl 1: p. 68-73.
Cattaneo, A.G., et al., Nanotechnology and human health: risks and benefits. J Appl
Toxicol, 2010. 30(8): p. 730-44.
Castranova, V., Overview of current toxicological knowledge of engineered
nanoparticles. J Occup Environ Med, 2011. 53(6 Suppl): p. S14-7.
Nurkiewicz, T.R., et al., Systemic microvascular dysfunction and inflammation after
pulmonary particulate matter exposure. Environ Health Perspect, 2006. 114(3): p. 412-9.
Stapleton, P.A., et al., Xenobiotic particle exposure and microvascular endpoints: a call
to arms. Microcirculation, 2012. 19(2): p. 126-42.
Nel, A.E., et al., Understanding biophysicochemical interactions at the nano-bio
interface. Nat Mater, 2009. 8(7): p. 543-57.
Nurkiewicz, T.R., et al., Particulate matter exposure impairs systemic microvascular
endothelium-dependent dilation. Environ Health Perspect, 2004. 112(13): p. 1299-306.
Nurkiewicz, T.R., et al., Pulmonary particulate matter and systemic microvascular
dysfunction. Res Rep Health Eff Inst, 2011. 164: p. 3-48.
142

38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.

Gill, H.S., et al., Molecular and immune toxicity of CoCr nanoparticles in MoM hip
arthroplasty. Trends Mol Med, 2012. 18(3): p. 145-55.
Ingham, E. and J. Fisher, Biological reactions to wear debris in total joint replacement.
Proceedings of the Institution of Mechanical Engineers Part H-Journal of Engineering in
Medicine, 2000. 214(H1): p. 21-37.
Song, Y., X. Li, and X. Du, Exposure to nanoparticles is related to pleural effusion,
pulmonary fibrosis and granuloma. . Eur Respir J, 2009. 34: p. 559-567.
Donaldson, K., et al., The biologically effective dose in inhalation nanotoxicology. Acc
Chem Res, 2013. 46(3): p. 723-32.
Hubbs, A.F., et al., Nanotoxicology--a pathologist's perspective. Toxicol Pathol, 2011.
39(2): p. 301-24.
Lison, D., G. Vietti, and S. van den Brule, Paracelsus in nanotoxicology. Part Fibre
Toxicol, 2014. 11(1): p. 35.
Boverhof, D.R. and R.M. David, Nanomaterial characterization: considerations and
needs for hazard assessment and safety evaluation. Anal Bioanal Chem, 2010. 396(3): p.
953-61.
Richman, E.K. and J.E. Hutchison, The nanomaterial characterization bottleneck. ACS
Nano, 2009. 3(9): p. 2441-6.
Bohnsack, J.P., et al., The primacy of physicochemical characterization of nanomaterials
for reliable toxicity assessment: a review of the zebrafish nanotoxicology model. Methods
Mol Biol, 2012. 926: p. 261-316.
Takhar, P. and S. Mahant, In vitro methods for nanotoxicity assessment: advantages and
applications. Arch Appl Sci Res, 2011. 3(2): p. 389-403.
Papageorgiou, I., et al., The effect of nano- and micron-sized particles of cobaltchromium alloy on human fibroblasts in vitro. Biomaterials, 2007. 28(19): p. 2946-2958.
Papageorgiou, I., et al., Macrophages detoxify the genotoxic and cytotoxic effects of
surgical cobalt chrome alloy particles but not quartz particles on human cells in vitro.
Mutat Res, 2008. 643(1-2): p. 11-9.
Papageorgiou, I., et al., Genotoxic effects of particles of surgical cobalt chrome alloy on
human cells of different age in vitro. Mutat Res, 2007. 619(1-2): p. 45-58.
Sun, L., et al., Cytotoxicity and mitochondrial damage caused by silica nanoparticles.
Toxicol In Vitro, 2011. 25(8): p. 1619-29.
Park, E.J., et al., Oxidative stress and apoptosis induced by titanium dioxide
nanoparticles in cultured BEAS-2B cells. Toxicol Lett, 2008. 180(3): p. 222-9.
Wilhelmi, V., et al., Evaluation of apoptosis induced by nanoparticles and fine particles
in RAW 264.7 macrophages: facts and artefacts. Toxicol In Vitro, 2012. 26(2): p. 32334.
Guadagnini, R., et al., Toxicity screenings of nanomaterials: challenges due to
interference with assay processes and components of classic in vitro tests. .
Nanotoxicology, 2013. Epub ahead of print: p. DOI 0.3109/17435390.2013.829590.
Holder, A.L., et al., Particle-induced artifacts in the MTT and LDH viability assays.
Chem Res Toxicol, 2012. 25(9): p. 1885-92.
Kroll, A., et al., Interference of engineered nanoparticles with in vitro toxicity assays.
Arch Toxicol, 2012. 86(7): p. 1123-36.

143

57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.

Lupu, A.R. and T. Popescu, The noncellular reduction of MTT tetrazolium salt by TiO(2)
nanoparticles and its implications for cytotoxicity assays. Toxicol In Vitro, 2013. 27(5):
p. 1445-50.
Guadagnini, R., et al., Toxicity screenings of nanomaterials: challenges due to
interference with assay processes and components of classic in vitro tests.
Nanotoxicology, 2013. epub ahead of print: p. DOI 10.3109/17435390.2013.829590.
Fischer, H.C. and W.C.W. Chan, Nanotoxicity: the growing need for in vivo study.
Current Opinion in Biotechnology, 2007. 18(6): p. 565-571.
Rizzo, L.Y., et al., In vivo nanotoxicity testing using the zebrafish embryo assay. Journal
of Materials Chemistry B, 2013. 1(32): p. 3918-3925.
Shelley, M.L., et al., Modeling the In Vivo Case with In Vitro Nanotoxicity Data.
International Journal of Toxicology, 2008. 27(5): p. 359-367.
Henderson, R.F., et al., A comparison of the inflammatory response of the lung to inhaled
versus instilled particles in F344 rats. Fundam Appl Toxicol, 1995. 24(2): p. 183-97.
Blum, J.L., et al., Short-term inhalation of cadmium oxide nanoparticles alters
pulmonary dynamics associated with lung injury, inflammation, and repair in a mouse
model. Inhal Toxicol, 2014. 26(1): p. 48-58.
Pauluhn, J., Subchronic inhalation toxicity of iron oxide (magnetite, Fe(3) O(4) ) in rats:
pulmonary toxicity is determined by the particle kinetics typical of poorly soluble
particles. J Appl Toxicol, 2012. 32(7): p. 488-504.
Minarchick, V.C., et al., Pulmonary cerium dioxide nanoparticle exposure differentially
impairs coronary and mesenteric arteriolar reactivity. Cardiovasc Toxicol, 2013. 13(4):
p. 323-37.
Choi, M., et al., Chitosan nanoparticles show rapid extrapulmonary tissue distribution
and excretion with mild pulmonary inflammation to mice. Toxicol Lett, 2010. 199(2): p.
144-52.
Brown, C., et al., Consequences of exposure to peri-articular injections of micro- and
nano-particulate cobalt-chromium alloy. Biomaterials, 2013. 34(34): p. 8564-80.
Wang, Z., et al., Reproductive toxicity in adult male rats following intra-articular
injection of cobalt-chromium nanoparticles. Journal of Orthopaedic Science, 2013. 18(6):
p. 1020-1026.
Gaiser, B.K., et al., Effects of silver and cerium dioxide micro- and nano-sized particles
on Daphnia magna. J Environ Monit, 2011. 13(5): p. 1227-35.
Yao, Z., J. Stiglich, and T. Sudarshan, Nanosized WC-Co holds promise for the future.
Metal Powder Report, 1998. 53(3): p. 26-33.
Yao, Z., J. Stiglich, and T. Sudarshan, Nano-grained Tungsten Carbide-Cobalt (WC/Co).
Materials Modification Inc., 1995.
http://www.matmod.com/publications/armor_1.pdf: p. 1-27.
Linnainmaa, M., J. Kangas, and P. Kalliokoski, Exposure to airborne metals in the
manufacture and maintenance of hard metal and stellite blades. Am Ind Hyg Assoc J,
1996. 57(2): p. 196-201.
Balmes, J.R., Respiratory effects of hard-metal dust exposure. Occup Med, 1987. 2(2): p.
327-44.
Broding, H.C., et al., Comparison between exhaled breath condensate analysis as a
marker for cobalt and tungsten exposure and biomonitoring in workers of a hard metal
alloy processing plant. Int Arch Occup Environ Health, 2009. 82(5): p. 565-73.
144

75.

76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.

Day, G.A., M.A. Virji, and A.B. Stefaniak, Characterization of exposures among
cemented tungsten carbide workers. Part II: Assessment of surface contamination and
skin exposures to cobalt, chromium and nickel. J Expo Sci Environ Epidemiol, 2009.
19(4): p. 423-34.
Guffey, S.E., et al., Hard metal exposures. Part 1: Observed performance of three local
exhaust ventilation systems. Appl Occup Environ Hyg, 2000. 15(4): p. 331-41.
Kraus, T., et al., Exposure assessment in the hard metal manufacturing industry with
special regard to tungsten and its compounds. Occup Environ Med, 2001. 58(10): p. 6314.
Stefaniak, A.B., M.A. Virji, and G.A. Day, Characterization of exposures among
cemented tungsten carbide workers. Part I: Size-fractionated exposures to airborne
cobalt and tungsten particles. J Expo Sci Environ Epidemiol, 2009. 19(5): p. 475-91.
Stefaniak, A.B., et al., Characteristics of dusts encountered during the production of
cemented tungsten carbides. Ind Health, 2007. 45(6): p. 793-803.
National Toxicology, P., Cobalt-tungsten carbide: powders and hard metals. Rep
Carcinog, 2011. 12: p. 115-20.
Demedts, M. and J.L. Ceuppens, Respiratory diseases from hard metal or cobalt
exposure. Solving the enigma. Chest, 1989. 95(1): p. 2-3.
Kumagai, S., Y. Kusaka, and S. Goto, Cobalt exposure level and variability in the hard
metal industry of Japan. Am Ind Hyg Assoc J, 1996. 57(4): p. 365-9.
Kusaka, Y. and S. Goto, Is there an occupational exposure limit (TLV) present for
cobalt? A lesson from hard metal disease in Japan. Advances in the Prevention of
Occupational Respiratory Diseases, 1998. 1153: p. 388-392.
Anttila, S., et al., Hard metal lung disease: a clinical, histological, ultrastructural and Xray microanalytical study. Eur J Respir Dis, 1986. 69(2): p. 83-94.
Chiappino, G., Hard metal disease: clinical aspects. Sci Total Environ, 1994. 150(1-3):
p. 65-8.
Cullen, M.R., Respiratory diseases from hard metal exposure. A continuing enigma.
Chest, 1984. 86(4): p. 513-4.
Fischbein, A., et al., Hard metal disease: a multidisciplinary evaluation of two cases. N
Y State J Med, 1986. 86(11): p. 600-3.
Galy, P., et al., Pulmonary disorders in the hard metal industry. Rev Inst Hyg Mines
(Hasselt), 1974. 29(3): p. 130-7.
Hartmann, A., B. Wuthrich, and G. Bolognini, Occupation-related lung diseases in hard
metal production and manufacturing. An allergic process? Schweiz Med Wochenschr,
1982. 112(33): p. 1137-41.
Hartung, M., Etiology, pathogenesis and clinical aspects of hard metal fibrosis of the
lung. Pneumologie, 1990. 44(2): p. 49-54.
Hartung, M. and H. Valentin, Pulmonary fibrosis caused by hard-metal dusts. Zentralbl
Bakteriol Mikrobiol Hyg B, 1983. 177(3-4): p. 237-50.
Kishimoto, T., I. Yamadori, and Y. Kawabata, Interstitial pneumonia induced by the
inhalation of hard metal. Nihon Kokyuki Gakkai Zasshi, 1999. 37(9): p. 704-9.
Kitaichi, M. and Y. Kitagawa, Hard metal disease. Ryoikibetsu Shokogun Shirizu,
1994(3): p. 566-8.
Kusaka, Y., et al., Bronchopulmonary diseases due to ultra-hard metal dust, with special
reference to the result of the dust analysis. Sangyo Igaku, 1983. 25(3): p. 155-60.
145

95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.

Kusaka, Y., O. Kuwabara, and H. Kitamura, A case of diffuse lung disease associated
with lung cancer in a hard metal worker. Nihon Kyobu Shikkan Gakkai Zasshi, 1984.
22(9): p. 804-8.
Kusaka, Y., et al., Bronchopulmonary diseases due to the hard metal dust. Sangyo Igaku,
1982. 24(6): p. 636-48.
Lasfargues, G., et al., Lung cancer mortality in a French cohort of hard-metal workers.
Am J Ind Med, 1994. 26(5): p. 585-95.
Meyer-Bisch, C., et al., Respiratory hazards in hard metal workers: a cross sectional
study. Br J Ind Med, 1989. 46(5): p. 302-9.
Montero, M.A., J. de Gracia, and F. Morell, Hard metal interstitial lung disease. Arch
Bronconeumol, 2010. 46(9): p. 489-91.
Moulin, J.J., et al., Lung cancer risk in hard-metal workers. Am J Epidemiol, 1998.
148(3): p. 241-8.
Nemery, B. and J.L. Abraham, Hard metal lung disease: still hard to understand. Am J
Respir Crit Care Med, 2007. 176(1): p. 2-3.
Nemery, B., E.K. Verbeken, and M. Demedts, Giant cell interstitial pneumonia (hard
metal lung disease, cobalt lung). Semin Respir Crit Care Med, 2001. 22(4): p. 435-48.
Ott, G. and G. Mikuz, Hard metal pulmonary fibrosis. Dtsch Med Wochenschr, 1982.
107(37): p. 1396-9.
Rivolta, G., et al., Hard metal lung disorders: analysis of a group of exposed workers.
Sci Total Environ, 1994. 150(1-3): p. 161-5.
Rizzato, G., et al., The differential diagnosis of hard metal lung disease. Sci Total
Environ, 1994. 150(1-3): p. 77-83.
Rochat, T., et al., Rapidly progressive interstitial lung disease in a hard metal coating
worker undergoing hemodialysis. Eur J Respir Dis, 1987. 71(1): p. 46-51.
Ruokonen, E.L., et al., A fatal case of hard-metal disease. Scand J Work Environ Health,
1996. 22(1): p. 62-5.
Scherrer, M. and J.M. Maillard, Hard metal pneumopathies. Schweiz Med Wochenschr,
1982. 112(6): p. 198-207.
Scherrer, M., et al., 3 cases of hard metal dust lung disease. Schweiz Med Wochenschr,
1970. 100(52): p. 2251-5.
Forni, A., Bronchoalveolar lavage in the diagnosis of hard metal disease. Sci Total
Environ, 1994. 150(1-3): p. 69-76.
Kinoshita, M., et al., Giant cell interstitial pneumonia in two hard metal workers: the
role of bronchoalveolar lavage in diagnosis. Respirology, 1999. 4(3): p. 263-6.
Bezerra, P.N., et al., Hard metal lung disease in an oil industry worker. J Bras Pneumol,
2009. 35(12): p. 1254-8.
Dunlop, P., et al., Hard metal lung disease: high resolution CT and histologic correlation
of the initial findings and demonstration of interval improvement. J Thorac Imaging,
2005. 20(4): p. 301-4.
Moriyama, H., et al., Two-dimensional analysis of elements and mononuclear cells in
hard metal lung disease. Am J Respir Crit Care Med, 2007. 176(1): p. 70-7.
Potolicchio, I., et al., Susceptibility to hard metal lung disease is strongly associated with
the presence of glutamate 69 in HLA-DP beta chain. Eur J Immunol, 1997. 27(10): p.
2741-3.
146

116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.

Rizzato, G., et al., Trace of metal exposure in hard metal lung disease. Chest, 1986.
90(1): p. 101-6.
Tanaka, J., et al., An observational study of giant cell interstitial pneumonia and lung
fibrosis in hard metal lung disease. BMJ Open, 2014. 4(3): p. e004407.
Wahbi, Z.K., A.G. Arnold, and A.J. Taylor, Hard metal lung disease and pneumothorax.
Respir Med, 1997. 91(2): p. 103-5.
Nureki, S., et al., Hard metal lung disease successfully treated with inhaled
corticosteroids. Intern Med, 2013. 52(17): p. 1957-61.
Enriquez, L.S., et al., Hard metal pneumoconiosis: a case of giant-cell interstitial
pneumonitis in a machinist. Respir Care, 2007. 52(2): p. 196-9.
Kaneko, Y., et al., Upper lobe-dominant pulmonary fibrosis showing deposits of hard
metal component in the fibrotic lesions. Intern Med, 2010. 49(19): p. 2143-5.
Okuno, K., et al., A case of hard metal lung disease resembling a hypersensitive
pneumonia in radiological images. Intern Med, 2010. 49(12): p. 1185-9.
Blanc, P.D., Is giant cell interstitial pneumonitis synonymous with hard metal lung
disease? Am J Respir Crit Care Med, 2007. 176(8): p. 834; author reply 834-5.
Naqvi, A.H., et al., Pathologic spectrum and lung dust burden in giant cell interstitial
pneumonia (hard metal disease/cobalt pneumonitis): review of 100 cases. Arch Environ
Occup Health, 2008. 63(2): p. 51-70.
Ohori, N.P., et al., Giant-cell interstitial pneumonia and hard-metal pneumoconiosis. A
clinicopathologic study of four cases and review of the literature. Am J Surg Pathol,
1989. 13(7): p. 581-7.
Tabatowski, K., et al., Giant cell interstitial pneumonia in a hard-metal worker.
Cytologic, histologic and analytical electron microscopic investigation. Acta Cytol,
1988. 32(2): p. 240-6.
Wada, M., et al., A case report of hard metal lung with giant cell interstitial pneumonia.
Nihon Kyobu Shikkan Gakkai Zasshi, 1986. 24(6): p. 703-9.
Lison, D., et al., Experimental research into the pathogenesis of cobalt/hard metal lung
disease. Eur Respir J, 1996. 9(5): p. 1024-8.
Ruediger, H.W., Hard metal particles and lung disease: coincidence or causality?
Respiration, 2000. 67(2): p. 137-8.
Huaux, F., et al., Lung toxicity of hard metal particles and production of interleukin-1,
tumor necrosis factor-alpha, fibronectin, and cystatin-c by lung phagocytes. Toxicol
Appl Pharmacol, 1995. 132(1): p. 53-62.
Antonini, J.M., et al., Changes in F-actin organization induced by hard metal particle
exposure in rat pulmonary epithelial cells using laser scanning confocal microscopy. In
Vitr Mol Toxicol, 2000. 13(1): p. 5-16.
Bastian, S., et al., Toxicity of tungsten carbide and cobalt-doped tungsten carbide
nanoparticles in mammalian cells in vitro. Environ Health Perspect, 2009. 117(4): p.
530-6.
Busch, W., et al., Tungsten carbide cobalt nanoparticles exert hypoxia-like effects on the
gene expression level in human keratinocytes. BMC Genomics, 2010. 11: p. 65.
De Boeck, M., et al., In vitro genotoxic effects of different combinations of cobalt and
metallic carbide particles. Mutagenesis, 2003. 18(2): p. 177-86.
Edel, J., et al., Trace metal lung disease: in vitro interaction of hard metals with human
lung and plasma components. Sci Total Environ, 1990. 95: p. 107-17.
147

136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.

Fenoglio, I., et al., The oxidation of glutathione by cobalt/tungsten carbide contributes to
hard metal-induced oxidative stress. Free Radic Res, 2008. 42(8): p. 437-45.
Kuhnel, D., et al., Agglomeration of tungsten carbide nanoparticles in exposure medium
does not prevent uptake and toxicity toward a rainbow trout gill cell line. Aquat Toxicol,
2009. 93(2-3): p. 91-9.
Kuhnel, D., et al., Comparative evaluation of particle properties, formation of reactive
oxygen species and genotoxic potential of tungsten carbide based nanoparticles in vitro.
J Hazard Mater, 2012. 227-228: p. 418-26.
Lison, D., Human toxicity of cobalt-containing dust and experimental studies on the
mechanism of interstitial lung disease (hard metal disease). Crit Rev Toxicol, 1996.
26(6): p. 585-616.
Lison, D., et al., Physicochemical mechanism of the interaction between cobalt metal and
carbide particles to generate toxic activated oxygen species. Chem Res Toxicol, 1995.
8(4): p. 600-6.
Lison, D. and R. Lauwerys, In vitro cytotoxic effects of cobalt-containing dusts on mouse
peritoneal and rat alveolar macrophages. Environ Res, 1990. 52(2): p. 187-98.
Lison, D. and R. Lauwerys, Biological responses of isolated macrophages to cobalt metal
and tungsten carbide-cobalt powders. Pharmacol Toxicol, 1991. 69(4): p. 282-5.
Lison, D. and R. Lauwerys, Study of the mechanism responsible for the elective toxicity
of tungsten carbide-cobalt powder toward macrophages. Toxicol Lett, 1992. 60(2): p.
203-10.
Lison, D. and R. Lauwerys, Evaluation of the role of reactive oxygen species in the
interactive toxicity of carbide-cobalt mixtures on macrophages in culture. Arch Toxicol,
1993. 67(5): p. 347-51.
Lison, D. and R. Lauwerys, Cobalt bioavailability from hard metal particles. Further
evidence that cobalt alone is not responsible for the toxicity of hard metal particles. Arch
Toxicol, 1994. 68(8): p. 528-31.
Lison, D. and R. Lauwerys, The interaction of cobalt metal with different carbides and
other mineral particles on mouse peritoneal macrophages. Toxicol In Vitro, 1995. 9(3):
p. 341-7.
Lombaert, N., et al., Hard-metal (WC-Co) particles trigger a signaling cascade involving
p38 MAPK, HIF-1alpha, HMOX1, and p53 activation in human PBMC. Arch Toxicol,
2012. 87(2): p. 259-68.
Lombaert, N., et al., Evaluation of the apoptogenic potential of hard metal dust (WC-Co),
tungsten carbide and metallic cobalt. Toxicol Lett, 2004. 154(1-2): p. 23-34.
Lombaert, N., et al., In vitro expression of hard metal dust (WC-Co)--responsive genes in
human peripheral blood mononucleated cells. Toxicol Appl Pharmacol, 2008. 227(2): p.
299-312.
Anard, D., et al., In vitro genotoxic effects of hard metal particles assessed by alkaline
single cell gel and elution assays. Carcinogenesis, 1997. 18(1): p. 177-84.
Ding, M., et al., Size-dependent effects of tungsten carbide-cobalt particles on oxygen
radical production and activation of cell signaling pathways in murine epidermal cells.
Toxicol Appl Pharmacol, 2009. 241(3): p. 260-8.
Roesems, G., et al., In vitro cytotoxicity of various forms of cobalt for rat alveolar
macrophages and type II pneumocytes. Toxicol Appl Pharmacol, 2000. 162(1): p. 2-9.
148

153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.

Zhang, X.D., et al., Tungsten carbide-cobalt particles activate Nrf2 and its downstream
target genes in JB6 cells possibly by ROS generation. J Environ Pathol Toxicol Oncol,
2010. 29(1): p. 31-40.
Kitamura, H., et al., Effects of cemented tungsten carbide dust on rat lungs following
intratracheal injection of saline suspension. Acta Pathol Jpn, 1980. 30(2): p. 241-53.
Lasfargues, G., et al., The delayed lung responses to single and repeated intratracheal
administration of pure cobalt and hard metal powder in the rat. Environ Res, 1995.
69(2): p. 108-21.
Lasfargues, G., et al., Comparative study of the acute lung toxicity of pure cobalt powder
and cobalt-tungsten carbide mixture in rat. Toxicol Appl Pharmacol, 1992. 112(1): p. 4150.
De Boeck, M., et al., In vivo genotoxicity of hard metal dust: induction of micronuclei in
rat type II epithelial lung cells. Carcinogenesis, 2003. 24(11): p. 1793-800.
Fedan, J.S. and D. Cutler, Hard metal-induced disease: effects of metal cations in vitro
on guinea pig isolated airways. Toxicol Appl Pharmacol, 2001. 174(3): p. 199-206.
Rengasamy, A., et al., Effects of hard metal on nitric oxide pathways and airway
reactivity to methacholine in rat lungs. Toxicol Appl Pharmacol, 1999. 157(3): p. 178-91.
Kerfoot, E.J., W.G. Fredrick, and E. Domeier, Cobalt metal inhalation studies on
miniature swine. Am Ind Hyg Assoc J, 1975. 36(1): p. 17-25.
Adamis, Z., et al., A study on lung toxicity of respirable hard metal dusts in rats. Ann
Occup Hyg, 1997. 41(5): p. 515-26.
Hartung, M., K.H. Schaller, and E. Brand, On the question of the pathogenetic
importance of cobalt for hard metal fibrosis of the lung. Int Arch Occup Environ Health,
1982. 50(1): p. 53-7.
Migliori, M., et al., Hard metal disease: eight workers with interstitial lung fibrosis due
to cobalt exposure. Sci Total Environ, 1994. 150(1-3): p. 187-96.
Geraets, L., et al., Tissue distribution of inhaled micro- and nano-sized cerium oxide
particles in rats: results from a 28-day exposure study. Toxicol Sci, 2012. 127(2): p. 46373.
He, X., et al., Lung deposition and extrapulmonary translocation of nano-ceria after
intratracheal instillation. Nanotechnology, 2010. 21(28): p. 285103.
Kang, G.S., et al., Long-term inhalation exposure to nickel nanoparticles exacerbated
atherosclerosis in a susceptible mouse model. Environ Health Perspect, 2011. 119(2): p.
176-81.
Kang, G.S., et al., Comparative pulmonary toxicity of inhaled nickel nanoparticles; role
of deposited dose and solubility. Inhal Toxicol, 2011. 23(2): p. 95-103.
Knuckles, T.L., et al., Nanoparticle inhalation alters systemic arteriolar vasoreactivity
through sympathetic and cyclooxygenase-mediated pathways. Nanotoxicology, 2012.
6(7): p. 724-35.
LeBlanc, A.J., et al., Nanoparticle inhalation impairs coronary microvascular reactivity
via a local reactive oxygen species-dependent mechanism. Cardiovasc Toxicol, 2010.
10(1): p. 27-36.
Ma, J.Y., et al., Cerium oxide nanoparticle-induced pulmonary inflammation and
alveolar macrophage functional change in rats. Nanotoxicology, 2011. 5(3): p. 312-25.

149

171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.

McKinney, W., et al., Pulmonary and cardiovascular responses of rats to inhalation of a
commercial antimicrobial spray containing titanium dioxide nanoparticles. Inhal
Toxicol, 2012. 24(7): p. 447-57.
Nurkiewicz, T.R., et al., Pulmonary nanoparticle exposure disrupts systemic
microvascular nitric oxide signaling. Toxicol Sci, 2009. 110(1): p. 191-203.
Sriram, K., et al., Neurotoxicity following acute inhalation exposure to the oil dispersant
COREXIT EC9500A. J Toxicol Environ Health A, 2011. 74(21): p. 1405-18.
Zhu, M.T., et al., Particokinetics and extrapulmonary translocation of intratracheally
instilled ferric oxide nanoparticles in rats and the potential health risk assessment.
Toxicol Sci, 2009. 107(2): p. 342-51.
Oberdorster, G., Lung particle overload: implications for occupational exposures to
particles. Regul Toxicol Pharmacol, 1995. 21(1): p. 123-35.
Li, J.J., et al., Nanoparticle-induced pulmonary toxicity. Exp Biol Med (Maywood),
2010. 235(9): p. 1025-33.
Cugell, D.W., The hard metal diseases. Clin Chest Med, 1992. 13(2): p. 269-79.
Trautmann, H., Pneumoconiosis due to inhaltion of hard metal dusts. Hefte Unfallheilkd,
1958. 56: p. 99-103.
Bech, A.O., M.D. Kipling, and J.C. Heather, Hard metal disease. Br J Ind Med, 1962. 19:
p. 239-52.
Heuer, W., Pulmonary fibrosis in hard metal-production workers. Int Arch
Gewerbepathol Gewerbehyg, 1962. 19: p. 613-32.
Beritic, T., et al., Pheumoconiosis Caused by Hard Metal Dust. Arh Hig Rada Toksikol,
1963. 14: p. 261-8.
Joseph, M., Hard metal pneumoconiosis. Australas Radiol, 1968. 12(2): p. 92-5.
Schutze, S., et al., Inhibition of receptor internalization by monodansylcadaverine
selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol
Chem, 1999. 274(15): p. 10203-12.
Nunez, J., et al., Competitive inhibition of colchicine binding to tubulin by microtubuleassociated proteins. Proc Natl Acad Sci U S A, 1979. 76(1): p. 86-90.
Cooper, J.A., Effects of cytochalasin and phalloidin on actin. J Cell Biol, 1987. 105(4): p.
1473-8.
Val, S., et al., Carbon black and titanium dioxide nanoparticles induce pro-inflammatory
responses in bronchial epithelial cells: need for multiparametric evaluation due to
adsorption artifacts. Inhal Toxicol, 2009. 21 Suppl 1: p. 115-22.
Canton, I. and G. Battaglia, Endocytosis at the nanoscale. Chem Soc Rev, 2012. 41(7): p.
2718-39.
Champion, J.A. and S. Mitragotri, Role of target geometry in phagocytosis. Proc Natl
Acad Sci U S A, 2006. 103(13): p. 4930-4.
dos Santos, T., et al., Effects of transport inhibitors on the cellular uptake of carboxylated
polystyrene nanoparticles in different cell lines. PLoS One, 2011. 6(9): p. e24438.
Wu, Y.-L., et al., Biophysical Responses upon the Interaction of Nanomaterials with
Cellular Interfaces. Acc Chem Res, 2012. 46(3): p. 782-91.
Zhang, L.W. and N.A. Monteiro-Riviere, Mechanisms of quantum dot nanoparticle
cellular uptake. Toxicol Sci, 2009. 110(1): p. 138-55.
Shivapurkar, N., et al., Apoptosis and lung cancer: a review. J Cell Biochem, 2003.
88(5): p. 885-98.
150

193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.

Stieber, P. and S. Holdenrieder, Lung cancer biomarkers - Where we are and what we
need. Cancer Biomark, 2010. 6(3-4): p. 221-4.
Holdenrieder, S. and P. Stieber, Circulating apoptotic markers in the management of
non-small cell lung cancer. Cancer Biomark, 2010. 6(3-4): p. 197-210.
Stearns, R.C., J.D. Paulauskis, and J.J. Godleski, Endocytosis of ultrafine particles by
A549 cells. Am J Respir Cell Mol Biol, 2001. 24(2): p. 108-15.
Gotway, M.B., et al., Hard metal interstitial lung disease: high-resolution computed
tomography appearance. J Thorac Imaging, 2002. 17(4): p. 314-8.
Mariano, A., P. Sartorelli, and A. Innocenti, Evolution of hard metal pulmonary fibrosis
in two artisan grinders of woodworking tools. Sci Total Environ, 1994. 150(1-3): p. 21921.
Matejka, M.H., et al., Heavy metal deposits in pathologically modified hard tissues.
Clinical and experimental studies. Wien Med Wochenschr, 1985. 135(21): p. 523-5.
Rizzato, G., et al., Multi-element follow up in biological specimens of hard metal
pneumoconiosis. Sarcoidosis, 1992. 9(2): p. 104-17.
Armstead, A. and B. Li, Nanomedicine as an emerging approach against intracellular
pathogens. International Journal of Nanomedicine, 2011. 6(1): p. 3281-3293.
Luo, H., et al., Kaempferol nanoparticles achieve strong and selective inhibition of
ovarian cancer cell viability. Int J Nanomedicine, 2012. 7: p. 3951-9.
Wang, X.F., B. Ding, and B.Y. Li, Biomimetic electrospun nanofibrous structures for
tissue engineering. Materials Today, 2013. 16(6): p. 229-241.
Goddette, D.W. and C. Frieden, Actin polymerization. The mechanism of action of
cytochalasin D. J Biol Chem, 1986. 261(34): p. 15974-80.
Elkjaer, M.L., et al., Effects of microtubule disruption on endocytosis, membrane
recycling and polarized distribution of Aquaporin-1 and gp330 in proximal tubule cells.
Eur J Cell Biol, 1995. 67(1): p. 57-72.
Geiser, M., Morphological aspects of particle uptake by lung phagocytes. Microsc Res
Tech, 2002. 57(6): p. 512-22.
Muhlfeld, C., et al., Interactions of nanoparticles with pulmonary structures and cellular
responses. Am J Physiol Lung Cell Mol Physiol, 2008. 294(5): p. L817-29.
Miyata, R. and S.F. van Eeden, The innate and adaptive immune response induced by
alveolar macrophages exposed to ambient particulate matter. Toxicol Appl Pharmacol,
2011. 257(2): p. 209-26.
Gosens, I., et al., Impact of agglomeration state of nano- and submicron sized gold
particles on pulmonary inflammation. Part Fibre Toxicol, 2010. 7(1): p. 37.
Niwa, Y., et al., Inhalation exposure to carbon black induces inflammatory response in
rats. Circ J, 2008. 72(1): p. 144-9.
Azad, N., Y. Rojanasakul, and V. Vallyathan, Inflammation and lung cancer: roles of
reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev, 2008. 11(1): p. 115.
Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. J
Clin Invest, 2012. 122(3): p. 787-95.
Mosser, D.M., The many faces of macrophage activation. J Leukoc Biol, 2003. 73(2): p.
209-12.
Mantovani, A., et al., The chemokine system in diverse forms of macrophage activation
and polarization. Trends Immunol, 2004. 25(12): p. 677-86.
151

214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.

Aron-Wisnewsky, J., et al., Human adipose tissue macrophages: m1 and m2 cell surface
markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol
Metab, 2009. 94(11): p. 4619-23.
Daigneault, M., et al., The identification of markers of macrophage differentiation in
PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One, 2010. 5(1):
p. e8668.
Chao, J., J.G. Wood, and N.C. Gonzalez, Alveolar macrophages initiate the systemic
microvascular inflammatory response to alveolar hypoxia. Respir Physiol Neurobiol,
2011. 178(3): p. 439-48.
Martinez, F.O., et al., Transcriptional profiling of the human monocyte-to-macrophage
differentiation and polarization: new molecules and patterns of gene expression. J
Immunol, 2006. 177(10): p. 7303-11.
Hao, N.B., et al., Macrophages in tumor microenvironments and the progression of
tumors. Clin Dev Immunol, 2012. 2012: p. 948098.
Quatromoni, J.G. and E. Eruslanov, Tumor-associated macrophages: function,
phenotype, and link to prognosis in human lung cancer. Am J Transl Res, 2012. 4(4): p.
376-89.
Gustafsson, A., et al., Lung exposure of titanium dioxide nanoparticles induces innate
immune activation and long-lasting lymphocyte response in the Dark Agouti rat. J
Immunotoxicol, 2011. 8(2): p. 111-21.
Haberl, N., et al., Cytotoxic and proinflammatory effects of PVP-coated silver
nanoparticles after intratracheal instillation in rats. Beilstein J Nanotechnol, 2013. 4: p.
933-40.
Armstead, A.L., C.B. Arena, and B. Li, Exploring the potential role of tungsten carbide
cobalt (WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial
cells in vitro. Toxicol Appl Pharmacol, 2014. 278(1): p. 1-8.
Meissner, T., et al., Physical-chemical characterization of tungsten carbide nanoparticles
as a basis for toxicological investigations. Nanotoxicology, 2010. 4(2): p. 196-206.
Takashiba, S., et al., Differentiation of monocytes to macrophages primes cells for
lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor kappaB.
Infect Immun, 1999. 67(11): p. 5573-8.
Maess, M.B., et al., Reduced PMA enhances the responsiveness of transfected THP-1
macrophages to polarizing stimuli. J Immunol Methods, 2014. 402(1-2): p. 76-81.
Napierska, D., et al., Cytokine production by co-cultures exposed to monodisperse
amorphous silica nanoparticles: the role of size and surface area. Toxicol Lett, 2012.
211(2): p. 98-104.
Wottrich, R., S. Diabate, and H.F. Krug, Biological effects of ultrafine model particles in
human macrophages and epithelial cells in mono- and co-culture. Int J Hyg Environ
Health, 2004. 207(4): p. 353-61.
Antonios, J.K., et al., Macrophage polarization in response to wear particles in vitro.
Cell Mol Immunol, 2013. 10(6): p. 471-82.
Pfeffer, K., Biological functions of tumor necrosis factor cytokines and their receptors.
Cytokine Growth Factor Rev, 2003. 14(3-4): p. 185-91.
Dinarello, C.A., Immunological and Inflammatory Functions of the Interleukin-1 Family.
Annual Review of Immunology, 2009. 27: p. 519-550.
152

231.
232.
233.
234.
235.
236.
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.
249.
250.

Dinarello, C.A., Interleukin-1 beta and the Autoinflammatory Diseases. New England
Journal of Medicine, 2009. 360(23): p. 2467-2470.
Gee, K., et al., The IL-12 family of cytokines in infection, inflammation and autoimmune
disorders. Inflamm Allergy Drug Targets, 2009. 8(1): p. 40-52.
Trinchieri, G., Interleukin-12: a proinflammatory cytokine with immunoregulatory
functions that bridge innate resistance and antigen-specific adaptive immunity. Annu
Rev Immunol, 1995. 13: p. 251-76.
Hamza, T., J.B. Barnett, and B. Li, Interleukin 12 a Key Immunoregularoty Cytokine in
Infection Applications. International Journal of Molecular Sciences, 2010. 11: p. 789-806.
Li, B., et al., Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention
in open fractures. J Orthop Res, 2010. 28(1): p. 48-54.
Boyce, B.M., et al., Additive effects of exogenous IL-12 supplementation and antibiotic
treatment in infection prophylaxis. J Orthop Res, 2012. 30(2): p. 196-202.
Li, B., et al., Multilayer polypeptide nanoscale coatings incorporating IL-12 for the
prevention of biomedical device-associated infections. Biomaterials, 2009. 30(13): p.
2552-8.
Albanese, A., P.S. Tang, and W.C. Chan, The effect of nanoparticle size, shape, and
surface chemistry on biological systems. Annu Rev Biomed Eng, 2012. 14: p. 1-16.
Du, Z., et al., Cardiovascular toxicity of different sizes amorphous silica nanoparticles in
rats after intratracheal instillation. Cardiovasc Toxicol, 2013. 13(3): p. 194-207.
Porter, D.W., et al., Pulmonary toxicity of Expancel microspheres in the rat. Toxicol
Pathol, 2007. 35(5): p. 702-14.
Sjogren, I., et al., Hard metal lung disease: importance of cobalt in coolants. Thorax,
1980. 35(9): p. 653-9.
Toya, T., et al., Pulmonary toxicity induced by intratracheal instillation of coarse and
fine particles of cerium dioxide in male rats. Ind Health, 2010. 48(1): p. 3-11.
Porter, D.W., et al., Mouse pulmonary dose- and time course-responses induced by
exposure to multi-walled carbon nanotubes. Toxicology, 2010. 269(2-3): p. 136-47.
Dulin, A.M., M.J. Paape, and B.T. Weinland, Cytospin centrifuge in differential counts of
milk somatic cells. J Dairy Sci, 1982. 65(7): p. 1247-51.
Porter, D.W., et al., Nitric oxide and reactive oxygen species production causes
progressive damage in rats after cessation of silica inhalation. Toxicol Sci, 2006. 90(1):
p. 188-97.
Castranova, V., et al., Enhancement of nitric oxide production by pulmonary cells
following silica exposure. Environ Health Perspect, 1998. 106 Suppl 5: p. 1165-9.
Allen, R.C., Evaluation of serum opsonic capacity by quantitating the initial
chemiluminescent response from phagocytizing polymorphonuclear leukocytes. Infect
Immun, 1977. 15(3): p. 828-33.
Renwick, L.C., et al., Increased inflammation and altered macrophage chemotactic
responses caused by two ultrafine particle types. Occup Environ Med, 2004. 61(5): p.
442-7.
Silva, R.M., et al., Biological response to nano-scale titanium dioxide (TiO2): role of
particle dose, shape, and retention. J Toxicol Environ Health A, 2013. 76(16): p. 953-72.
Tada, Y., et al., Acute phase pulmonary responses to a single intratracheal spray
instillation of magnetite (fe(3)o(4)) nanoparticles in Fischer 344 rats. J Toxicol Pathol,
2012. 25(4): p. 233-9.
153

251.
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
262.
263.
264.
265.
266.
267.
268.
269.

Nel, A., et al., Toxic potential of materials at the nanolevel. Science, 2006. 311: p. 622627.
Seale-Goldsmith, M.M. and J.F. Leary, Nanobiosystems. Wiley Interdiscip Rev Nanomed
Nanobiotechnol, 2009. 1(5): p. 553-67.
Srimok, B. and M.S. Yim, Examining the importance of the particle size effect in
inhalation dose assessment for short-term radiological events. Radiat Prot Dosimetry,
2011. 147(3): p. 439-50.
Kim, K.P., et al., Influence of particle size distribution on inhalation doses to workers in
the Florida phosphate industry. Health Phys, 2006. 91(1): p. 58-67.
Bernstein, D., A review of the influence of particle size, puff volume, and inhalation
pattern on the deposition of cigarette smoke particles in the respiratory tract. Inhal
Toxicol, 2004. 16(10): p. 675-89.
Cassee, F.R., et al., Particle size-dependent total mass deposition in lungs determines
inhalation toxicity of cadmium chloride aerosols in rats. Application of a multiple path
dosimetry model. Arch Toxicol, 2002. 76(5-6): p. 277-86.
Pauluhn, J. and M. Wiemann, Siderite (FeCO(3)) and magnetite (Fe(3)O(4)) overloaddependent pulmonary toxicity is determined by the poorly soluble particle not the iron
content. Inhal Toxicol, 2011. 23(13): p. 763-83.
Courbiere, B., et al., Ultrastructural interactions and genotoxicity assay of cerium
dioxide nanoparticles on mouse oocytes. Int J Mol Sci, 2013. 14(11): p. 21613-28.
Gaiser, B.K., et al., Interspecies comparisons on the uptake and toxicity of silver and
cerium dioxide nanoparticles. Environ Toxicol Chem, 2012. 31(1): p. 144-54.
Hussain, S., et al., Cerium dioxide nanoparticles induce apoptosis and autophagy in
human peripheral blood monocytes. ACS Nano, 2012. 6(7): p. 5820-9.
Verstraelen, S., et al., Gene expression profiles reveal distinct immunological responses
of cobalt and cerium dioxide nanoparticles in two in vitro lung epithelial cell models.
Toxicol Lett, 2014. 228(3): p. 157-169.
Zhou, X., et al., Uptake of cerium oxide nanoparticles and their influences on functions
of A549 cells. J Nanosci Nanotechnol, 2013. 13(1): p. 204-15.
Goode, A.E., et al., Chemical speciation of nanoparticles surrounding metal-on-metal
hips. Chemical Communications, 2012. 48(67): p. 8335-8337.
Germain, M.A., et al., Comparison of the cytotoxicity of clinically relevant cobaltchromium and alumina ceramic wear particles in vitro. Biomaterials, 2003. 24(3): p.
469-479.
Hosman, A.H., et al., Effects of metal-on-metal wear on the host immune system and
infection in hip arthroplasty. Acta Orthop, 2010. 81(5): p. 526-34.
Ogunwale, B., et al., Investigating the immunologic effects of CoCr nanoparticles. Clin
Orthop Relat Res, 2009. 467(11): p. 3010-6.
Allen, M.J., et al., The effects of particulate cobalt, chromium and cobalt-chromium alloy
on human osteoblast-like cells in vitro. Journal of Bone and Joint Surgery-British
Volume, 1997. 79B(3): p. 475-482.
Behl, B., et al., Biological effects of cobalt-chromium nanoparticles and ions on dural
fibroblasts and dural epithelial cells. Biomaterials, 2013. 34(14): p. 3547-58.
Bhabra, G., et al., Nanoparticles can cause DNA damage across a cellular barrier.
Nature Nanotechnology, 2009. 4(12): p. 876-883.
154

270.
271.
272.

273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.

Christian, W.V., et al., Toxicology-based cancer causation analysis of CoCr-containing
hip implants: a quantitative assessment of genotoxicity and tumorigenicity studies.
Journal of Applied Toxicology, 2014. 34(9): p. 939-967.
Figgitt, M., et al., The genotoxicity of physiological concentrations of chromium (Cr(III)
and Cr(VI)) and cobalt (Co(II)): An in vitro study. Mutation Research-Fundamental and
Molecular Mechanisms of Mutagenesis, 2010. 688(1-2): p. 53-61.
Landsiedel, R., et al., Genotoxicity investigations on nanomaterials: Methods,
preparation and characterization of test material, potential artifacts and limitationsMany questions, some answers. Mutation Research-Reviews in Mutation Research, 2009.
681(2-3): p. 241-258.
Potnis, P.A., D.K. Dutta, and S.C. Wood, Toll-like receptor 4 signaling pathway mediates
proinflammatory immune response to cobalt-alloy particles. Cellular Immunology, 2013.
282(1): p. 53-65.
Raghunathan, V.K., et al., Influence of particle size and reactive oxygen species on cobalt
chrome nanoparticle-mediated genotoxicity. Biomaterials, 2013. 34(14): p. 3559-3570.
Sood, A., et al., Signalling of DNA damage and cytokines across cell barriers exposed to
nanoparticles depends on barrier thickness. Nature Nanotechnology, 2011. 6(12): p. 824833.
Tan, H.C., et al., Covalently grafted BMP-7 peptide to reduce macrophage/monocyte
activity: An in vitro study on cobalt chromium alloy. Biotechnology and Bioengineering,
2013. 110(3): p. 969-979.
Tan, H.C., et al., Anti-fibrosis effect of BMP-7 peptide functionalization on cobalt
chromium alloy. Journal of Orthopaedic Research, 2013. 31(6): p. 983-990.
Thomas, I.T. and E.J. Evans, The Effect of Cobalt Chromium Molybdenum Powder on
Collagen Formation by Fibroblasts Invitro. Biomaterials, 1986. 7(4): p. 301-304.
Hosman, A.H., et al., The influence of Co-Cr and UHMWPE particles on infection
persistence: an in vivo study in mice. J Orthop Res, 2012. 30(3): p. 341-7.
Scharf, B., et al., Molecular analysis of chromium and cobalt-related toxicity. Sci Rep,
2014. 4: p. 5729.
Taylor, U., et al., Impact of Metal Nanoparticles on Germ Cell Viability and
Functionality. Reproduction in Domestic Animals, 2012. 47: p. 359-368.
Nielsen, J., J.R. Jepsen, and F. Egede, The hard-metal lung. Cobalt-induced
pneumoconiosis. Ugeskr Laeger, 1986. 148(21): p. 1311-2.
Kusaka, Y., et al., Effect of hard metal dust on ventilatory function. Br J Ind Med, 1986.
43(7): p. 486-9.
Demedts, M., Cobalt and hard metal. Chest, 1986. 89(2): p. 316.
Rystedt, I. and T. Fischer, Relationship between nickel and cobalt sensitization in hard
metal workers. Contact Dermatitis, 1983. 9(3): p. 195-200.
Perdrix, A., et al., Cobalt and sintered metal carbides. Value of the determination of
cobalt as a tracer of exposure to hard metals. Toxicol Eur Res, 1983. 5(5): p. 233-40.
Hillerdal, G. and M. Hartung, On cobalt in tissues from hard metal workers. Int Arch
Occup Environ Health, 1983. 53(1): p. 89-90.
Fischer, T. and I. Rystedt, Cobalt allergy in hard metal workers. Contact Dermatitis,
1983. 9(2): p. 115-21.
Lundgren, K.D. and H. Ohman, Pneumoconiosis in hard metal industry; technical and
medical problems. Virchows Arch, 1954. 325(3): p. 259-84.
155

290.
291.
292.
293.
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.

Morgenroth, K., et al., Morphology and pathogenesis of pneumoconiosis in dental
technicians. Pathol Res Pract, 1985. 179(4-5): p. 528-36.
Rom, W.N., et al., Pneumoconiosis and exposures of dental laboratory technicians. Am J
Public Health, 1984. 74(11): p. 1252-7.
Sherson, D., N. Maltbaek, and O. Olsen, Small Opacities among Dental Laboratory
Technicians in Copenhagen. British Journal of Industrial Medicine, 1988. 45(5): p. 320324.
Sherson, D., N. Maltbaek, and K. Heydorn, A dental technician with pulmonary fibrosis:
a case of chromium-cobalt alloy pneumoconiosis? Eur Respir J, 1990. 3(10): p. 1227-9.
Choudat, D., Occupational lung diseases among dental technicians. Tuber Lung Dis,
1994. 75(2): p. 99-104.
Oberdorster, G., J. Ferin, and B.E. Lehnert, Correlation between particle size, in vivo
particle persistence, and lung injury. Environ Health Perspect, 1994. 102 Suppl 5: p.
173-9.
Selden, A., et al., Three cases of dental technician's pneumoconiosis related to cobaltchromium-molybdenum dust exposure. Chest, 1996. 109(3): p. 837-42.
Selden, A.I., et al., Exposure to cobalt chromium dust and lung disorders in dental
technicians. Thorax, 1995. 50(7): p. 769-72.
Simoes, T., et al., Synthesis and characterization of Cobalt Chromium nanoparticles by
mechanochemical milling route.
Fischbein, A., et al., Clinical findings among hard metal workers. Br J Ind Med, 1992.
49(1): p. 17-24.
Gatti, A.M. and F. Rivasi, Biocompatibility of micro- and nanoparticles. Part I: in liver
and kidney. Biomaterials, 2002. 23(11): p. 2381-7.
Oberdorster, G., Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ
Health, 2001. 74(1): p. 1-8.
Moreira, M.A., et al., Hard metal pneumoconiosis with spontaneous bilateral
pneumothorax. J Bras Pneumol, 2010. 36(1): p. 148-51.
Oberdorster, G., E. Oberdorster, and J. Oberdorster, Nanotoxicology: an emerging
discipline evolving from studies of ultrafine particles. Environ Health Perspect, 2005.
113(7): p. 823-39.
Tsaousi, A., E. Jones, and C.P. Case, The in vitro genotoxicity of orthopaedic ceramic
(Al2O3) and metal (CoCr alloy) particles. Mutat Res, 2010. 697(1-2): p. 1-9.
Brody, J.S. and A. Spira, State of the art. Chronic obstructive pulmonary disease,
inflammation, and lung cancer. Proc Am Thorac Soc, 2006. 3(6): p. 535-7.
Scansetti, G., et al., Absorption and excretion of cobalt in the hard metal industry. Sci
Total Environ, 1994. 150(1-3): p. 141-4.
Zanetti, G. and B. Fubini, Surface interactions between metallic cobalt and tungsten
carbide particles as a primary cause of hard metal disease. J Mater Chem, 1997. 7: p.
1647-1654.
Gauldie, J., M. Jordana, and G. Cox, Cytokines and pulmonary fibrosis. Thorax, 1993.
48(9): p. 931-5.

156

APPENDIX I:

Curriculum Vitae
Andrea Lynn Armstead

157

Andrea Lynn Armstead, PhD.
140 Hoffman Avenue

Phone: (304) 906-6138

Morgantown, WV 26505

Email: aarmstead@hsc.wvu.edu

Education
Washburn University (2003-09)

College of Liberal Arts & Sciences
Department: Biochemistry
Degree: B.S.

West Virginia University (2009-present)

GPA: 3.82

School of Pharmacy
Department: Pharmaceutical & Pharmacological
Sciences
Degree: Doctor of Philosophy

GPA: 3.86

Awards and Honors


Outstanding Graduate Student Achievement Award, School of Pharmacy, West Virginia
University (2014)



3rd Place “Chapter of the Year”, Chapter Chair, American Association of Pharmaceutical
Scientists (AAPS) West Virginia University Student Chapter (2013)



West Virginia University School of Pharmacy Graduate Student Travel Award ($500;
2013)



West Virginia University Research and Graduate Education Student Travel Award ($400;
2013)



American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in
Pharmaceutical Sciences (2013-14)



E.J. Van Liere Research Day, West Virginia University, 2nd Place Poster Award (2013)



4th Annual AAPS Pittsburgh Chapters Student Research Symposium, “Most Outstanding
Research Presentation” (Podia; 2012)



American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in
Pharmaceutical Sciences (2012-13)
158



Rho Chi Pharmacy Scholarship Society Induction (2012)



WV Nano Graduate Research Fellowship (2010-11, 2011-12)



American Chemical Society “Undergraduate Analytical Chemistry” Award (2009)



Washburn University “Analytical Chemistry Student of the Year” Award (2009)



Kansas Academy of Sciences, “First Place Oral Competition” Award (2009)



KINBRE Research Training Scholarship (2008-09)



Dean’s Honor Roll, Washburn University (2004, 2008-09)



Washburn University Academic Scholarship (2003-04, 2006, 2008)

Leadership and Service


Chair: American Association of Pharmaceutical Scientists (AAPS) West Virginia
University Student Chapter (2013-14)



Pharmaceutical Sciences Graduate Student Representative, School of Pharmacy, West
Virginia University Chancellor’s Health Sciences Center Student Advisory Board (201314)



Student Volunteer, “Science Days” at the Children’s Discovery Museum, Morgantown,
WV (2013)



Student Committee Chair: Inaugural West Virginia University School of Pharmacy
American Association of Pharmaceutical Scientists (AAPS) Regional Meeting &
Research Forum (2013)



Treasurer: American Association of Pharmaceutical Scientists (AAPS) West Virginia
University Student Chapter (2012-13)



Graduate Student Representative, Organizational Committee: Center for Drug Discovery
and Therapeutics Retreat, Morgantown, WV (2012)



Medical Student Research Mentor (Ketu Patel): West Virginia University E.J. Van Liere
Summer Medical Student Research Program (2011)



Medical Student Research Mentor (Christopher Arena): West Virginia University E.J.
Van Liere Summer Medical Student Research Program (2010)



Student volunteer, “Nano Days” at the Children’s Discovery Museum, Morgantown, WV
(2012)

159

Dissertation Research Summary


Identifying the toxicity of hard metal tungsten carbide cobalt (WC-Co) nano- and microparticles using in vitro cell culture models to assess cell viability, oxidative stress and
induction of apoptosis



Examining WC-Co nanoparticle internalization using cytoskeletal inhibitor assays and
transmission electron microscopy (TEM)



Determining the effects of WC-Co particle exposure in vitro on immune functions such
as cytokine secretion and macrophage activation in a co-culture model



Establishing an in vivo rat model for the assessment of potential systemic effects induced
by WC-Co nanoparticle exposure via intra-tracheal instillation

Laboratory Experience and Techniques


Mammalian cell culture and aseptic technique



Cell viability assays (MTT-based, lactate dehydrogenase (LDH)-based)



Flow cytometry (cell preparation, staining and sample analysis)



Phase-contrast and fluorescence microscopy



Dynamic light scattering analysis and nano/micro-particle suspension



Limited in vivo experience with animal anesthesia, exsanguination, bronchio-alveolar
lavage

Dissertation Committee


Dr. Bingyun Li (Mentor): Department of Orthopedics, School of Medicine, West Virginia
University



Dr. Rae Matsumoto: Dean, School of Pharmacy, Touro University California



Dr. Peter Gannett: Department of Basic Pharmaceutical Sciences, School of Pharmacy,
West Virginia University



Dr. Yon Rojanasakul: Department of Basic Pharmaceutical Sciences, School of
Pharmacy, West Virginia University



Dr. Tim Nurkiewicz: Department of Physiology & Pharmacology, School of Medicine,
West Virginia University

160

Publications
Peer Reviewed Manuscripts


Armstead, A.L; Arena, C.B and B. Li. Exploring the potential role of tungsten carbide
cobalt (WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial
cells in vitro. Tox App Pharmacol 2014: 278 (1): 1-8.
http://dx.doi.org/10.1016/j.taap.2014.04.008



Armstead, A.L. and B. Li. Nanomedicine as an Emerging Approach against Intracellular
Pathogens. Int J Nanomedicine 2011: 6; 3281-3293.
http://www.dovepress.com/articles.php?article_id=8838



Armstead, A.L; Minarchick, V; Porter, D; Nurkiewicz, T and B. Li. Acute inflammatory
responses of nanoparticles in an intra-tracheal instillation rat model. PLoS One (under
review 11/2014)



Armstead, A.L; Wang, X and B. Li. Toxicity of cobalt chromium molybdenum
orthopedic implant wear nanoparticles in human cells. PLoS One. (to be submitted)

Workshop Participation


Science and Technology Entrepreneurship Academy, August 7-12, 2011. Erickson
Alumni Center, Morgantown, WV.



Science: Becoming the Messenger Workshop, presented by the National Science
Foundation. October 11, 2011. Erickson Alumni Center, Morgantown, WV.



Succeeding in the People Business, presented by the WV Nano Initiative. January 12,
2012. Chestnut Ridge Research Building, Morgantown, WV.



Creating Elevator Pitches that Pack a Punch, presented by Ninja Communications, July
12, 2014. WestVaco Center, Morgantown, WV.

Memberships


Association for Women in Science (2013-present)



American Association for the Advancement of Science, Excellence in Science Program
(2013-present)



Society of Toxicology, Allegheny-Erie Regional Chapter (2012-present)



Rho Chi Society (2012-present)
161



American Association of Pharmaceutical Sciences (2010-present)



American Chemical Society (2010-present)

Presentations
Seminars and Podia presentations:


West Virginia University Graduate Student Seminar Series, Fall 2014: “Understanding
Hard Metal (WC-Co) Toxicity: In vitro Studies and In vivo Exploration”



West Virginia University Graduate Student Seminar Series, Spring 2014: “Hard Metal
(WC-Co) Particle Exposure: In Vitro Toxicity and Potential Role of Macrophage
Polarization”



West Virginia University Graduate Student Seminar Series, Fall 2013: “Exploring the
systemic effects of WC-Co nanoparticle exposure in vivo using an intra-tracheal
instillation model”



West Virginia University Graduate Student Seminar Series, Spring 2013: “Hard Metal
Toxicity: from in vitro studies to in vivo exploration”



4th Annual Pittsburgh AAPS Student Research Symposium, November 2012: “Hard
Metal (WC-Co) Nano-particles Induce Cellular Toxicity and Apoptosis in a DoseDependent Manner” (Abstract one of six selected for podia presentation; received “Most
Outstanding Research Presentation” award)



West Virginia University Graduate Student Seminar Series, Fall 2012: “Toxicity and
Inflammatory Response to Hard Metal (WC-Co) Particles in a Co-culture Model”



West Virginia University Graduate Student Seminar Series, Spring 2012: “Nanoparticle
Internalization contributes to Nano-Toxicity”



Interdisciplinary Research Team (IRT3) Meeting, 2012: “BEAS-2B Cellular Response to
Organic and Inorganic Particle Exposure”



West Virginia University Graduate Student Seminar Series, Fall 2011: “Cellular
Response to Organic and Inorganic Particle Exposure”



West Virginia Nano Brown Bag Lunch Seminar Series, Spring 2011: “Nanomedicine: An
Emerging Therapeutic Strategy against Intracellular Pathogens”

162



Interdisciplinary Research Team (IRT3) Meeting, 2011: “Examining Cell-Nanoparticle
Interactions”



West Virginia University Graduate Student Seminar Series, Spring 2011: “Examining
Cell-Nanoparticle Interactions”



West Virginia University Graduate Student Seminar Series, Fall 2010: “Treating
Intracellular Pathogens: Nanoparticles as an Alternative Therapeutic Approach”



Kansas Academy of Science Annual Meeting, 2009: “Benzylic Oxidation of Pyrroles by
Oxone®” (first place winner, oral competition)

Poster presentations:


E.J Van Liere Research Day, West Virginia University, 2013: “Examining the
Inflammatory Response to Hard Metal (WC-Co) Nanoparticle Exposure in Vivo”



American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, 2013:
“Understanding Hard Metal (WC-Co) Toxicity: Potential Role of Nanoparticle
Internalization”



5th Annual Pittsburgh Chapters AAPS Student Research Symposium, 2013: “Exploring
the Systemic Effects of Hard Metal (WC-Co) Nanoparticle Exposure in vivo”



Allegheny-Erie Society of Toxicology Regional Meeting, 2013: “Hard metal (WC-Co)
Nanoparticles Induce Cellular Toxicity and Apoptosis in a Dose-Dependent Manner”



E.J Van Liere Research Day, West Virginia University, 2013: “Hard metal (WC-Co)
Nanoparticles Induce Cellular Toxicity and Apoptosis in a Dose-Dependent Manner”
(2nd place winner, poster competition)



NanoBio Seattle, Seattle WA, 2012: “Heavy metal (WC-Co) Nanoparticles Induce
Cellular Toxicity and Apoptosis in a Dose-Dependent Manner”



E.J Van Liere Research Day, West Virginia University, 2012: Co-presentation with
Christopher Arena “Cellular Responses to Heavy Metal Particle Exposure” (first place
winner, poster competition)



E.J Van Liere Research Day, West Virginia University, 2012: “Potential Role of WC-Co
Nano-Particle Internalization in Hard Metal Lung Disease”

163



E.J. Van Liere Research Day, West Virginia University, 2010: Co-Presentation with
Therwa Hamza “In vitro models for intracellular S. aureus infections of osteoblasts and
macrophages”



School of Pharmacy Research Day, West Virginia University, 2010: Co-Presentation
with Therwa Hamza “In vitro models for intracellular S. aureus infections of osteoblasts
and macrophages”



KINBRE Regional Meeting, 2009: “Further Studies on the Benzylic Oxidation of
Pyrroles by Oxone®”



Kansas Academy of Science Annual Meeting, 2009: “Benzylic Oxidation of Pyrroles by
Oxone®”

164

APPENDIX II:

Nanomedicine as an Emerging Approach against Intracellular Pathogens

Supplemental Literature Review

Original Review Article

Armstead, A.L and Li, B. 2011. Nanomedicine as an emerging approach against intracellular
pathogens. Int J Nanomedicine 6, 3281-3293. http://dx.doi.org/10.2147/IJN.S27285

165

ABSTRACT
Diseases such as tuberculosis, hepatitis and HIV/AIDS are caused by intracellular
pathogens and are a major burden to the global medical community. Conventional treatments for
these diseases typically consist of long-term therapy with a combination of drugs which may lead
to side effects and contribute to low patient compliance. The pathogens reside within
intracellular compartments of the cell which provide additional barriers to effective treatment.
Therefore, there is a need for improved and more effective therapies for such intracellular
diseases. This review will summarize, for the first time, the intracellular compartments in which
pathogens can reside and discuss how nanomedicine has the potential to improve intracellular
disease therapy by offering properties such as targeting, sustained drug release and drug delivery
to the pathogen’s intracellular location. The characteristics of nanomedicine may prove
advantageous in developing improved or alternative therapies for intracellular diseases.

Keywords: intracellular pathogen; infection; nanomedicine; nanoparticle; drug delivery
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INTRODUCTION
Worldwide, a number of diseases (eg HIV/AIDS, hepatitis and tuberculosis) are caused by
intracellular pathogens. Such diseases can be due to viral [1-8], bacterial [9-16], fungal [17, 18]
or other parasitic [19-21] infection as summarized in Table 1. The prevalence of each disease
may differ geographically but the intracellular nature of these pathogens, which may protect
them from a variety of antibiotic therapies and host immune responses, presents a treatment
challenge for the global medical community. Some antibiotic drugs like aminoglycosides and
beta-lactams have limited cellular penetration, while others such as fluoroquinolones or
macrolides have the ability to penetrate host cells but are poorly retained and therefore inefficient
[22]. Therapeutic drugs targeting the intracellular pathogens should overcome the cell membrane
barriers, and release and retain the drug intracellularly at the therapeutic level for a desired time
period. Moreover, multi-drug resistance is increasing [23-29] and is making intracellular disease
treatment more challenging. Therefore, there is a need for the development of advanced
treatment methods to better control intracellular infections. This review will summarize the
status of intracellular disease treatments, the current therapeutic strategies against common
intracellular diseases and present how nanomedicine is emerging as an attractive platform for
advanced intracellular drug therapy. Note that therapeutic treatments that tune the cell-mediated
immune responses against intracellular pathogens are important but will not be discussed here.

INTRACELLULAR PATHOGENS AND CURRENT TREATMENT APPROACHES
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A wide variety of pathogens are capable of causing intracellular diseases such as
HIV/AIDS, hepatitis and tuberculosis (see Table 1). In this section, a brief description of
selected viral and bacterial diseases is given along with a discussion of the current therapeutic
strategies against the causative pathogens.

Table 1: Summary of Disease-Causing Intracellular Pathogens
Associated Disease(s)

[Ref]

Viral Pathogens
Herpes simplex

Type I: oral herpes (cold sore, fever
blister)

[1, 8]

Type II: genital herpes (warts, ulcers)
Hepatitis C

Liver cirrhosis, hepatocellular carcinoma
(HCC)

[2, 6]

Respiratory syncytial virus

Pediatric viral respiratory disease

[4, 7]

Human immunodeficiency virus (HIV)

Acquired immunodeficiency syndrome

[3, 5]

Mycobacterium tuberculosis

Tuberculosis

[9, 10]

Salmonella enterica serovars Typhi,
Paratyphi

Typhoid fever

[11,
12]

Brucella species B. melitensis, B. abortus, B.
suis

Malta fever or undulant fever

Listeria monocytogenes

Listeriosis, meningitis in newborn babies

Bacterial Pathogens
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[13-15]

[16]

Table 1: Summary of Disease-Causing Intracellular Pathogens (continued)
Associated Disease(s)

[Ref]

Fungal Pathogens
Multiple cutaneous and mucosal forms:
frequently encountered oral form is
thrush

[17]

Pulmonary aspergillosis

[18]

Leishmania (parasite)

Cutaneous or tegumentary
leishmaniasis

[19,
20]

Plasmodium species (protist) P. vivas, P.
ovale, P. malariae, P. falciparum, P.
knowlesi

Malaria

Candidia albicans

Aspergillus fumigatus
Other Pathogens

[21]

Table A2.1. Summary of disease-causing intracellular pathogens.

Tuberculosis (TB)
Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M. tuberculosis).
It is estimated that up to 2.2 billion people carry latent TB infections worldwide [30]. Exposure
to TB does not necessarily lead to an active infection, as normal human immune systems are able
to effectively control bacteria and most people remain in a symptom-free latent stage of infection
[30]. However, susceptible individuals with poor immune response or complicating factors such
as HIV infection may develop an active TB infection [31]. People with active infections typically
experience pain in the chest and a cough with blood or sputum (phlegm) lasting more than three
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weeks [32]. These symptoms could also be accompanied by fatigue, weight loss, fever, chills or
night sweats [33]. M. tuberculosis is a gram-positive bacterium with a very thick cell wall
characteristic of the Mycobacterium species. The thick cell wall provides an excellent
permeability barrier, making Mycobacteria resistant to a wide variety of antimicrobial agents
[23]. M. tuberculosis bacteria may reside and duplicate within macrophages of the lung [34]; a
full description of M. tuberculosis pathogenesis is beyond the scope of this discussion and is
reviewed elsewhere [35, 36]. However, an important factor is the bacteria’s ability to avoid the
cell-mediated immune response through granuloma formation [10], such that treatment of TB
remains a challenge.
At present, the treatment of choice for an active TB infection is long-term antibiotic
therapy, with an initial “intensive phase” consisting of the four first-line anti-tuberculosis drugs
(isoniazid, rifampicin, ethambutol and pyrazinamide) followed by a typical four month course of
rifampicin and isoniazid alone [37]. This has been the most effective treatment to date although,
due to the length of antibiotic therapy, side effects frequently develop [38] and the cost is high
[39]. These factors may lead to low patient compliance and contribute to the development of
drug resistant bacteria [40].
Human Immunodeficiency Virus (HIV)
Infection with human immunodeficiency virus (HIV) is a significant ongoing problem
worldwide.

As

HIV

infection

progresses,

infected

individuals

develop

acquired

immunodeficiency syndrome (AIDS). According to the latest statistics from the World Health
Organization (WHO), there are 33.3 million people living with HIV/AIDS [41]. Many of those
infected live in sub-saharan Africa, where access to treatment is extremely costly or unavailable.
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There have been major developments in the treatment of HIV/AIDS since the approval of
Retrovir® (zidovudine) in 1987 [5]. Current therapeutic efforts consist of a combination of
several drugs [42], typically from different classes of antiviral drugs [43, 44]. This regimen is
referred to as “highly active anti-retroviral therapy” or HAART and has become the standard of
care for those infected with HIV. There are five classes of drugs available for HIV/AIDS
treatment, including: nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase
inhibitors, non-nuceloside reverse transcriptase inhibitors, protease inhibitors and viral fusion
and integrase inhibitors. Typical regimens are combinations of three or four drugs, with
subsequent modifications made based on the patient’s response to therapy [45]. Changes made to
a patient’s regimen are often based on drug resistance testing, and take into consideration
toxicity and tolerability of the new treatment strategy [45]. Although HAART has increased the
median survival time of HIV/AIDS patients from less than a year to about ten years [29], patients
often develop multi-drug resistant strains of the virus [41] over the course of therapy, leading to
poor treatment outcomes [46].
Hepatitis C Virus (HCV)
It is estimated that at least three percent of the world’s population is infected with HCV
[2, 47]. The virus only affects humans and is considered a “silent” disease, as infected
individuals are usually symptom free until later stages of infection when liver inflammation [48]
occurs. HCV can cause liver scarring and cirrhosis, which ultimately leads to hepatocarcinoma
(liver cancer) and death [2, 48]. Unfortunately, there is no effective vaccine [49] against HCV
and the “gold-standard” of HCV treatment is combination antiviral therapy with ribavirin and
interferon alpha [6]; however, both of these compounds are highly toxic and may cause severe
side effects. Several months of treatment are usually required to eradicate a chronic infection and
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the cost of therapy is high [49]. These factors contribute to low patient compliance, making
therapy less effective and potentially contributing to the development of viral resistance [29].
Typhoid Fever
Typhoid fever is an acute illness caused by the bacterium Salmonella enterica serovar
Typhi (S. Typhi) or Paratyphi that cause about 20 million cases of illness per year [50]. These
bacteria are usually ingested by consuming contaminated food or water [51]. Once ingested, the
bacteria translocate across intestinal epithelial cells and establish an intracellular growth
environment within macrophages [52]. The bacteria survive within ‘Salmonella-containing
vacuoles’ in infected macrophages and later spread to organs such as the liver and spleen [11, 12,
53]. Infected individuals often experience sustained high fevers (up to 103°F), stomach pains,
headache, weakness and appetite loss [51].

Several vaccines against S. Typhi have been

developed [54] although they provide only short-term protection against the disease due to
failure of the immune system to build a lasting response [50, 54]. Typhoid fever is endemic in
many developing countries [55], where access to vaccines and antibiotic drugs is limited and
expensive even if available. Standard treatment for S. Typhi infection is the antibiotic
chloramphenicol, although resistance has been reported [50]. Newer antibiotics like the
fluoroquinolones have also proven effective in treating typhoid fever, but the widespread use of
these drugs for a range of febrile illnesses in developing countries is contributing to the
development of more drug-resistant strains of the bacterium [55].
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MAJOR CHALLENGES IN TREATING INTRACELLULAR PATHOGENS
Tables 2A and 2B summarize the common intracellular viruses and bacteria and their
related current therapeutic approaches. One can see that intracellular treatment approaches
generally involve long-term therapy with a combination of drugs. Side effects can develop due to
the drug’s inherent toxicity or due to the length of drug exposure. One of the critical challenges
in treating these types of infections is to get enough drugs to reach the pathogens within their
intracellular compartments. After reviewing the literature, we found evidence that intracellular
pathogens reside in phagosomes [15, 34, 56], vacuoles [52, 53], cytosol [16, 57, 58], nucleus [1,
59, 60], and may interact with the golgi apparatus [61] and endoplasmic reticulum [62-66] of
host cells (Figure 1). The host cell membranes make it a challenge for many drugs to reach the
invading pathogens. Moreover, some antiviral and antibiotic medications have short half-lives,
requiring frequent and large doses to obtain a therapeutic effect which may lead to high cost, low
patient compliance, and severe side effects. In addition, drug resistance may be developed when
patients do not fully comply with their treatment regimens [28] or when pathogens are exposed
to drugs at sub-optimal concentrations [67] for an extended time period. An alerting new
phenomenon is that some pathogens, that have been traditionally considered extracellular, are
emerging as intracellular pathogens and may lead to new types of intracellular diseases. As an
example, Staphylococcus aureus (S. aureus) has long been considered an extracellular pathogen
although recent evidence in the literature demonstrates that this bacterium is capable of being
internalized and surviving within host cells (e.g. osteoblasts [68-72]), and may contribute to
recurrent infections [73]. In order to reduce side effects, improve patient compliance, and reduce
the development of drug-resistance, more effective therapeutic approaches need to be developed.
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An ideal drug treatment method to eradicate intracellular pathogens is one that has the
following characteristics: the ability to penetrate host cells and reach the pathogens, high efficacy
and low toxicity and sustained and site-specific drug release [22]. Recent evidence from the
literature shows that nanomedicine is emerging as a promising potential treatment for
intracellular pathogens, as nanomedicine has the capacity to address these specific challenges.

Figure A2.1. Potential Locations of Intracellular Pathogens. In a typical eukaryotic cell, pathogens may
be internalized via endocytic mechanisms before establishing their intracellular life cycle. Pathogens may
reside in various locations, including: the cytosol, phagosome, lysosome or vacuole compartments, the
nucleus, and some may associate with the golgi apparatus or endoplasmic reticulum. (1) Cytosol (F.
tularensis [57], L. monocytogenes [58], Shigella [64]) (2)Phagosome/lysosome or vacuole (M. tuberculosis
[43, 45], Brucella species [15], Salmonella [52, 53], Leigonella [56]), (3)Nucleus (Herpes Simplex virus
[1, 60], HIV [59]), (4)Golgi apparatus (Chlamydia [61]) and (5)Endoplasmic reticulum (Hepatitis C virus
[65], Brucella [63], T. gondii [66], L. pneumophilia [62, 64]).
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TABLE 2A: Current Therapeutic Strategies against Selected Viral Pathogens
Drugs
Type of
Current Treatment
Virus Name
Commonly
Drug Class/Mode of Action
Virus
Options
Prescribed
PEG‐IFN is an
immunomodulatory drug
and helps enhance natural
anti‐viral mechanisms
(degradation of viral RNA,
Combination
translation inhibition, etc.)
although the exact
RNA virus treatment with
pegylated
interferon and
mechanism is unkown.
(single
Hepatitis C
interferon 2‐
strand,
ribavirin is a purine analog
broad‐spectrumB
Virus (HCV)
alpha and
positive antiviral drugs.
and is incorporated into the
ribavirin
sense)
genome of the virus,
Treatment duration
causing lethal mutations. It
is several months.
is ineffective against HCV
when administered alone; it
must be administered
concomitantly with PEG‐
IFN.
Ribavirin is a broad‐
spectrum antiviral drug that
Prophylactic
has shown some clinical
administration
of
benefit in FSV infections. It
RNA virus
antibodies as disease
is the only FDA‐approved
Respiratory
(single
Ribavirin or
prevention, or
drug for RSV treatment.
syncytial
strand,
palvizumab
virus (RSV)
negative disease treatment
Palivizumab is a monoclonal
with broad‐spectrum
sense)
anti‐RSV antibody (mAb). It
targets the RSV F
antiviral drugs.C
glycoprotein, inhibiting viral
entry into host cells.
guanosine analog; these are
acyclovir,
potent inhibitors of the viral
valacyclovir,
DNA polymerase. Requires
famiclovir,
Antiviral drug
phosphorylation by viral
ganciclovir
administration until
thymidine kinase.
Herpes
DNA virus symptoms and viral
competitive inhibitor of
Simplex
(double shedding are
viral DNA polymerase;
Virus (HSV) stranded) reduced. Suppressive
cidofovir
reserved for cases of
therapy is often
acyclovir resistance due to
recommended.
high toxicity.
pyrophosphate; inhibits
foscarnet
viral DNA polymerase .
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[Ref]

[5,
42‐
45]

[4, 7]

[1, 8]

TABLE 2A: Current Therapeutic Strategies against Selected Viral Pathogens
Current
Drugs
Type of
Drug Class/Mode of
Virus Name
Treatment
Commonly
[Ref]
Virus
Action
Options
Prescribed
nevirapine,
non‐nucleoside reverse
delavirdine,
transcriptase inhibitior
efavirenz,
(NNRTI)
etravirine
tenofovir
disoprozil
fumarate (TDF),
Highly active
azidothymidine, nucleoside/nucleotide
anti‐retroviral
reverse transcriptast
therapy (HAART; abacavir,
lamivudine,
inhibitor (NRTI)
combination
zalcitabine,
therapy using
didanosine,
three or more
stavudine
antivirals
Human
[5,
Retrovirus simutaneously). atazanavir,
Immunodeficiency
42‐
darunavir,
(lentivirus) Drugs may be
Virus (HIV)
45]
fosamprenavir,
administered
individually or as lopinavir,
tipranavir,
combination
A
protease inhibitor (PI)
pills. Treatment indinavir,
entricitabine,
duration is often
saquinavir,
lifetime of the
lopinavir,
patient.
ritonivir,
nelfinavir
entry/fusion inhibitor
enfuvirtide
(FI)
maraviroc
CCR5 antagonist
raltegravir
integrase inhibitor
Notes: AExamples of combination pills include: Combivir, Kaletra, Truvada, Trizivir, Atripla,
Epizicom/Kivexa (all registered trademarks of their respective companies); BHCV‐specific antivirals are
currently under development in clinical trials. None have been FDA‐approved to date; CThere are
multiple RSV‐targeted therapies currently under development, including: improved mAb preparations
(motavizumab), antisense anti‐RSV siRNAs, fusion inhibitors and other small molecule RSV viral epitope
inhibitors. A variety of vaccine options are being explored as well (live, attenuated vaccines, vector
vaccines and subunit vaccines).

Table 2.2A. Current therapeutic strategies against selected viral pathogens.
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TABLE 2B: Current Therapeutic Strategies against Common Intracellular Bacterial Pathogens
Drugs
Associated
Current Treatment
Drug Class/Mode
Bacteria
Commonly
Disease(s)
Options
of Action
Prescribed
first‐line drugs
effective against
Long‐term antibiotic isoniazid,
pyrazinamide,
non‐resistant M.
treatment in two
rifampicin,
tuberculosis
phases: intensive 2‐
ethambutol
infections. (non‐
month initial phase
MDR‐TB)
(four first‐line drugs)
Mycobacterium
then 4‐month follow ethionamide,
Tuberculosis
tuberculosis
up (isoniazid and
prothionamide,
second‐line drugs
rifampicin only).
cycloserine,
effective against
Drug resistant strains capreomycin,
multi‐drug
require additional
para‐
resistant strains
treatment for up to
aminosalicylic
of M.tuberculosis.
12 months.
acid,
(MDR‐TB)
fluorquinolones
broad‐spectrum
protein synthesis
Best therapy is
inhibitor;
prevention through
chloramphenicol
emerging
vaccination.
bacterial
Chloramphenicol is a
resistance to this
first‐line drug of
antibiotic
choice, although
fluoroquinolones
there is increasing
Salmonella
ciprofloxacin
(inhibit bacterial
bacterial resistance
enterica
Typhoid
DNA replication)
to this drug. Other
(Serovars Typhi,
fever
recommendations
cephalosporins
Paratyphi)
include treatment
(inhibit cell wall
ceftriaxone,
with cephalosporins,
synthesis; a type
cefotaxime
fluorquinolones or
of beta‐lactam
azithromycin in the
antibiotic)
case of highly drug
macrolide
resistant strains of
antibiotic
azithromycin
Salmonella.
(inhibits bacterial
protein synthesis)
Long‐term antibiotic
tetracycline‐
Brucella
doxycycline with
treatment;
aminoglycoside
(melitensis,
Brucellosis,
streptomycin,
combination therapy
combination
abortus, suis,
Malta fever
gentamicin or
more effective than
(protein synthesis
canis)
rifampicin
monotherapy.
inhibitors)

Table 2.2B. Current therapeutic strategies against common intracellular bacterial pathogens.
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[Ref]

[30,
31,
34,
37,
38]

[50,
52,
54,
55,
74]

[13‐
15]

NANOMEDICINE AS AN EMERGING THERAPEUTIC APPROACH
Conventional therapies for the treatment of intracellular diseases have existed for many
years. These treatments may be further improved as we enter a new era of therapies based on
nanomedicine. Nanomedicine can be most succinctly defined as “the application of
nanotechnology to medicine” [75]. There are many potential advantages of using nanomedicine
over the conventional therapies previously described. Combining new knowledge of
nanomaterials with our current understanding of cellular and molecular functions may allow for
the development of novel and advanced nanomedicines. As discussed below, nanomedicine has
the capacity to incorporate, encapsulate or conjugate a variety of drugs, to target specific cell
populations and to offer tunable and site-specific drug release; nanomedicine could be
advantageous in treating intracellular diseases.
Biocompatibility and Nanotoxicity
Biocompatibility is an important feature of any drug delivery system and the goal is to
minimize nonspecific cytotoxic effects to healthy tissues while maximizing drug effects at the
target tissue or against invasive pathogens [76]. Nanoparticles have been fabricated using a
variety of materials including poly(lactide-co-glycolide) or PLGA [77-82], poly-lactic acid
(PLA) [78, 83, 84], polymethacrylic acid (PMA) [85, 86], polyethylene glycol (PEG) [87, 88],
“natural” polymers such as chitosan [89, 90], gelatin [91, 92] or alginate [93, 94], and other
materials such as lipids [95-97], gold [76, 98] and silica [99-102].
PLGA has been approved by the US Food and Drug Administration (FDA) for several
biomedical applications including surgical sutures, implants and prosthetic devices [79]. PLGA
micro- or nano-particles have also been used for a variety of drug-delivery applications [80].
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PLGA displays good biocompatibility, biodegradability, suitable degradation kinetics and
mechanical properties and is easy to process. For this reason, PLGA is an attractive candidate for
nanoparticle-based drug delivery systems and there is a large body of ongoing research in this
area. Other polymers such as PLA, PMA, PEG, chitosan, gelatin and alginate also show promise
as drug delivery vehicles due to their biocompatible properties. PEG may be used as a “coating”
to prevent the rapid removal of nanoparticles from the blood stream by the mononuclear
phagocytic system, which may increase nanoparticle circulation time and theoretically improve
the therapeutic capacity of the nanoparticle [84, 87]. Chitosan and alginate are polymers derived
from natural sources and may offer more “friendly” conditions for the encapsulation or
incorporation of DNA or peptides since the use of organic solvents can be avoided [94].
Lipids are also being explored as potential nano-delivery systems, either as liposomes or
lipid nanocapsules (LNCs).

Liposomes are composed of lipid bi-layers surrounding a

hydrophilic “core” and can be designed to incorporate hydrophobic drugs within the lipid bilayer or hydrophilic drugs within the aqueous core [95].

Liposome-encapsulated

aminoglycosides (such as gentamicin) have shown higher therapeutic efficacy than conventional
amingoglycoside preparations in the liver and spleen using a murine S. typhi infection
model[95].

Amphotercin B (an anti-fungal) has also been encapsulated in lipids and

administered to mice with an Aspergillus fumigatis infection [96]. Liposome-treated mice have
survived longer than mice treated with other amphotercin B preparations, with reduced renal
toxicity and a prolonged drug circulation time[96]. These liposome formulations could be a
better treatment for diseases affecting the liver or spleen (eg typhoid fever, hepatitis). LNCs are
another type of lipid mediated delivery system under exploration. LNCs are considered a
“hybrid” between a polymer nanoparticle and a liposome, with an oily core surrounded by a
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membrane composed of PEGylated surfactants [97]. LNCs have shown promise in in vitro and
some animal models encapsulating anti-cancer drugs such as paclitaxel, doxorubicin, and
etoposide [97]. The results of these studies have indicated higher intracellular drug delivery and
reduced tumor size in vivo when LNC formulations were administered.
In contrast to these “soft” polymer-based nanoparticle systems, metals such as gold have
also been explored as potential drug delivery vectors. Gold is an attractive drug delivery vector
due to the ease with which biomolecules, such as protein or DNA, can be attached to the gold
surface using thiol chemistry [76]. This process can also allow attachment of multiple targeting
or functional groups to the nanoparticle surface to produce a multifunctional nanoparticle.
Although gold nanoparticles can be easily functionalized, these nanoparticles may accumulate in
tissues over time because they are not biodegradable. The effects of long-term nanoparticle
accumulation are unknown, so in many cases it may be better to use a material that is fully
biodegradable. Silica-based compounds are another option, as the biodegradation of silica avoids
tissue-accumulation concerns [99] and it has been demonstrated that a variety of agents have
been successfully incorporated into silica-based nanoparticles [100-102] for drug delivery
applications.
Although each of these materials offers its own set of characteristics and biocompatible
properties, some materials may be more suited to certain applications than others. It is important
to determine the desired properties of the nanomedicine for defined applications.
Cellular Penetration and Intracellular Delivery
One critical challenge in treating intracellular pathogens is to get enough drugs to reach
the pathogen within an intracellular compartment. Nanoparticles can be internalized by endocytic
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mechanisms which include receptor-mediated or clathrin-coated pit endocytosis [103].
Nanoparticles may reside within acidic endo-lysosome compartments following endocytosis [80]
and premature drug release within this acidic compartment may cause drug degradation and
render treatment ineffective. It is therefore important for the nanoparticle to escape this
compartment and gain access to the cytosol where either the drug cargo may be directly released
or the nanoparticle

goes on to further target a specific organelle. For instance, PLGA

nanoparticles carrying doxorubicin are reportedly capable of escape of the endo-lysosomal
compartment by a reversal of their surface charge. This allows the particles to interact with the
membrane and escape into the cytosol where the doxorubicin is released [80].
There are a number of sources which report time and concentration-dependent uptake of
nanoparticles by a variety of cell types such as smooth muscle cells [80], endothelial cells [104,
105], macrophages [40, 106-108] and tumor cells [109-114]. The uptake of PLGA nanoparticles
containing bovine serum albumin as a model drug was found to be concentration dependent in
human vascular endothelial cells, approaching first order kinetics [104]. An in vitro uptake and
cellular trafficking study using mesoporous hybrid silica nanoparticles demonstrated that the
particles were internalized by receptor-mediated endocytosis, localized in the endocytic
compartment and then released their cargo within the cytosol [101]. Another in vitro study
examined the uptake of drug-loaded thiolated PMA hydrogel capsules [114]. The tracking
experiments revealed that nanocapsules were taken up by endocytic mechanisms in a timedependent manner and the drug was released throughout the cell. Collectively, these studies
demonstrate that nanoparticles are capable of cellular penetration and are capable of intracellular
drug release. This is an important characteristic of a nanomedicine that targets intracellular
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pathogens and promotes direct killing, as the drug must be able to effectively reach the invading
pathogens within the intracellular compartment.
Targeting to Specific Cell Types
The goal of targeting nanomedicines to specific cell populations is to increase the
therapeutic efficacy of the drug while minimizing damage to healthy cells and tissues, thereby
reducing the incidence and severity of side effects. Presently, the majority of experiments
demonstrating the targeting of nanoparticles are related to cancer/tumor targeting although these
same concepts can be applied to pathogen-infected cells and the intracellular compartments [99]
where the pathogens reside. Nanoparticles can be targeted toward specific cell populations by
conjugating targeting ligands to the surface of the nanoparticles. These targeting ligands can be
attached directly to nanoparticle surfaces or attached via a spacer (eg PEG), which acts to
enhance the flexibility of the targeting ligand and increase the likelihood it will bind the
appropriate receptor on the target cell [111, 115]. There are a variety of methods available to
attach ligands to nanoparticle surfaces [116, 117]. Targeting ligands can include antibodies
(whole or fragment), receptors or receptor ligands, peptides, aptamers or other small molecules
[115]. A few examples are presented below.
When incorporating antibodies on nanoparticle surfaces, it is important to consider
whether attachment will affect the binding site or structure of the antibody. Hybrid lipid
nanoparticles composed of PLGA, phospholipids and an outer PEG layer have shown targeting
capacity to pancreatic cancer cells when coupled with an anti-carcinoembryonic antigen (CEA)
half-antibody [113]. Nanoparticles incubated with CEA-presenting pancreatic cancer cells
showed selective uptake of targeted nanoparticles over non-targeted control nanoparticles.
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Receptor ligands can also act as targeting moieties. It has been recently reported that
nanosized poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) micelles bearing a
surface epidermal growth factor (EGF) have been targeted to breast cancer cells over-expressing
the epidermal growth factor receptor (EGFR) in vitro and in vivo [109]. The uptake of the nanomicelles was two-fold higher using EGFR over-expressing cells compared to cells which express
low levels of EGFR. These results were confirmed using a xenograft mouse model, with mice
bearing EGFR over-expressing tumors demonstrating increased tumor uptake of the particles
compared to mice bearing low EGFR expressing tumors.
Polyester nanoparticles carrying paclitaxel can be targeted to irradiated tumor cells with a
short peptide, Gly-Ile-Arg-Leu-Arg-Gly (GIRLRG), which binds specifically to GRP78
receptors expressed by glioma and breast tumor cells in response to radiation therapy [110]. In
vitro and in vivo studies were used to compare tumor volumes following treatment with control
and targeted nanoparticles. Mice treated with nanoparticles bearing the targeting component had
a significant decrease in tumor volume compared to control.
Conjugation of an A10 aptamer to PLGA/PEG nanoparticles has also been shown to be
an effective targeting strategy [117]. The A10 aptamer binds to the prostate-specific membrane
antigen (PSMA) on the surface of prostate cancer cells, and the A10 aptamer conjugated
nanoparticles showed higher uptake by PSMA positive cells than by PSMA negative cells.
Site-Specific and Tunable Drug Release
In order to effectively eradicate intracellular pathogens, drugs that are intended to kill the
pathogens directly should reach the intracellular locations of infected host cells. As we have
summarized in Figure 1, locations may include phagosomes [15, 34, 56], vacuoles [52, 53],
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cytosol [16, 57, 58], nucleus [1, 59, 60], and may interact with the golgi apparatus [61] or
endoplasmic reticulum [62-66]. With proper engineering and design, nanoparticles can be
tailored to carry their drug payloads into the infected cells and then release the drug within
specific intracellular compartments. One way to accomplish site-specific drug release is to use
pH-responsive polymers. In one study, short peptides were conjugated to pH-responsive
polymers designed specifically to disrupt the endosomal membrane at pH 5.5 and subsequently
release the peptide into the cytosol [118]. The polymers had no membrane disruptive activity at
pH 7.4 due to a “masking” PEG group, which is later cleaved to expose the membrane disruption
domain at pH 5.5. Peptide-polymer conjugates demonstrated a diffuse cytosolic distribution after
one hour, the time normally required for macrophage endosomes to mature into lysosomes.
Unconjugated peptide was located primarily in the lysosome after the same time period,
indicating the peptide itself was unable to escape into the cytosol. This polymer technology may
allow for local drug delivery to the cytosol, although it is more critical to reach the specific
intracellular location of the pathogen, such as a vacuole or the nucleus.
It has been demonstrated that nanoparticles can be specifically targeted to mitochondria
[119] or nucleus [120] and may be capable of entering vacuoles [121] where pathogens such as
Salmonella may reside during an infection process. Although intracellular pathogens do not
typically live within mitochondria, pathogens such as Listeria monocytogenes can secrete toxins
which interfere with normal mitochondrial function [122]. So, the ability to target mitochondria
may provide a means to treat these types of infection and attenuate the effects of secreted toxins.
One study successfully localized fluorescent nanodiamonds conjugated with mitochondrial
protein antibodies to mitochondria in live cells [119]. The inherent fluorescence of these
nanodiamonds allowed for tracking the localization of the nanoparticles, and the microscopy
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experiments revealed that these nanodiamonds were capable of specifically binding the
mitochondria compared to control nanodiamonds without conjugated antibody.
Nuclear targeting has been demonstrated in a similar manner, by conjugating nuclear
localization signal (NLS) peptides on the surface of PLGA nanoparticles for the nuclear delivery
of doxorubicin to cancer cells [120]. The NLS-targeted nanoparticles demonstrated a 6-fold
increase in uptake compared to free doxorubicin in solution, and also a 2.5-fold increase in
uptake over non-targeted nanoparticles. Cells treated with NLS-targeted nanoparticles also
showed a higher toxicity than control nanoparticles, which was expected due to the increased
delivery of drug to its nuclear target site. Nuclear targeting would be especially useful in viral
infections such as HIV and HSV, as these viruses must enter the nucleus to begin their
replicative life cycles.
There is also evidence that demonstrates nanoparticles loaded with ampicillin are capable of
entering cells and delivering the drug within Salmonella-containing vacuoles (SCV) [121].
Ampicillin was tritium-labeled and found to localize within both the cytosol and SCV’s using
ultrastructural autoradiography. The co-localization of the drug with the bacteria led to enhanced
bacterial killing and elimination compared to control cells treated with ampicillin in solution.
The co-localization of the drug within the SCV is an important step in effectively targeting
intracellular pathogen compartments.
Another issue plaguing intracellular pathogen treatments is the lower concentration of drug at
the target site and the short duration of efficacy of the drug administered. Large and frequent
doses of the drugs are often required to obtain a therapeutic effect. Nanoparticles have the
potential to overcome this issue by offering sustained release of drugs, which would lower the
required dose and decrease the frequency of administration [123]. As an example, polymer-based
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nanoparticles composed of PLGA are able to sustain release of a variety of drugs, such as
rolipram for seven days [124], gentamicin for 25 days [125, 126] and dexamethasone for 15 days
[127]. Hyperbranched poly(amine-ester)-PLGA nanoparticles have also demonstrated sustained
release of isoniazid, an important anti-TB drug, up to 14 days [82]. Another study targeted
gelatin nanoparticles loaded with rifampicin, another anti-TB drug, to macrophages [92]. Test
results indicated that the rifampicin-loaded gelatin nanoparticles were capable of localizing in the
lungs and reducing bacterial loads in a mouse model of TB. In addition, nanoparticle treatment
was as effective as traditional daily oral rifampicin at a reduced dosing frequency (every three
days), due to the sustained release of rifampicin from the gelatin matrix [92].

PERSPECTIVES FOR THE FUTURE
We have reviewed the current therapeutic strategies against commonly encountered
intracellular pathogens like viruses and bacteria, and have evaluated the potential of
nanomedicine to improve upon the current treatments. When treating intracellular diseases, it is
important to avoid or prevent further development of pathogen resistance, which is becoming a
major problem for the management of TB [23]. Generally speaking, the success of an antibiotic
drug relies on its ability to penetrate the bacterial cell wall and membranes and to bind to its
target site (protein, enzyme, etc) [128]. Bacteria may develop resistance by mutating various
drug target sites [27], and viruses may also develop drug resistance through genetic mutation and
recombination events [29] that can render our current treatments ineffective. For this reason,
there is a need for new drugs with novel mechanisms of action that may slow or stop the
development of pathogen resistance.
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As an example, recent literature has emerged touting the potential of cationic
antimicrobial peptides (CAMPs) to serve as an alternative to conventional antibiotic therapy
[129-133]. Antimicrobial peptides are short, positively charged peptides which are produced
endogenously by human epithelial tissues where they function to prevent invasion of pathogens,
demonstrating broad-spectrum killing activity against bacteria, yeast and fungi [130, 134]. The
complete mechanism of CAMP action is yet to be fully understood, but one proposed mechanism
suggests that the CAMPs interact electrostatically with the negatively charged molecules on the
outer surface of bacteria, where they can insert themselves into the membrane and form a pore
[130]. Such a disruption in the bacterial cell wall and membranes will affect the osmolytic
balance of the bacterium and ultimately cause cell death. Because CAMPs do not have a specific
molecular target per se, pathogens may have more difficulty in developing resistance to these
peptides. There is also some evidence indicating that CAMPs can help modulate exogenous
antibiotic action against several strains of S. aureus [135]. Bacterial cultures treated with both
CAMPs and antibiotics had lower antibiotic “minimum inhibitory concentration” (MIC) values
than for cultures treated with antibiotics alone, indicating complementary action between the
CAMPs and antibiotics.
As a result, these CAMPs are attractive targets for the development of novel
nanomedicines to treat intracellular diseases. It may be possible to design nanoparticles capable
of carrying CAMPs into the cell, or to develop self-assembled CAMP nanoparticles. The
development of such nanoparticles may greatly improve intracellular drug therapy by offering
high efficacy against a variety of pathogens, and also offer very high biocompatibility, as
endogenous CAMPs can be used. We anticipate that CAMP nanoparticles will be a potential
advanced nanomedicine for intracellular disease treatments.
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Another potential strategy to improve intracellular disease treatments is to take advantage
of the preferential accumulation of nanoparticles by the reticuloendothelial system (RES). The
RES can also be referred to as the “mononuclear phagocytic system” and is composed of
macrophages residing in the liver, spleen and lungs. Normally, this phenomenon is avoided in
nanomedicine, as the RES removes the nanoparticles from circulation and may prevent drugs
from reaching target tissues. However, this treatment modality may be particularly useful in
treating intracellular diseases such as TB (affecting the lungs) or typhoid fever (affecting the
liver and spleen), as these pathogens primarily live and duplicate within macrophages of the
affected organs. Using nanoparticles to deliver drugs of interest to fight these diseases may be
aided by the natural tendency of these cells to internalize nanoparticles, which would help reduce
unnecessary tissue exposure and likely decrease the amount of drug required since it is being
delivered to the appropriate cell.
To create the “perfect” intracellular drug delivery system for fighting infections, certain
characteristics of nanoparticles or nanomedicine must be successfully incorporated such that the
medicine exhibits acceptable biocompatibility, possesses targeting capacity and offers efficient
and sustained drug release at the target site. Figure 2 illustrates an “ideal” nanoparticle drug
delivery system with such characteristics suited to treat intracellular diseases. The nanomaterial
used will vary with each application, but there are a variety of biocompatible materials available
as summarized in Table 3.
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Figure A2.2. Components of an “ideal” nanoparticle for intracellular drug delivery. The important
components of a nanoparticle used for intracellular drug delivery include: choice of nanomaterials
(polymer, gold, etc), targeting molecules, cell penetrating peptides (to promote internalization) and the
incorporated drug molecules of interest.

The drug may be used to form the nanoparticle, encapsulated within a polymer matrix, or
attached to the surface of a solid “carrier” nanoparticle. The incorporation of surface targeting
components to help localize to the affected tissue may improve therapeutic efficacy, along with
the presence of molecules to enhance cellular penetration such as cell penetrating peptides
(CPPs). CPPs are short, cationic peptides, typically derived from the HIV TAT proteins [136]
which have been shown to readily translocate through cell membranes. The addition of CPPs,
such as TAT, to the surface of a nanoparticle can increase the efficiency with which the
nanoparticles are delivered intracellularly [137, 138]; although the mechanism by which these
CPPs are able to enter cells is currently under debate. It is suggested that either the CPPs
promote direct translocation through the membrane via electrostatic interactions, or the CPPs
bind to specific receptors on the membrane and induce rapid receptor-mediated endocytosis
[138]. In either case, promoting efficient cellular penetration is critical for the treatment of
intracellular diseases.
Nanomedicine meets the requirements for an “ideal” drug delivery system to improve
intracellular disease therapy; however, we are still exploring this relatively new field. It is early
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to assess how quickly nanomedicine will be adopted and integrated into the mainstream
healthcare. Research on nanomedicine is relatively well-funded[139], so it is likely that many
new treatment methods will be approved and available in the future. However, this investment
cost for drug development is still high from an economic standpoint [140], and the price will
probably be passed down to patients via high prescription co-pays and may not be available for
years in developing areas where these improved therapies are needed most. Initially, this may be
a deterrent to promoting nanomedicine, but over the long-term with new cost-effective
technologies, higher drug efficacy, and better treatment outcomes, the price will become
acceptable.

Table 3: Examples of Biocompatible Nanoparticles

Type of Nanoparticle

Materials Used

[Ref]

Poly (lactide-co-glycolide) (PLGA)

[77-81]

Poly-lactic acid (PLA)

[78, 83, 84]

Synthetic or Man-made Polymers
Polymethacrylic acid (PMA)
Polyethylene glycol (PEG)

[85, 86]
[78, 87, 88]

Chitosan

[89, 90]

Gelatin

[91, 92]

Alginate

[93, 94]

Lipids

[95-97]

Gold

[76, 98]

Silica-based compounds

[99-102]

Natural Polymers

Other Types of Nanoparticles

Table A2.3. Examples of biocompatible nanoparticles.
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CONCLUDING REMARKS
The burden of treating intracellular diseases is continually increasing due to the sheer number
of people living with diseases such as HIV/AIDS, hepatitis and tuberculosis worldwide, along
with the increasing incidence of drug resistance. We have summarized the locations where these
pathogens reside, such as phagosomes [15, 34, 56], vacuoles [52, 53], cytosol [16, 57, 58],
nucleus [1, 59, 60], golgi apparatus [61] or endoplasmic reticulum [62-66]. The major challenges
in treating these invasive pathogens include getting enough drugs to penetrate the host cell and
reach the pathogen, having high drug efficacy and low toxicity, and maintaining sustained, sitespecific drug release throughout the duration of treatment. In the future, it may be possible to
improve disease treatment by utilizing the uptake of nanoparticles by the reticuloendothelial
system, especially in the case of TB or hepatitis which affects macrophages. Additionally,
looking to endogenous sources such as CAMPs or other immunomodulatory compounds such as
interleukins (not covered) may further improve upon current therapies.
The literature presented here shows the potential for nanomedicine to address these
challenges and improve upon the current therapeutic strategies. The incorporation of
nanomedicine into mainstream healthcare is a lofty, but achievable, goal. Researchers from
multiple disciplines must work together, push the boundaries of science at the nanoscale and
incorporate concepts from biology, engineering and drug design in order to make this goal a
reality.
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